verapamil has been researched along with Angor Pectoris in 545 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In hypertensive patients with prior MI, a verapamil-SR-based strategy was equivalent to a beta-blocker-based strategy for blood pressure control and prevention of cardiovascular events, with greater subjective feeling of well-being and a trend toward lower incidence of angina pectoris and stroke in the verapamil-SR-based group." | 9.13 | Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. ( Bacher, PH; Bangalore, S; Champion, A; Cohen, JD; Kowey, P; Mancia, G; Messerli, FH; Pepine, CJ; Sleight, P; Zhou, Q, 2008) |
| "A randomized blind cross-over study with placebo lead-in compared efficacy of calcium antagonists diltiazem and verapamil in 71 patients with stable angina concurrent with arterial hypotension (group 1) and 38 normotensive patients with ischemic heart disease (group 2)." | 9.11 | [Diltiazem and verapamil therapy in patients with angina pectoris associated with arterial hypotension]. ( Borovkova, NV; Chernov, VI; Idrisova, EM; Karpov, RS; Poponina, IuS; Stepacheva, TA; Vorob'eva, EV, 2004) |
| "The effects of 1 month of treatment with either verapamil or metoprolol on several aspects of platelet function were studied at rest and during physical exercise or mental stress in patients with stable angina pectoris participating in the Angina Prognosis Study in Stockholm." | 9.08 | Platelet aggregability in vivo is attenuated by verapamil but not by metoprolol in patients with stable angina pectoris. ( Held, C; Hjemdahl, P; Rehnqvist, N; Wallén, NH, 1995) |
| "To study long-term treatment effects of metoprolol or verapamil on combined cardiovascular end points and psychological variables in patients with stable angina pectoris." | 9.08 | Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS) ( Billing, E; Björkander, I; Eriksson, SV; Forslund, L; Held, C; Hjemdahl, P; Näsman, P; Rehnqvist, N; Wallén, NH, 1996) |
| "In the Angina Prognosis Study in Stockholm (APSIS), patients with stable angina pectoris were studied prospectively during double-blind treatment with metoprolol or verapamil." | 9.08 | Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. ( Björkander, I; Eriksson, SV; Forslund, L; Held, C; Hjemdahl, P; Rehnqvist, N; Wallén, NH; Wiman, B, 1997) |
| ", death, repeat infarction, unstable angina pectoris, or repeat admission because of heart failure) was 14% in patients treated with verapamil and trandolapril and 35% in patients treated with trandolapril (p = 0." | 9.08 | Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial. ( Bjergaard, OP; Hagerup, L; Hansen, JF; Mellemgaard, K; Pedersen, F; Sigurd, B, 1997) |
| " Out of 809 patients with stable angina pectoris, lipid variables were obtained in 786 patients at baseline, and after one month's double-blind treatment with metoprolol or verapamil, to evaluate treatment effects on these lipid variables." | 9.08 | Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol: results from the Angina Prognosis Study in Stockholm (APSIS). ( Angelin, B; Berglund, L; Björkander, I; Brodin, U; Forslund, L; Held, C; Hjemdahl, P; Rehnqvist, N, 1997) |
| "The antianginal efficacy of 240 mg sustained release verapamil once daily doses and 300 mg diltiazem was studied in 20 normotensive patients with chronic stable angina pectoris, using a randomized, double-blind crossover design." | 9.08 | Antianginal efficacy over 24 hours and exercise hemodynamic effects of once daily sustained-release 300 mg diltiazem and 240 mg verapamil in stable angina pectoris. ( Ciaburri, F; De Rosa, ML; Della Guardia, D; Giordano, A; Melfi, M; Rengo, F, 1998) |
| "The prognostic significance of angina pectoris and the effect of intervention with verapamil on the incidence of angina pectoris were studied in patients recovering from myocardial infarction and included in the Danish Verapamil Infarction Trial II." | 9.07 | The prognostic significance of post-infarction angina pectoris and the effect of verapamil on the incidence of angina pectoris and prognosis. The Danish Study Group on Verapamil in Myocardial Infarction. ( Hansen, JF; Jespersen, CM; Mortensen, LS, 1994) |
| "In a double-blind, randomized, placebo-controlled study comparing verapamil and placebo in late secondary intervention after acute myocardial infarction, the physicians were asked to try to identify the treatment in 100 consecutive patients." | 9.06 | Assessment of blindness in the Danish Verapamil Infarction Trial II (DAVIT II). Danish Study Group on Verapamil in Myocardial Infarction. ( Jespersen, CM, 1990) |
| "The calcium antagonist bepridil (bepridil monohydrochloride monohydrate, Org 5730, Cordium) was investigated in comparison with verapamil in a double-blind cross-over design in patients with angina pectoris." | 9.06 | Bepridil versus verapamil in stable angina pectoris--a controlled clinical trial. ( Husted, SE; Krusell, LR; Nielsen, HK; Pluymers, RJ, 1989) |
| "The antianginal effects of propranolol 160 mg/day, diltiazem 240 mg/day, nicardipine 80 mg/day, nifedipine 40 to 80 mg/day and verapamil 320 mg/day were compared in 12 patients with chronic stable angina pectoris using a symptom-limited exercise test." | 9.06 | Comparison of the antianginal efficacy of four calcium antagonists and propranolol in stable angina pectoris. ( Azzollini, F; Cereda, A; Pelosi, G; Picca, M, 1989) |
| "The efficacy of a sustained-release preparation of verapamil (verapamil-SR) has been compared with that of a conventional instant-release formulation (verapamil-IR) in 10 patients with stable angina pectoris treated for 3 weeks with both preparations." | 9.06 | Sustained-release and instant-release verapamil in treatment of angina pectoris. ( Hansen, JF; Jespersen, CM; Klitgaard, NA; Nielsen, H, 1989) |
| "We have studied the antiaggregatory effect of fenflumizole, a new non-steroidal antiinflammatory imidazole derivative, in ten patients with unstable angina pectoris." | 9.06 | The influence of fenflumizole on platelet aggregation in patients with unstable angina pectoris. ( Grande, P; Grauholt, AM; Wadt, J, 1987) |
| "The antianginal efficacy of nitroglycerin (NTG), given in a new transdermal therapeutic system (TTS), was compared with that of nifedipine and verapamil, both in slow-release (SR) formulation, in a randomized, double-blind, placebo-controlled study, carried out in 8 patients with stable exercise-induced angina pectoris." | 9.06 | Effects of a transdermal patch system containing nitroglycerin on exercise tolerance in patients with angina pectoris. Double-blind, placebo controlled, comparison with slow-release nifedipine and verapamil. ( De Ponti, C; Gibelli, G; Mazzocchi, F; Negrini, M; Pollavini, P; Prina, L, 1986) |
| "The comparative effects of prolonged chronic therapy with diltiazem, nicardipine, tiapamil and verapamil on exercise tolerance, ST-segment changes and heart rate were examined in 63 patients with established chronic stable angina pectoris." | 9.06 | Comparative effects of prolonged therapy with four calcium ion antagonists (diltiazem, nicardipine, tiapamil and verapamil) in patients with chronic stable angina pectoris. ( Khurmi, NS; Raftery, EB, 1987) |
| "The effectiveness of a sustained-release preparation of verapamil (verapamil-SR) was compared with the regular formulation of verapamil and with placebo in 12 patients with chronic stable angina pectoris." | 9.06 | Efficacy of sustained-release verapamil in chronic stable angina pectoris. ( Cutler, SS; Klein, MD; Weiner, DA, 1987) |
| "The efficacy and effect on cardiac function of verapamil 120 mg three times a day and atenolol 100 mg once a day, singly and in combination, were evaluated in 15 patients with angina pectoris." | 9.06 | A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris. ( Aitchison, T; Dargie, HJ; Elliott, AT; Findlay, IN; Gillen, G; MacLeod, K, 1987) |
| " In a double blind cross-over study the effect of verapamil (Isoptin) 360 mg/d and propranolol 180 mg/d was evaluated in patients with stable angina pectoris." | 9.05 | Verapamil and beta-adrenoceptor blockade in the treatment of stable angina pectoris. ( Grytter, C; Hansen, JF; Sigurd, B; Thomsen, S, 1982) |
| "The effectiveness and safety of the beta-adrenergic blocking agent propranolol and the calcium channel antagonist verapamil were compared in 22 patients with chronic stable angina pectoris using a double-blind randomized placebo-controlled crossover protocol." | 9.05 | Calcium channel blockade as primary therapy for stable angina pectoris. A double-blind placebo-controlled comparison of verapamil and propranolol. ( Bowles, MJ; Davies, AB; Raftery, EB; Subramanian, VB, 1982) |
| "The relative efficacies of oral verapamil, a calcium-entry blocking drug, and propranolol, a beta-adrenergic blocking drug, were compared in 12 patients who had both stable angina pectoris and mild to moderate systemic hypertension, using a placebo-controlled, double-blind, randomized crossover protocol." | 9.05 | Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris. A placebo-controlled double-blind randomized crossover trial. ( Frishman, WH; Klein, NA; Klein, P; LeJemtel, TH; Pollack, S; Roth, S; Sonnenblick, EH; Strair, R; Strom, JA; Tawil, R; Wong, B, 1982) |
| "The efficacy of two beta-receptor antagonists, propranolol and pindolol, was compared with that of a calcium antagonist, verapamil, in the treatment of exertional angina pectoris in 22 men (mean age 51 years)." | 9.05 | The clinical and hemodynamic effects of propranolol, pindolol and verapamil in the treatment of exertional angina pectoris. ( Johnston, DL; Kostuk, WJ; Manyari, DE, 1984) |
| "The long-term efficacy and safety of high-dose verapamil therapy (480 mg/day) was assessed in 26 patients with chronic stable angina pectoris during a 3-phase protocol: Phase 1--an initial, 6-week placebo-controlled, double-blind crossover assessment; Phase 2--an open label, 1-year follow-up; and Phase 3--a final drug withdrawal and rechallenge 10-week study." | 9.05 | Efficacy and safety of verapamil in patients with angina pectoris after 1 year of continuous, high-dose therapy. ( Creager, MA; Cutler, SS; Klein, MD; McCabe, CH; Ryan, TJ; Weiner, DA, 1983) |
| "The orthostatic changes in heart rate (HR) and blood pressure (BP) were recorded in ten patients with stable angina pectoris before and after simultaneous sublingual nitroglycerin administration." | 9.05 | Orthostatic response before and after nitroglycerin in metoprolol- and verapamil-treated angina pectoris. ( Hyldstrup, L; Mogensen, NB; Nielsen, PE, 1983) |
| "The effects of the calcium-channel-blocking agent Gallopamil (D 600) were assessed in 20 patients with stable exertional angina pectoris in a randomized placebo-controlled double-blind protocol using serial exercise tests." | 9.05 | [Acute and long-term effects of gallopamil (D 600) in stable angina pectoris--a randomized double-blind study]. ( Bette, L; Rettig, G; Schieffer, H; Sen, S, 1983) |
| " Both verapamil and propranolol caused a significant reduction in nitroglycerin consumption, days with angina pectoris and in severe angina attacks as compared to placebo." | 9.05 | Verapamil or propranolol in the treatment of stable angina pectoris of effort. ( Hansen, JF; Sigurd, B, 1984) |
| "The effectiveness of verapamil in the management of patients with unstable angina pectoris associated with obstructive coronary artery disease was evaluated in 2 double-blind placebo-controlled randomized clinical trials." | 9.05 | Verapamil therapy for unstable angina pectoris: review of double-blind placebo-controlled randomized clinical trials. ( Conti, CR; Mehta, J, 1982) |
| "Plasma levels of verapamil and norverapamil were evaluated in 77 patients who received oral verapamiL for treatment of angina pectoris." | 9.05 | Clinical relevance of verapamil plasma levels in stable angina pectoris. ( Frishman, W; Hillis, LD; Johnson, SM; Kates, R; Kirsten, E; Klein, M; Packer, M; Pine, M, 1982) |
| "To assess the effects of verapamil and nifedipine on left ventricular function at rest and during exercise in patients with Prinzmetal's variant angina pectoris, 10 patients (6 men and 4 women with a mean age of 52 years) with variant angina were each treated for 2 months periods with placebo, verapamil (400 +/- 80 mg/day, mean +/- standard deviation [SD]) and nifedipine (82 +/- 31 mg/day)." | 9.05 | Effect of verapamil and nifedipine on left ventricular function at rest and during exercise in patients with Prinzmetal's variant angina pectoris. ( Corbett, J; Dehmer, GJ; Hillis, LD; Johnson, SM; Lewis, SE; Mauritson, DR; Willerson, JT, 1981) |
| "Clinical and exercise responses to therapy with the calcium-channel blocking agent verapamil were assessed in 26 patients with stable exertional angina pectoris using a double-blind, placebo-controlled, randomized crossover study design." | 9.05 | Verapamil therapy for stable exertional angina pectoris. ( Klein, MD; Weiner, DA, 1982) |
| "The clinical responses to 12 months' treatment with verapamil were evaluated in 63 patients with stable and unstable angina pectoris in whom the effectiveness of verapamil had been established in short-term double-blind placebo-controlled randomized clinical trials." | 9.05 | Long-term effectiveness of verapamil in stable and unstable angina pectoris. One-year follow-up of patients treated in placebo-controlled double-blind randomized clinical trials. ( Frishman, WH; Mehta, J; Packer, M; Parodi, O; Scheidt, S; Subramanian, VB, 1982) |
| "The potential hazards of abrupt withdrawal of propranolol have been described in patients with angina pectoris; however, the effects of abrupt withdrawal from long-term therapy with verapamil have not previously been investigated." | 9.05 | Comparative effects of abrupt withdrawal of propranolol and verapamil in angina pectoris. ( Cohen, MN; Frishman, WH; Iorio, L; Klein, N; Klein, P; LeJemtel, T; Pollack, S; Roth, S; Shamoon, H; Sonnenblick, EH; Strom, J; Willens, H, 1982) |
| "Because of recurrent chest pain, 17 patients with documented spasm in coronary arteries without severe atherosclerotic obstructions were treated with verapamil in an open trial, using doses of 120 mg/day to 480 mg/day (mean, 240 mg/day)." | 9.05 | Coronary spasm management with verapamil (Isoptin). ( Freedman, B; Kelly, DT; Richmond, DR, 1980) |
| "This study was performed to compare the relative efficacies of propranolol and verapamil in patients with stable angina pectoris." | 9.05 | Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. ( Corbett, JR; Hillis, LD; Johnson, SM; Mauritson, DR; Willerson, JT; Woodward, W, 1981) |
| "The clinical and hemodynamic effects of propranolol, propranolol-verapamil (P-V), propranolol-nifedipine (P-N) and propranolol-diltiazem (P-D) were studied in 19 patients with chronic exertional angina pectoris." | 9.05 | Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris: a placebo-controlled, double-blind, randomized, crossover study. ( Humen, DP; Johnston, DL; Kostuk, WJ; Lesoway, R, 1985) |
| " The basis of this assumption was examined in a rest and exercise hemodynamic study of the effects of verapamil and the cardioselective beta-blocking drug, metoprolol, in 22 patients with stable angina pectoris and angiographically confirmed coronary artery disease." | 9.05 | The effects on left ventricular performance of verapamil and metoprolol singly and together in exercise-induced angina pectoris. ( Forsyth, D; Frais, MA; Hussain, M; Nelson, GI; Silke, B; Taylor, SH; Verma, SP, 1985) |
| "In thirteen patients with coronary insufficiency and angina pectoris the therapeutic effects of verapamil, 80 mg three times/day and practolol, 100 mg three times/day, were compared and tested against placebo in a double-blind cross-over fashion." | 9.04 | Double-blind comparison of verapamil and practolol in the treatment of angina pectoris. ( Fagher, B; Persson, S; Svensson, SE, 1977) |
| "In the treatment of angina pectoris a double-blind evaluation of verapamil (Cordilox) at two dose levels-namely, 80 mg thrice daily and 120 mg thrice daily-propranolol (Inderal) 100 mg thrice daily, and isosorbide dinitrate (Vascardin) 20 mg thrice daily has been made against a placebo." | 9.04 | Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris. ( Campbell, RC; Catley, PF; Livesley, B; Oram, S, 1973) |
| "In all patients combined, the incidence of constipation (13% vs 2%), dizziness (6% vs 2%), and back pain (3% vs 1%) was higher in patients treated with COER verapamil than with placebo." | 8.81 | Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease. ( Anders, RJ; Black, HR; Elliott, WJ; Johnson, MF; White, WB, 2001) |
| "Verapamil is well tolerated in patients with stable and unstable angina pectoris, as well as in patients with threatened infarction." | 8.80 | Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trials. ( Jespersen, CM, 1999) |
| "Verapamil is well tolerated in patients with stable and unstable angina pectoris, as well as in patients with threatened infarction." | 8.80 | Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trials. ( Jespersen, CM, 2000) |
| "The present review discusses the prognostic significance of post-infarction angina pectoris, and the significance of post-infarction intervention with verapamil on the prevalence of post-infarction ischaemia and prognosis." | 8.79 | Anti-ischaemic intervention with verapamil in patients recovering from acute myocardial infarction. ( Jespersen, CM, 1995) |
| "To study the dose-ranging population pharmacokinetics of controlled release verapamil in healthy subjects and patients with angina or hypertension." | 7.71 | Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina. ( Aarons, L; Gupta, S; Ho Pl, PL; Modi, NB; Sathyan, G, 2002) |
| "Efficacy and tolerance of gallopamil (Procorum) were investigated over a period of 1 year under practice conditions in a total of 455 patients (254 male, 201 female), aged 62 years (male) and 66 (female) on an average, with electrocardiographically confirmed coronary heart disease." | 7.67 | [Multicenter long-term study of gallopamil in patients with coronary heart disease]. ( Schiemann, J; Sućić, M, 1984) |
| " The haemodynamic effects of equivalent hypotensive doses of nifedipine and verapamil were therefore compared in 20 patients with severe angina pectoris associated with angiographically documented coronary artery disease." | 7.67 | The effects on left ventricular performance of nifedipine and verapamil in exercise-induced angina pectoris. ( Ahuja, RC; Hussain, M; Nelson, GI; Silke, B; Taylor, SH; Verma, SP, 1984) |
| "In a 67-year-old man with multiple myocardial infarctions in the past, the use of oral verapamil for control of angina pectoris was followed by the appearance of two previously undiagnosed abnormalities, namely, a dual-pathway AV node conduction pattern, and paroxysms of AV nodal reentrant tachycardia precipitated by premature ventricular beats (PVB)." | 7.67 | Verapamil-mediated atrioventricular nodal reentrant tachycardia and the uncovering of dual-pathway AV nodal conduction. ( Massumi, RA; Udhoji, VN, 1988) |
| " The pharmacokinetics and pharmacodynamics of oral verapamil and propranolol were studied in patients with stable angina pectoris during chronic mono- and dual therapy." | 7.67 | The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ( Lennard, MS; McCourty, JC; Silas, JH; Tucker, GT, 1988) |
| "Verapamil has been shown to be effective in reducing the frequency of episodes of ischemic pain in patients with unstable angina pectoris, and to be more effective than beta-adrenoceptor antagonists in such patients." | 7.67 | Verapamil in unstable angina pectoris: failure to demonstrate a relationship between efficacy and plasma levels. ( Elliott, SL; Horowitz, JD; Powell, AC, 1988) |
| "Oxygen utilization, arterial and venous blood gas levels, hemodynamic values and exercise tolerance were compared before and after administration of propranolol and verapamil in 10 patients with stable angina pectoris." | 7.67 | Effect of propranolol and verapamil on oxygen utilization, acidosis and fatigue during exercise in stable angina pectoris. ( Anderson, SD; Devenish-Meares, S; Harris, PJ; Kelly, DT; Roubin, GS; Sadick, NA, 1987) |
| "Pharmacokinetics of verapamil and of its three primary metabolites [norverapamil, 2-(3,4-dimethoxyphenyl)-2-isopropyl-6-azaheptanitrile (D-617) and 2-(3,4-dimethoxyphenyl)-2-propylamino-3-methylbutyronitrile (D-260)] was studied after oral administration in 7 patients with stable angina pectoris." | 7.67 | Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris. ( Metelitsa, VI; Nikolenko, SA; Piotrovskii, VK; Riabokon, OS; Rumiantsev, DO, 1986) |
| "We observed gingival hyperplasia, similar clinically to the hyperplasia caused by diphenylhydantoin during the last 11 months in two patients treated by verapamil, suffering from angina pectoris pains." | 7.67 | [Hypertrophic gingivitis caused by verapamil]. ( Cucchi, G; Giustiniani, S; Robustelli, F, 1985) |
| "The cardioselective beta adrenoceptor blocking agent metoprolol was compared with the calcium antagonist verapamil in relation to effects on angina pectoris." | 7.66 | Comparison of metoprolol and verapamil in the treatment of angina pectoris. ( Arnman, K; Rydén, L, 1982) |
| " A long-term, open clinical trial of verapamil therapy was conducted in ninety-three patients with coronary artery disease, selected on the basis of having stable angina pectoris and of being unsuitable for treatment with beta-adrenoceptor blocking drugs." | 7.66 | Verapamil in the long-term treatment of angina pectoris. ( Raftos, J, 1982) |
| "A long-term, open clinical trial of verapamil therapy was conducted in 93 patients with coronary artery disease, selected on the basis of having stable angina pectoris and of being unsuitable for treatment with beta-adrenergic blocking drugs." | 7.66 | Verapamil in the long-term treatment of angina pectoris. ( Raftos, J, 1980) |
| "Angina and hypertension are common in patients with coronary artery disease (CAD); however, the effect on mortality is unclear." | 6.78 | Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST). ( Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Pepine, CJ; Winchester, DE, 2013) |
| "This multicenter, randomized, double-blind, parallel group, placebo lead-in, placebo-controlled study compared the antianginal and anti-ischemic effects of once-daily bedtime dosing of controlled-onset extended-release (COER-24) verapamil to a once-daily morning dosing of amlodipine +/- atenolol in patients with chronic stable angina." | 6.69 | Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. ( Deedwania, PC; Fakouhi, TD; Frishman, WH; Glasser, S; Johnson, M; Stone, P, 1999) |
| " This verapamil formulation can be clinically titrated within a 180 to 540 mg dosing range, permitting effective once-daily administration for the treatment of chronic stable angina." | 6.68 | Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. ( Anders, RJ; Awan, NA; Bultas, J; Cutler, NR; Jhee, SS; Lahiri, A; Sramek, JJ; Woroszylska, M, 1995) |
| " Left ventricular ejection fractions at rest or exercise were not significantly changed following either acute intravenous (rest 33%; exercise 38%) or chronic oral dosing with verapamil (rest 35%; exercise 43%) when compared with placebo (rest 34%; exercise 42%)." | 6.67 | Low-dose verapamil in middle-aged and elderly patients with angina pectoris: no evidence of increased susceptibility to the cardiac effects. ( Ahmed, JH; Elliott, HL; Meredith, PA; Reid, JL, 1992) |
| " In 2 patients, verapamil caused weakness, lightheadedness, and severe sinus bradycardia (40 to 48 beats/min), and the dosage was reduced (blindly) to 240 mg/day, with the alleviation of bradycardia and associated symptoms." | 6.66 | Propranolol-verapamil versus propranolol-nifedipine in severe angina pectoris of effort: a randomized, double-blind, crossover study. ( Corbett, JR; Croft, CH; Fulton, KL; Hillis, LD; Winniford, MD, 1985) |
| "Verapamil is an effective antianginal drug that appears most efficacious at a dose of 360 mg/day, but side effects are common at a dose of 480 mg/day." | 6.65 | Verapamil versus placebo in relieving stable angina pectoris. ( Bailly, DJ; Butman, S; Citron, PD; Landa, DW; Pine, MB; Plasencia, GO; Wong, RK, 1982) |
| " At the higher dosage verapamil produced a significant improvement in frequency of angina, trinitrin consumption, and exercise tolerance, and had a favourable and significant effect on the amount and duration of ischaemic S-T depression occurring in the electrocardiogram during exercise." | 6.63 | Clinical evaluation of verapamil in angina pectoris. ( Clayton, GA; Sandler, G; Thornicroft, SG, 1968) |
| "Fourteen male patients with exertion-related angina pectoris and reproducible ST-segment depression on stress testing were each treated with isosorbide dinitrate (ISDN) 40 mg three times daily, verapamil 120 mg three times daily and placebo three times daily for two weeks according to a double-blind cross-over protocol." | 6.16 | Comparison of the antianginal efficacy of isosorbide dinitrate (ISDN) 40 mg and verapamil 120 mg three times daily in the acute trial and following two-week treatment. ( Bussmann, WD; Hör, G; Kaltenbach, M; Lang, E; Maul, FD; Schneider, W, 1988) |
| "Verapamil has the same anti-anginal effect during exercise as beta-adrenoceptor blockers but has the advantage of increasing rather than decreasing the cardiac output and so fatigue both at rest and exercise commonly seen with beta-adrenoceptor blockers is not found with verapamil." | 5.27 | Verapamil in angina pectoris. ( Kelly, DT, 1986) |
| "In hypertensive patients with prior MI, a verapamil-SR-based strategy was equivalent to a beta-blocker-based strategy for blood pressure control and prevention of cardiovascular events, with greater subjective feeling of well-being and a trend toward lower incidence of angina pectoris and stroke in the verapamil-SR-based group." | 5.13 | Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. ( Bacher, PH; Bangalore, S; Champion, A; Cohen, JD; Kowey, P; Mancia, G; Messerli, FH; Pepine, CJ; Sleight, P; Zhou, Q, 2008) |
| "A randomized blind cross-over study with placebo lead-in compared efficacy of calcium antagonists diltiazem and verapamil in 71 patients with stable angina concurrent with arterial hypotension (group 1) and 38 normotensive patients with ischemic heart disease (group 2)." | 5.11 | [Diltiazem and verapamil therapy in patients with angina pectoris associated with arterial hypotension]. ( Borovkova, NV; Chernov, VI; Idrisova, EM; Karpov, RS; Poponina, IuS; Stepacheva, TA; Vorob'eva, EV, 2004) |
| "The prognostic significance of ambulatory ischemia, alone and in relation to ischemia during exercise was assessed in 686 patients (475 men) with chronic stable angina pectoris taking part in the Angina Prognosis Study In Stockholm (APSIS), who had 24-hour ambulatory electrocardiographic registrations and exercise tests at baseline (n = 678) and after 1 month (n = 607) of double-blind treatment with metoprolol or verapamil." | 5.09 | Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study in Stockholm [APSIS]). ( Björkander, I; Eriksson, SV; Forslund, L; Held, C; Hjemdahl, P; Rehnqvist, N, 1999) |
| "Four hundred seventy-five patients with angina pectoris were randomized to double-blind treatment with PPR (physiological pattern release) verapamil hydrochloride, amlodipine besylate, amlodipineatenolol combination, or placebo." | 5.09 | Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension. ( Anderson, R; Hollenberg, NK; Williams, GH, 2000) |
| "In the Angina Prognosis Study in Stockholm (APSIS), 809 patients with stable angina pectoris were studied prospectively during double-blind treatment with verapamil or metoprolol." | 5.09 | Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. ( Björkander, I; Eriksson, SV; Forslund, L; Held, C; Hjemdahl, P; Rehnqvist, N, 2001) |
| "The effects of 1 month of treatment with either verapamil or metoprolol on several aspects of platelet function were studied at rest and during physical exercise or mental stress in patients with stable angina pectoris participating in the Angina Prognosis Study in Stockholm." | 5.08 | Platelet aggregability in vivo is attenuated by verapamil but not by metoprolol in patients with stable angina pectoris. ( Held, C; Hjemdahl, P; Rehnqvist, N; Wallén, NH, 1995) |
| "To study long-term treatment effects of metoprolol or verapamil on combined cardiovascular end points and psychological variables in patients with stable angina pectoris." | 5.08 | Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS) ( Billing, E; Björkander, I; Eriksson, SV; Forslund, L; Held, C; Hjemdahl, P; Näsman, P; Rehnqvist, N; Wallén, NH, 1996) |
| "In the Angina Prognosis Study in Stockholm (APSIS), patients with stable angina pectoris were studied prospectively during double-blind treatment with metoprolol or verapamil." | 5.08 | Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. ( Björkander, I; Eriksson, SV; Forslund, L; Held, C; Hjemdahl, P; Rehnqvist, N; Wallén, NH; Wiman, B, 1997) |
| ", death, repeat infarction, unstable angina pectoris, or repeat admission because of heart failure) was 14% in patients treated with verapamil and trandolapril and 35% in patients treated with trandolapril (p = 0." | 5.08 | Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial. ( Bjergaard, OP; Hagerup, L; Hansen, JF; Mellemgaard, K; Pedersen, F; Sigurd, B, 1997) |
| " Out of 809 patients with stable angina pectoris, lipid variables were obtained in 786 patients at baseline, and after one month's double-blind treatment with metoprolol or verapamil, to evaluate treatment effects on these lipid variables." | 5.08 | Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol: results from the Angina Prognosis Study in Stockholm (APSIS). ( Angelin, B; Berglund, L; Björkander, I; Brodin, U; Forslund, L; Held, C; Hjemdahl, P; Rehnqvist, N, 1997) |
| "The antianginal efficacy of 240 mg sustained release verapamil once daily doses and 300 mg diltiazem was studied in 20 normotensive patients with chronic stable angina pectoris, using a randomized, double-blind crossover design." | 5.08 | Antianginal efficacy over 24 hours and exercise hemodynamic effects of once daily sustained-release 300 mg diltiazem and 240 mg verapamil in stable angina pectoris. ( Ciaburri, F; De Rosa, ML; Della Guardia, D; Giordano, A; Melfi, M; Rengo, F, 1998) |
| "The prognostic significance of angina pectoris and the effect of intervention with verapamil on the incidence of angina pectoris were studied in patients recovering from myocardial infarction and included in the Danish Verapamil Infarction Trial II." | 5.07 | The prognostic significance of post-infarction angina pectoris and the effect of verapamil on the incidence of angina pectoris and prognosis. The Danish Study Group on Verapamil in Myocardial Infarction. ( Hansen, JF; Jespersen, CM; Mortensen, LS, 1994) |
| "The effects of verapamil, nifedipine, propranolol, and combinations of nifedipine+propranolol and nifedipine+verapamil were studied in 60 patients with stable angina pectoris." | 5.07 | [Effect of various antianginal agents on the frequency and duration of myocardial ischemic episodes in patients with stable angina pectoris]. ( Lysenko, AF; Voronkov, LG, 1992) |
| "In 9 patients with stable angina pectoris of effort the authors studied the relation between the effect of verapamil in single and regular administration and concentration of invariable preparation and its primary metabolites in the blood serum." | 5.06 | [Relation of the anti-anginal effect and blood serum level of verapamil in patients with exercise-induced stenocardia]. ( Metelitsa, VI; Piotrovskiĭ, VK; Rumiantsev, DO; Slastnikova, ID, 1990) |
| "In a double-blind, randomized, placebo-controlled study comparing verapamil and placebo in late secondary intervention after acute myocardial infarction, the physicians were asked to try to identify the treatment in 100 consecutive patients." | 5.06 | Assessment of blindness in the Danish Verapamil Infarction Trial II (DAVIT II). Danish Study Group on Verapamil in Myocardial Infarction. ( Jespersen, CM, 1990) |
| "The calcium antagonist bepridil (bepridil monohydrochloride monohydrate, Org 5730, Cordium) was investigated in comparison with verapamil in a double-blind cross-over design in patients with angina pectoris." | 5.06 | Bepridil versus verapamil in stable angina pectoris--a controlled clinical trial. ( Husted, SE; Krusell, LR; Nielsen, HK; Pluymers, RJ, 1989) |
| "The antianginal effects of propranolol 160 mg/day, diltiazem 240 mg/day, nicardipine 80 mg/day, nifedipine 40 to 80 mg/day and verapamil 320 mg/day were compared in 12 patients with chronic stable angina pectoris using a symptom-limited exercise test." | 5.06 | Comparison of the antianginal efficacy of four calcium antagonists and propranolol in stable angina pectoris. ( Azzollini, F; Cereda, A; Pelosi, G; Picca, M, 1989) |
| "Circadian variation in the metabolism of verapamil was investigated in 10 patients with stable angina pectoris during treatment with sustained-release verapamil 360 mg at 08." | 5.06 | Circadian variation in the pharmacokinetics of verapamil. ( Frederiksen, M; Hansen, JF; Jespersen, CM; Klitgaard, NA; Sørum, C, 1989) |
| "The efficacy of a sustained-release preparation of verapamil (verapamil-SR) has been compared with that of a conventional instant-release formulation (verapamil-IR) in 10 patients with stable angina pectoris treated for 3 weeks with both preparations." | 5.06 | Sustained-release and instant-release verapamil in treatment of angina pectoris. ( Hansen, JF; Jespersen, CM; Klitgaard, NA; Nielsen, H, 1989) |
| "We have studied the antiaggregatory effect of fenflumizole, a new non-steroidal antiinflammatory imidazole derivative, in ten patients with unstable angina pectoris." | 5.06 | The influence of fenflumizole on platelet aggregation in patients with unstable angina pectoris. ( Grande, P; Grauholt, AM; Wadt, J, 1987) |
| "The efficacy of a once daily, sustained release formulation of verapamil (Verapamil SR, 360 mg) was evaluated in 19 patients with chronic angina pectoris using a double-blind placebo-controlled crossover protocol." | 5.06 | Sustained release verapamil, a once daily preparation: objective evaluation using exercise testing, ambulatory monitoring and blood levels in patients with stable angina. ( Hughes, LO; Kohli, RS; Lahiri, A; Raftery, EB; Rodrigues, EA, 1987) |
| "The antianginal efficacy of nitroglycerin (NTG), given in a new transdermal therapeutic system (TTS), was compared with that of nifedipine and verapamil, both in slow-release (SR) formulation, in a randomized, double-blind, placebo-controlled study, carried out in 8 patients with stable exercise-induced angina pectoris." | 5.06 | Effects of a transdermal patch system containing nitroglycerin on exercise tolerance in patients with angina pectoris. Double-blind, placebo controlled, comparison with slow-release nifedipine and verapamil. ( De Ponti, C; Gibelli, G; Mazzocchi, F; Negrini, M; Pollavini, P; Prina, L, 1986) |
| "The comparative effects of prolonged chronic therapy with diltiazem, nicardipine, tiapamil and verapamil on exercise tolerance, ST-segment changes and heart rate were examined in 63 patients with established chronic stable angina pectoris." | 5.06 | Comparative effects of prolonged therapy with four calcium ion antagonists (diltiazem, nicardipine, tiapamil and verapamil) in patients with chronic stable angina pectoris. ( Khurmi, NS; Raftery, EB, 1987) |
| "The effectiveness of a sustained-release preparation of verapamil (verapamil-SR) was compared with the regular formulation of verapamil and with placebo in 12 patients with chronic stable angina pectoris." | 5.06 | Efficacy of sustained-release verapamil in chronic stable angina pectoris. ( Cutler, SS; Klein, MD; Weiner, DA, 1987) |
| "To examine the effects of chronic oral therapy with verapamil, 120 mg three times a day, and nifedipine, 20 mg four times daily, on left ventricular ejection fraction and regional wall motion at rest and exercise, 10 patients with chronic stable angina pectoris underwent serial rest and exercise radionuclide angiography." | 5.06 | Improved left ventricular performance during exercise with verapamil or nifedipine in patients with chronic stable angina. ( Cairns, JA; Gill, JB; McEwan, MP, 1987) |
| "The efficacy and effect on cardiac function of verapamil 120 mg three times a day and atenolol 100 mg once a day, singly and in combination, were evaluated in 15 patients with angina pectoris." | 5.06 | A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris. ( Aitchison, T; Dargie, HJ; Elliott, AT; Findlay, IN; Gillen, G; MacLeod, K, 1987) |
| "Nifedipine, diltiazem and verapamil are three effective calcium-antagonists in the treatment of angina pectoris." | 5.06 | [Comparative evaluation using an ergometric test of the efficacy of the 3 major calcium antagonists on exertion stable angina]. ( Acanfora, D; Artiaco, D; Cicatiello, M; Covelluzzi, F; De Caprio, L; De Rosa, ML; Papa, M; Rengo, F; Santangelo, L, 1987) |
| "The efficacy of verapamil (360 mg daily) in the treatment of patients with chronic stable angina pectoris was compared with placebo." | 5.05 | Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise. ( Lahiri, A; Paramasivan, R; Raftery, EB; Subramanian, VB, 1980) |
| " In a double blind cross-over study the effect of verapamil (Isoptin) 360 mg/d and propranolol 180 mg/d was evaluated in patients with stable angina pectoris." | 5.05 | Verapamil and beta-adrenoceptor blockade in the treatment of stable angina pectoris. ( Grytter, C; Hansen, JF; Sigurd, B; Thomsen, S, 1982) |
| "The effectiveness and safety of the beta-adrenergic blocking agent propranolol and the calcium channel antagonist verapamil were compared in 22 patients with chronic stable angina pectoris using a double-blind randomized placebo-controlled crossover protocol." | 5.05 | Calcium channel blockade as primary therapy for stable angina pectoris. A double-blind placebo-controlled comparison of verapamil and propranolol. ( Bowles, MJ; Davies, AB; Raftery, EB; Subramanian, VB, 1982) |
| "The relative efficacies of oral verapamil, a calcium-entry blocking drug, and propranolol, a beta-adrenergic blocking drug, were compared in 12 patients who had both stable angina pectoris and mild to moderate systemic hypertension, using a placebo-controlled, double-blind, randomized crossover protocol." | 5.05 | Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris. A placebo-controlled double-blind randomized crossover trial. ( Frishman, WH; Klein, NA; Klein, P; LeJemtel, TH; Pollack, S; Roth, S; Sonnenblick, EH; Strair, R; Strom, JA; Tawil, R; Wong, B, 1982) |
| "The efficacy of two beta-receptor antagonists, propranolol and pindolol, was compared with that of a calcium antagonist, verapamil, in the treatment of exertional angina pectoris in 22 men (mean age 51 years)." | 5.05 | The clinical and hemodynamic effects of propranolol, pindolol and verapamil in the treatment of exertional angina pectoris. ( Johnston, DL; Kostuk, WJ; Manyari, DE, 1984) |
| "The long-term efficacy and safety of high-dose verapamil therapy (480 mg/day) was assessed in 26 patients with chronic stable angina pectoris during a 3-phase protocol: Phase 1--an initial, 6-week placebo-controlled, double-blind crossover assessment; Phase 2--an open label, 1-year follow-up; and Phase 3--a final drug withdrawal and rechallenge 10-week study." | 5.05 | Efficacy and safety of verapamil in patients with angina pectoris after 1 year of continuous, high-dose therapy. ( Creager, MA; Cutler, SS; Klein, MD; McCabe, CH; Ryan, TJ; Weiner, DA, 1983) |
| "Propranolol (240 mg daily) and verapamil (360 mg daily) were objectively compared for their respective efficacy in the treatment of chronic stable angina pectoris." | 5.05 | Double-blind randomized crossover trial of verapamil and propranolol in chronic stable angina. ( Bala Subramanian, V; Bowles, MJ; Davies, AB; Raftery, EB, 1983) |
| "In 12 male patients with angiographically confirmed coronary heart disease and stable angina the antianginal effects of 50 mg Gallopamil have been studied in comparison with 10 mg Nifedipine and placebo." | 5.05 | [Anti-angina effect of gallopamil in comparison with another calcium antagonist and a placebo]. ( Drews, H; Hopf, R; Kaltenbach, M, 1984) |
| "The orthostatic changes in heart rate (HR) and blood pressure (BP) were recorded in ten patients with stable angina pectoris before and after simultaneous sublingual nitroglycerin administration." | 5.05 | Orthostatic response before and after nitroglycerin in metoprolol- and verapamil-treated angina pectoris. ( Hyldstrup, L; Mogensen, NB; Nielsen, PE, 1983) |
| "The effects of the calcium-channel-blocking agent Gallopamil (D 600) were assessed in 20 patients with stable exertional angina pectoris in a randomized placebo-controlled double-blind protocol using serial exercise tests." | 5.05 | [Acute and long-term effects of gallopamil (D 600) in stable angina pectoris--a randomized double-blind study]. ( Bette, L; Rettig, G; Schieffer, H; Sen, S, 1983) |
| " Both verapamil and propranolol caused a significant reduction in nitroglycerin consumption, days with angina pectoris and in severe angina attacks as compared to placebo." | 5.05 | Verapamil or propranolol in the treatment of stable angina pectoris of effort. ( Hansen, JF; Sigurd, B, 1984) |
| "The effectiveness of verapamil in the management of patients with unstable angina pectoris associated with obstructive coronary artery disease was evaluated in 2 double-blind placebo-controlled randomized clinical trials." | 5.05 | Verapamil therapy for unstable angina pectoris: review of double-blind placebo-controlled randomized clinical trials. ( Conti, CR; Mehta, J, 1982) |
| "The effectiveness and safety of verapamil, nifedipine, and placebo in patients with chronic stable angina pectoris were evaluated and compared in two double-blind randomized crossover trials." | 5.05 | Rationale for the choice of calcium antagonists in chronic stable angina. An objective double-blind placebo-controlled comparison of nifedipine and verapamil. ( Bowles, MJ; Davies, AB; Khurmi, NS; Raftery, EB; Subramanian, VB, 1982) |
| "Plasma levels of verapamil and norverapamil were evaluated in 77 patients who received oral verapamiL for treatment of angina pectoris." | 5.05 | Clinical relevance of verapamil plasma levels in stable angina pectoris. ( Frishman, W; Hillis, LD; Johnson, SM; Kates, R; Kirsten, E; Klein, M; Packer, M; Pine, M, 1982) |
| "To assess the efficacy and safety of verapamil in variant angina pectoris, we entered 16 patients in a double-blind, randomized trial of nine months, duration." | 5.05 | A controlled trial of verapamil for Prinzmetal's variant angina. ( Hillis, LD; Johnson, SM; Mauritson, DR; Willerson, JT, 1981) |
| "To assess the effects of verapamil and nifedipine on left ventricular function at rest and during exercise in patients with Prinzmetal's variant angina pectoris, 10 patients (6 men and 4 women with a mean age of 52 years) with variant angina were each treated for 2 months periods with placebo, verapamil (400 +/- 80 mg/day, mean +/- standard deviation [SD]) and nifedipine (82 +/- 31 mg/day)." | 5.05 | Effect of verapamil and nifedipine on left ventricular function at rest and during exercise in patients with Prinzmetal's variant angina pectoris. ( Corbett, J; Dehmer, GJ; Hillis, LD; Johnson, SM; Lewis, SE; Mauritson, DR; Willerson, JT, 1981) |
| "The long-term efficacy of verapamil in a dose of 360 mg daily in patients with chronic stable angina pectoris was assessed by quantitated serial treadmill exercise tests." | 5.05 | Long-term antianginal action of verapamil assessed with quantitated serial treadmill stress testing. ( Bowles, M; Davies, AB; Lahiri, A; Raftery, EB; Subramanian, B, 1981) |
| "Ten men with stable angina pectoris not fully relieved by optimal doses of propranolol (mean 218 mg daily) were given a single oral dose of 120 mg verapamil or a placebo on alternate mornings; the order of treatment was double blind." | 5.05 | Additive antianginal effect of verapamil in patients receiving propranolol. ( Bassan, M; Shalev, O; Weiler-Ravell, D, 1982) |
| "The effects of verapamil were assessed in 26 patients with stable exertional angina pectoris in a double-blind, placebo-controlled, randomized crossover protocol using serial treadmill tests." | 5.05 | Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled randomized crossover study. ( Brodsky, SJ; Cutler, SS; Klein, MD; McCabe, CH; Ryan, TJ; Weiner, DA, 1982) |
| " The efficacy of verapamil in a dose of 360 mg daily in patients with chronic stable angina pectoris was assessed by quantitative serial treadmill exercise tests and trinitrin consumption." | 5.05 | An objective comparison of verapamil and placebo in chronic stable angina. ( Balasubramanian, V; Raftery, EB, 1982) |
| "Clinical and exercise responses to therapy with the calcium-channel blocking agent verapamil were assessed in 26 patients with stable exertional angina pectoris using a double-blind, placebo-controlled, randomized crossover study design." | 5.05 | Verapamil therapy for stable exertional angina pectoris. ( Klein, MD; Weiner, DA, 1982) |
| "The clinical responses to 12 months' treatment with verapamil were evaluated in 63 patients with stable and unstable angina pectoris in whom the effectiveness of verapamil had been established in short-term double-blind placebo-controlled randomized clinical trials." | 5.05 | Long-term effectiveness of verapamil in stable and unstable angina pectoris. One-year follow-up of patients treated in placebo-controlled double-blind randomized clinical trials. ( Frishman, WH; Mehta, J; Packer, M; Parodi, O; Scheidt, S; Subramanian, VB, 1982) |
| "The potential hazards of abrupt withdrawal of propranolol have been described in patients with angina pectoris; however, the effects of abrupt withdrawal from long-term therapy with verapamil have not previously been investigated." | 5.05 | Comparative effects of abrupt withdrawal of propranolol and verapamil in angina pectoris. ( Cohen, MN; Frishman, WH; Iorio, L; Klein, N; Klein, P; LeJemtel, T; Pollack, S; Roth, S; Shamoon, H; Sonnenblick, EH; Strom, J; Willens, H, 1982) |
| "Because of recurrent chest pain, 17 patients with documented spasm in coronary arteries without severe atherosclerotic obstructions were treated with verapamil in an open trial, using doses of 120 mg/day to 480 mg/day (mean, 240 mg/day)." | 5.05 | Coronary spasm management with verapamil (Isoptin). ( Freedman, B; Kelly, DT; Richmond, DR, 1980) |
| "A double blind placebo-controlled study was performed in 12 patients with stable angina pectoris to evaluate the effects of oral verapamil (320 mg/day) on left ventricular function, as measured at rest and during exercise with gated equilibrium radionuclide ventriculography." | 5.05 | Verapamil in stable effort angina: effects on left ventricular function evaluated with exercise radionuclide ventriculography. ( Bautovich, G; Freedman, SB; Harris, PJ; Kelly, DT; Sadick, N; Tan, AT, 1982) |
| "This study was performed to compare the relative efficacies of propranolol and verapamil in patients with stable angina pectoris." | 5.05 | Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. ( Corbett, JR; Hillis, LD; Johnson, SM; Mauritson, DR; Willerson, JT; Woodward, W, 1981) |
| "The clinical and hemodynamic effects of propranolol, propranolol-verapamil (P-V), propranolol-nifedipine (P-N) and propranolol-diltiazem (P-D) were studied in 19 patients with chronic exertional angina pectoris." | 5.05 | Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris: a placebo-controlled, double-blind, randomized, crossover study. ( Humen, DP; Johnston, DL; Kostuk, WJ; Lesoway, R, 1985) |
| " The basis of this assumption was examined in a rest and exercise hemodynamic study of the effects of verapamil and the cardioselective beta-blocking drug, metoprolol, in 22 patients with stable angina pectoris and angiographically confirmed coronary artery disease." | 5.05 | The effects on left ventricular performance of verapamil and metoprolol singly and together in exercise-induced angina pectoris. ( Forsyth, D; Frais, MA; Hussain, M; Nelson, GI; Silke, B; Taylor, SH; Verma, SP, 1985) |
| "Because verapamil is effective in the treatment of "preinfarction" angina, a single-blind, placebo-controlled trial was performed in 17 patients admitted to the coronary care unit with transmural acute myocardial infarction (AMI) to assess the effects of verapamil on angina and reinfarction after AMI." | 5.05 | Effects of verapamil in preventing early postinfarction angina and reinfarction. ( Crea, F; Crean, P; Davies, G; Deanfield, J; Maseri, A; Sharom, M, 1985) |
| "To evaluate the effects of calcium entry blocking agents on cardiac sympathetic tone during angina pectoris, arterial and coronary sinus (CS) norepinephrine (NE) and epinephrine (E) concentrations and CS blood flow were determined at rest and during pacing-induced angina, both before and after verapamil in nine patients and after nifedipine in nine patients, all of whom had fixed obstructive coronary artery disease." | 5.05 | Myocardial catecholamine balance during angina: effects of calcium entry blockers, verapamil and nifedipine. ( Chatterjee, K; Curran, D; Kramer, P; Namekawa, M; Parmley, WW; Rouleau, JL; Swedberg, K, 1985) |
| "In thirteen patients with coronary insufficiency and angina pectoris the therapeutic effects of verapamil, 80 mg three times/day and practolol, 100 mg three times/day, were compared and tested against placebo in a double-blind cross-over fashion." | 5.04 | Double-blind comparison of verapamil and practolol in the treatment of angina pectoris. ( Fagher, B; Persson, S; Svensson, SE, 1977) |
| "The efficacy and duration of the effects of verapamil on angina threshold during exercise were examined in five patients with proved angina pectoris, with the experimental model of a latin square 5 X 5." | 5.04 | [The effects of verapamil on angina threshold during exercise (author's transl)]. ( Ciliberto, R; De Ponti, C; Foti, FA; Rovelli, F; Sozzi, G, 1976) |
| "In the treatment of angina pectoris a double-blind evaluation of verapamil (Cordilox) at two dose levels-namely, 80 mg thrice daily and 120 mg thrice daily-propranolol (Inderal) 100 mg thrice daily, and isosorbide dinitrate (Vascardin) 20 mg thrice daily has been made against a placebo." | 5.04 | Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris. ( Campbell, RC; Catley, PF; Livesley, B; Oram, S, 1973) |
| "In all patients combined, the incidence of constipation (13% vs 2%), dizziness (6% vs 2%), and back pain (3% vs 1%) was higher in patients treated with COER verapamil than with placebo." | 4.81 | Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease. ( Anders, RJ; Black, HR; Elliott, WJ; Johnson, MF; White, WB, 2001) |
| "Based on over 4,000 person-years of observation, patients with acute myocardial infarction (MI) treated with verapamil had a decreased risk of nonfatal reinfarction compared with placebo (relative risk 0." | 4.80 | Verapamil use in patients with cardiovascular disease: an overview of randomized trials. ( Faich, G; Makuch, R; Pepine, CJ, 1998) |
| "Verapamil is well tolerated in patients with stable and unstable angina pectoris, as well as in patients with threatened infarction." | 4.80 | Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trials. ( Jespersen, CM, 1999) |
| "Verapamil is well tolerated in patients with stable and unstable angina pectoris, as well as in patients with threatened infarction." | 4.80 | Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trials. ( Jespersen, CM, 2000) |
| "The present review discusses the prognostic significance of post-infarction angina pectoris, and the significance of post-infarction intervention with verapamil on the prevalence of post-infarction ischaemia and prognosis." | 4.79 | Anti-ischaemic intervention with verapamil in patients recovering from acute myocardial infarction. ( Jespersen, CM, 1995) |
| "Sustained-release Verapamil is suitable for treatment of angina pectoris." | 4.78 | [Isoptin Retard. Pharmacokinetics and pharmacodynamics in patients with angina pectoris]. ( Jespersen, CM, 1990) |
| " Although nifedipine is highly effective against vasospastic angina, its use in threatened myocardial infarction or severe unstable angina is not supported by recent studies, unless combined with a beta-blocker." | 4.77 | Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials. ( Opie, LH, 1988) |
| "Sustained-release diltiazem (D-SR) and sustained-release verapamil (V-SR) when given twice a day have been successfully used to treat both essential hypertension and angina pectoris." | 4.77 | Treatment of angina pectoris and hypertension with sustained-release calcium channel-blocking drugs. ( Klein, MD; Weiner, DA, 1987) |
| " Verapamil is extremely effective in patients with supraventricular tachyarrhythmias, hypertrophic cardiomyopathy, and the various anginal syndromes, but it appears to be ineffective or possibly even deleterious in those with pulmonary hypertension, congestive heart failure of any cause, and Raynaud's phenomenon or disease." | 4.77 | Calcium antagonists in patients with cardiovascular disease. Current perspectives. ( Hillis, LD; Winniford, MD, 1985) |
| " Nifedipine and diltiazem are effective in the relief of angina, and verapamil is used in the treatment of supraventricular tachyarrhythmias." | 4.77 | Calcium channel blocking agents: physiologic basis of nursing intervention. ( Touloukian, JE, 1985) |
| " Concomitant verapamil therapy for hypertension did not prevent the vasospastic effects of dihydroergotamine." | 3.77 | Dihydroergotamine-induced vasospastic angina in a patient taking a calcium channel blocker. ( Johnson, BD; Schenkat, DH; Schulz, LT, 2011) |
| " The pharmacokinetics of verapamil and of one of its metabolites, norverapamil, is changed after multiple oral dosing as has been described in patients with supraventricular tachyarrhythmias, angina pectoris or in patients with essential hypertension." | 3.76 | Pharmacokinetics of calcium channel blocking agents. ( Anderson, P, 1986) |
| " The higher dosage of verapamil prolonged the P-R interval (p less than 0." | 3.75 | Anti-anginal effect of oral verapamil: evidence of dose-dependence of the effect. ( Barbieri, E; Olivieri, D; Righetti, B; Rossi, L; Sheiban, I; Trevi, GP; Zanolla, L, 1983) |
| "In a prospective study of 809 patients with stable angina pectoris randomized to receive metoprolol or verapamil, a subgroup of 69 diabetic patients was compared with non-diabetic patients with respect to the risk of cardiovascular (CV) death, non-fatal myocardial infarction (MI) and revascularization." | 3.73 | The impact of diabetes or elevated fasting blood glucose on cardiovascular prognosis in patients with stable angina pectoris. ( Björkander, I; Forslund, L; Held, C; Hjemdahl, P; Rehnqvist, N, 2005) |
| "To study the dose-ranging population pharmacokinetics of controlled release verapamil in healthy subjects and patients with angina or hypertension." | 3.71 | Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina. ( Aarons, L; Gupta, S; Ho Pl, PL; Modi, NB; Sathyan, G, 2002) |
| "The intracardiac hemodynamics was studied in 33 patients with exertional angina pectoris undergoing an acute drug test with verapamil (n-15) and nifedipine (n-18) by using radionuclide ventriculography both at rest and during exercise." | 3.68 | [Anti-anginal effects of calcium antagonists and intra-cardiac hemodynamics]. ( Malov, AG; Mazur, NA; Rubanovich, AI; Sergienko, VB; Sumarokov, AB; Zeĭnalov, FI, 1991) |
| "Efficacy and tolerance of gallopamil (Procorum) were investigated over a period of 1 year under practice conditions in a total of 455 patients (254 male, 201 female), aged 62 years (male) and 66 (female) on an average, with electrocardiographically confirmed coronary heart disease." | 3.67 | [Multicenter long-term study of gallopamil in patients with coronary heart disease]. ( Schiemann, J; Sućić, M, 1984) |
| " The haemodynamic effects of equivalent hypotensive doses of nifedipine and verapamil were therefore compared in 20 patients with severe angina pectoris associated with angiographically documented coronary artery disease." | 3.67 | The effects on left ventricular performance of nifedipine and verapamil in exercise-induced angina pectoris. ( Ahuja, RC; Hussain, M; Nelson, GI; Silke, B; Taylor, SH; Verma, SP, 1984) |
| "The daily ECG monitoring was used in 20 patients with stable functional class II-III angina pectoris to study the antianginal and anti-ischemic effects of verapamil and nifedipine during the cross use of the drugs." | 3.67 | [Evaluation of the efficacy of a course of verapamil and nifedipine in patients with stable stenocardia by daily monitoring of the electrocardiogram]. ( Bochkareva, EV; Kokurina, EV; Metelitsa, VI; Urumbaev, RK; Vodop'ianova, RS, 1989) |
| "In a 67-year-old man with multiple myocardial infarctions in the past, the use of oral verapamil for control of angina pectoris was followed by the appearance of two previously undiagnosed abnormalities, namely, a dual-pathway AV node conduction pattern, and paroxysms of AV nodal reentrant tachycardia precipitated by premature ventricular beats (PVB)." | 3.67 | Verapamil-mediated atrioventricular nodal reentrant tachycardia and the uncovering of dual-pathway AV nodal conduction. ( Massumi, RA; Udhoji, VN, 1988) |
| " The pharmacokinetics and pharmacodynamics of oral verapamil and propranolol were studied in patients with stable angina pectoris during chronic mono- and dual therapy." | 3.67 | The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ( Lennard, MS; McCourty, JC; Silas, JH; Tucker, GT, 1988) |
| "Verapamil has been shown to be effective in reducing the frequency of episodes of ischemic pain in patients with unstable angina pectoris, and to be more effective than beta-adrenoceptor antagonists in such patients." | 3.67 | Verapamil in unstable angina pectoris: failure to demonstrate a relationship between efficacy and plasma levels. ( Elliott, SL; Horowitz, JD; Powell, AC, 1988) |
| "Oxygen utilization, arterial and venous blood gas levels, hemodynamic values and exercise tolerance were compared before and after administration of propranolol and verapamil in 10 patients with stable angina pectoris." | 3.67 | Effect of propranolol and verapamil on oxygen utilization, acidosis and fatigue during exercise in stable angina pectoris. ( Anderson, SD; Devenish-Meares, S; Harris, PJ; Kelly, DT; Roubin, GS; Sadick, NA, 1987) |
| "Pharmacokinetics of verapamil and of its three primary metabolites [norverapamil, 2-(3,4-dimethoxyphenyl)-2-isopropyl-6-azaheptanitrile (D-617) and 2-(3,4-dimethoxyphenyl)-2-propylamino-3-methylbutyronitrile (D-260)] was studied after oral administration in 7 patients with stable angina pectoris." | 3.67 | Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris. ( Metelitsa, VI; Nikolenko, SA; Piotrovskii, VK; Riabokon, OS; Rumiantsev, DO, 1986) |
| "14 patients with effort induced angina pectoris were treated with a specific TxB2 inhibitor Dazoxiben or verapamil for two weeks with a wash-out period of 14 days between the two regimens." | 3.67 | Effect of specific thromboxane-synthetase inhibition on thromboxane and prostaglandin synthesis in stable angina induced by exercise test. ( Gormsen, J; Kjøller, E; Knudsen, JB; Mogensen, F; Rasmussen, V, 1985) |
| "We observed gingival hyperplasia, similar clinically to the hyperplasia caused by diphenylhydantoin during the last 11 months in two patients treated by verapamil, suffering from angina pectoris pains." | 3.67 | [Hypertrophic gingivitis caused by verapamil]. ( Cucchi, G; Giustiniani, S; Robustelli, F, 1985) |
| " Our previous results have now been reviewed, and they show that according to both subjective and objective criteria, nifedipine adds benefits to the action of propranolol in the management of chronic stable angina pectoris." | 3.66 | Calcium-channel blockers and beta blockers: advantages and disadvantages of combination therapy in chronic stable angina pectoris. ( Harris, L; Krikler, DM; Rowland, E, 1982) |
| "Verapamil is effective primary therapy for angina pectoris at a dosage of about 120 mg three times a day." | 3.66 | Calcium channel blocking drugs for chronic, stable angina. Verapamil. ( Kelly, DT, 1982) |
| "The cardioselective beta adrenoceptor blocking agent metoprolol was compared with the calcium antagonist verapamil in relation to effects on angina pectoris." | 3.66 | Comparison of metoprolol and verapamil in the treatment of angina pectoris. ( Arnman, K; Rydén, L, 1982) |
| " A long-term, open clinical trial of verapamil therapy was conducted in ninety-three patients with coronary artery disease, selected on the basis of having stable angina pectoris and of being unsuitable for treatment with beta-adrenoceptor blocking drugs." | 3.66 | Verapamil in the long-term treatment of angina pectoris. ( Raftos, J, 1982) |
| "Verapamil, a calcium antagonist used to treat angina pectoris, inhibits insulin release in vitro and, when administered intravenously to humans, decreases glucose tolerance." | 3.66 | Oral verapamil does not affect glucose tolerance in non-diabetics. ( Beastall, GH; Lorimer, AR; Semple, CG; Thomson, JA, 1983) |
| " We administered 40-, 80- and 120-mg doses of verapamil orally to 15 patients with angina pectoris who were receiving high doses of propranolol or metoprolol." | 3.66 | Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. ( Gorlin, R; Guererro, J; Holt, J; McAllister, RG; Medina, N; Meller, J; Packer, M; Smith, H; Todd, GD; Yushak, M, 1982) |
| "A 35-year-old man with class 2 angina pectoris was enlisted in a serial exercise test protocol to evaluate oral verapamil therapy for angina pectoris." | 3.66 | Suppression of ischemic related ventricular tachycardia by verapamil during treadmill exercise testing. ( Brodsky, SJ; Cutler, SS; Klein, MD; Weiner, DA, 1982) |
| "A long-term, open clinical trial of verapamil therapy was conducted in 93 patients with coronary artery disease, selected on the basis of having stable angina pectoris and of being unsuitable for treatment with beta-adrenergic blocking drugs." | 3.66 | Verapamil in the long-term treatment of angina pectoris. ( Raftos, J, 1980) |
| "Rapid and slow venous infusion of various doses of Verapamil in a mixed series of 185 cases of arrhythmia since 1968 is reported." | 3.65 | [Anti-arrhythmic therapy with verapamil by intravenous infusion]. ( Disertori, M; Furlanello, F; Lanzetta, T; Piccolo, E; Trevi, GP, 1975) |
| "Angina and hypertension are common in patients with coronary artery disease (CAD); however, the effect on mortality is unclear." | 2.78 | Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST). ( Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Pepine, CJ; Winchester, DE, 2013) |
| "This multicenter, randomized, double-blind, parallel group, placebo lead-in, placebo-controlled study compared the antianginal and anti-ischemic effects of once-daily bedtime dosing of controlled-onset extended-release (COER-24) verapamil to a once-daily morning dosing of amlodipine +/- atenolol in patients with chronic stable angina." | 2.69 | Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. ( Deedwania, PC; Fakouhi, TD; Frishman, WH; Glasser, S; Johnson, M; Stone, P, 1999) |
| "Fibrinogen and WBC were independent predictors of CV death or non-fatal MI as well as disease progression leading to revascularization in patients with stable angina pectoris." | 2.69 | Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm. ( Björkander, I; Forslund, L; Håkan Wallén, N; Held, C; Hjemdahl, P; Rehnqvist, N; Wiman, B, 2000) |
| " This verapamil formulation can be clinically titrated within a 180 to 540 mg dosing range, permitting effective once-daily administration for the treatment of chronic stable angina." | 2.68 | Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. ( Anders, RJ; Awan, NA; Bultas, J; Cutler, NR; Jhee, SS; Lahiri, A; Sramek, JJ; Woroszylska, M, 1995) |
| " Left ventricular ejection fractions at rest or exercise were not significantly changed following either acute intravenous (rest 33%; exercise 38%) or chronic oral dosing with verapamil (rest 35%; exercise 43%) when compared with placebo (rest 34%; exercise 42%)." | 2.67 | Low-dose verapamil in middle-aged and elderly patients with angina pectoris: no evidence of increased susceptibility to the cardiac effects. ( Ahmed, JH; Elliott, HL; Meredith, PA; Reid, JL, 1992) |
| "The response to verapamil alone and combined with isosorbide dinitrate in a group of 12 patients with severe ischemic heart disease and stable effort angina was assessed by means of serial treadmill testing." | 2.66 | [Evaluation using serial exercise tests of verapamil alone and combined with isosorbide dinitrate in exertional angina]. ( Colman, T; González-Vílchez, F; Pajarón, A; Ruano, J; Vázquez de Prada, JA; Zueco, J, 1989) |
| "Treatment with Nifedipine significantly increased heart rate at rest (p less than 0." | 2.66 | [Comparative evaluation of 3 calcium antagonist drugs in patients with stable angina of effort. Double-blind placebo-controlled randomized study]. ( Buonamici, P; Buzzigoli, A; Fazzini, PF; Pucci, PD; Santoro, GM; Sarro, F, 1987) |
| " In 2 patients, verapamil caused weakness, lightheadedness, and severe sinus bradycardia (40 to 48 beats/min), and the dosage was reduced (blindly) to 240 mg/day, with the alleviation of bradycardia and associated symptoms." | 2.66 | Propranolol-verapamil versus propranolol-nifedipine in severe angina pectoris of effort: a randomized, double-blind, crossover study. ( Corbett, JR; Croft, CH; Fulton, KL; Hillis, LD; Winniford, MD, 1985) |
| "Verapamil is proving to be an important addition to existing drug regimens available for the treatment of stable angina pectoris." | 2.65 | Verapamil in treatment of chronic stable angina. ( Charlap, S; Frishman, WH, 1983) |
| "Twelve patients with variant angina combined with angina of effort were examined." | 2.65 | [Comparative study of the effectiveness of korinfar, izoptin and obzidan in patients with variant stenocardia combined with effort stenocardia]. ( Borisova, GA; Peres Peres, A; Shevchenko, OP; Sidorenko, BA, 1984) |
| " Adverse effects were few and consisted primarily of mild constipation in six patients taking verapamil, and pedal edema and transient flushing in 2 patients each using diltiazem." | 2.65 | The efficacy and safety of high-dose verapamil and diltiazem in the long-term treatment of stable exertional angina. ( Cutler, SS; Klein, MD; McCabe, CH; Ryan, TJ; Weiner, DA, 1984) |
| " In this dosage nifedipine did not show any significant change in exercise duration and the variables obtained using computer assisted exercise testing when compared to placebo." | 2.65 | Evaluation of verapamil and high dose nifedipine in patients with chronic stable angina with objective methods. ( Bowles, MJ; Davies, AB; Khurmi, NS; Raftery, EB; Subramanian, VB, 1984) |
| "Verapamil is an effective primary therapy and a satisfactory alternative to propranolol in patients with stable effort angina." | 2.65 | A double-blind randomized trial of propranolol and verapamil in the treatment of effort angina. ( Fletcher, PJ; Kelly, DT; Morris, J; Sadick, NN; Tan, AT, 1982) |
| "Verapamil is an effective antianginal drug that appears most efficacious at a dose of 360 mg/day, but side effects are common at a dose of 480 mg/day." | 2.65 | Verapamil versus placebo in relieving stable angina pectoris. ( Bailly, DJ; Butman, S; Citron, PD; Landa, DW; Pine, MB; Plasencia, GO; Wong, RK, 1982) |
| " At the higher dosage verapamil produced a significant improvement in frequency of angina, trinitrin consumption, and exercise tolerance, and had a favourable and significant effect on the amount and duration of ischaemic S-T depression occurring in the electrocardiogram during exercise." | 2.63 | Clinical evaluation of verapamil in angina pectoris. ( Clayton, GA; Sandler, G; Thornicroft, SG, 1968) |
| "Verapamil has well proven efficacy in the treatment of patients with hypertension, and early studies indicated its efficacy in the treatment of coronary artery disease." | 2.39 | Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. ( Benfield, P; Brogden, RN, 1996) |
| " Diltiazem with a beta-blocker is usually well-tolerated, with a low incidence of adverse effects, similar to the experience with diltiazem monotherapy." | 2.37 | Combined use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina. Rationale, efficacy, and adverse effects. ( Parisi, AF; Strauss, WE, 1988) |
| "Treatment with nifedipine can safely be combined with administration of a beta receptor blocking agent." | 2.36 | Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. ( Henry, PD, 1980) |
| "Clinical experience in the treatment of hypertension with this class of agents is confined to verapamil, nifedipine, and diltiazem." | 2.36 | Calcium antagonists. Clinical use in the treatment of systemic hypertension. ( Frishman, WH; Ocken, S; Spivack, C, 1983) |
| "Amiodarone is an extremely potent drug which is effective for both supraventricular as well as ventricular arrhythmias." | 2.36 | New antiarrhythmic drugs. ( Hess, DS; Scheinman, MM, 1983) |
| "Verapamil is a novel antiarrhythmic and antianginal agent which, although introduced in 1962, has only recently gained prominence not only as a significant agent in cardiovascular therapeutics but also as a powerful tool to examine the nature of some of the biophysical phenomena at the membrane of cardiac and other excitable tissues." | 2.36 | Verapamil: a review of its pharmacological properties and therapeutic use. ( Ellrodt, G; Peter, CT; Singh, BN, 1978) |
| "Radial artery spasm is a frequent complication of the transradial approach for coronary angiography and angioplasty." | 1.32 | Evaluation of a spasmolytic cocktail to prevent radial artery spasm during coronary procedures. ( Eccleshall, SC; Kiemeneij, F; Laarman, G; Slagboom, T; Vajifdar, BU; van der Wieken, R, 2003) |
| "Verapamil was administered in a 50 micrograms/kg dose followed by 2 micrograms/kg/min infusion." | 1.30 | Calcium antagonists and prevention of ventricular fibrillation induced by transient or persistent ischemia. ( Aupetit, JF; Bui-Xuan, B; Evreux, JC; Faucon, G; Freysz, M; Timour, Q, 1997) |
| "Platelet thrombus formation and whole blood platelet aggregation were measured in 18 stable coronary patients on three separate occasions: at baseline when receiving no active medications, after 7 days of receiving oral verapamil SR (240 mg/d), and after 7 days of receiving a combination of oral verapamil SR and aspirin (325 mg/d)." | 1.29 | Oral verapamil inhibits platelet thrombus formation in humans. ( Hung, J; L-Lacoste, L; Lam, JY; Waters, D, 1994) |
| " The calcium antagonist finoptin used in combination with alpha-tocopherol made it possible to decrease lipid hydroperoxide levels in low density lipoproteins and malondialdehyde concentrations in platelets, to prevent abnormal cyclic nucleotide metabolism in them and to increase tolerance to physical exercise." | 1.28 | [Effect of alpha-tocopherol combined with finoptin on the level of lipid hydroperoxides in plasma lipoproteins and on the functional activity of thrombocytes in patients with exertion-induced stable stenocardia]. ( Boklashchuk, MN; Gereliuk, IP; Levchenklo, VA; Serediuk, NN; Vakaliuk, IP, 1989) |
| "Verapamil plasma level was 149 +/- 1076 ng/ml; there was no significant correlation with the percentage variations of the echocardiographic parameters." | 1.28 | [Variations in left ventricular function during chronic therapy with verapamil in angina patients. Influence of the plasma concentration of the drug. Quantitative M-mode echocardiographic analysis]. ( Golia, G; Marino, P; Padrini, R; Prioli, MA; Zanolla, L; Zardini, P, 1989) |
| "Verapamil treatment increased the E/A-ratio to 1." | 1.28 | Effects of verapamil on left ventricular relaxation and filling dynamics in coronary artery disease: a study by pulsed Doppler echocardiography. ( Myhre, E; Myreng, Y, 1989) |
| "Nifedipine is a strong calcium antagonist; it blocks the excitation-contraction coupling, yet at therapeutic dosage levels it has few side effects." | 1.27 | What is preferable in unstable angina, beta-blockade or calcium-inhibition? ( Hugenholtz, PG; Serruys, PW; Simoons, ML, 1983) |
| " These results suggest that the chronic administration of calcium antagonists, at the usual therapeutic doses, does not effect the process of stimulus-secretion coupling of anterior pituitary hormones, ruling out any impairment of the related target glands which have been expected on the basis of previous studies." | 1.27 | Lack of inhibition of anterior pituitary hormone release during chronic treatment with calcium antagonists. ( Bigi, F; D'Armiento, M; de Cristofaro, AM; Greco, V; Pontecorvi, A; Reda, G, 1984) |
| "As an aid to clinical therapeutic decisions, the haemodynamic dose-response effects following intravenous verapamil were evaluated in ten male patients with angiographically confirmed and stable coronary artery disease." | 1.27 | Haemodynamic dose-response effects of i.v. verapamil in coronary artery disease. ( Ahuja, RC; Hussain, M; Nelson, GI; Silke, B; Taylor, SH; Verma, SP, 1984) |
| "Verapamil was found to be a more effective antianginal drug than nifedipine." | 1.27 | [Comparative effectiveness of finoptin, corinfar and their combination in patients with angina pectoris]. ( Mazur, NA; Romakov, AIu; Sagirov, AM; Sumarokov, AB, 1984) |
| " When the relationship between serum concentration at the end of the dosing interval and angina frequency was studied, it was observed that patients in whom angina was completely suppressed had concentrations greater than 160 ng/ml and patients with poor control (greater than 5 anginal episodes per week) had concentrations less than 60 ng/ml." | 1.27 | Pharmacokinetics of verapamil and norverapamil during long-term oral therapy. ( Lopez, LL; Mehta, J; Pieper, JA; Tartaglione, TA, 1983) |
| "They also have great potential for the treatment of hypertension, cerebrovascular disorders, and Raynaud's phenomenon." | 1.27 | Calcium channel blocking drugs. Part II: Clinical applications. ( Brill, DM; Fozzard, HA, 1985) |
| " However, as dosage adjustment and close observation may be necessary to minimise side effects, the use of this combination should be limited to hospital practice." | 1.27 | Tolerability of combined treatment with verapamil and beta-blockers in angina resistant to monotherapy. ( McGourty, JC; Silas, JH; Solomon, SA, 1985) |
| "Verapamil has the same anti-anginal effect during exercise as beta-adrenoceptor blockers but has the advantage of increasing rather than decreasing the cardiac output and so fatigue both at rest and exercise commonly seen with beta-adrenoceptor blockers is not found with verapamil." | 1.27 | Verapamil in angina pectoris. ( Kelly, DT, 1986) |
| "Patients with unstable angina pectoris exhibited signs of platelet activation, i." | 1.27 | [Unstable stenocardia: indicators of platelet activity and the effect of verapamil]. ( Chikvashvili, DI; Gratsianskiĭ, NA; Masenko, VP, 1987) |
| "When verapamil was injected a dose-dependent vasodilation was observed, which began to be significant with doses higher than 250 micrograms." | 1.27 | Dose-response scrutiny of coronary vasodilation after intracoronary verapamil in man. A quantitative cineangiographic study. ( De Nes, DM; L'Abbate, A; Michelassi, C; Parodi, O; Simonetti, I; Trivella, MG, 1986) |
| "Verapamil elimination was also found to be impaired after chronic dosing as compared to single administration." | 1.27 | The effect of oral verapamil therapy on antipyrine clearance. ( Kokurina, EV; Metelitsa, VI; Piotrovskii, VK; Riabokon, OS; Rumiantsev, DO; Slastnikova, ID, 1986) |
| "Coronary spasm is due to strong contraction of coronary vascular smooth muscle cells which is triggered by an increase of intracellular calcium ions; hyperventilation plus TRIS-buffer infusion induces coronary spasm by decreasing hydrogen ions which antagonize the action of calcium ions." | 1.26 | Pathophysiology and treatment of coronary arterial spasm. ( Yasue, H, 1980) |
| "Nitroglycerin was well suited for treatment of acute attacks." | 1.26 | Prinzmetal's variant angina. ( Efsen, F; Sandøe, E; Vilhelmsen, R, 1981) |
| "In 10 patients with stress stenocardia pharmacodynamics of Isoptin was studied with the aid of identical physical loads on the treadmill repeated with an hour's interval for 5-6 hours." | 1.26 | [Calcium antagonists in stress angina pectoris (pharmacodynamic study)]. ( Metelitsa, VI; Nikolenko, SA; Savvateev, KL; Shinbaeva, NA, 1982) |
| "Nifedipine was effective in all 5 cases with coronary stenosis of more than 75." | 1.26 | Effects of calcium antagonists, especially nifedipine, on variant angina, resting angina, and unstable angina. ( Hayakawa, H; Kimura, E; Kishida, H; Kusama, Y; Otsu, F; Takayama, M, 1982) |
| "Verapamil is a new anti-anginal and anti-arrhythmic drug whose pharmacological actions can be related to its specific blocking effect on the transmembrane transport of calcium ions." | 1.25 | Verapamil and the heart: Pharmacological and Therapeutic Considerations. ( DPhil, BN, 1975) |
| "Verapamil was administered i." | 1.25 | [Venous infusion of nerapamil in the treatment of refractory angina pectoris and arrhythmia due to associated electric instability]. ( Furlanello, F; Lanzetta, T; Pascotto, P; Piccolo, E; Trevi, GP, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 443 (81.28) | 18.7374 |
| 1990's | 69 (12.66) | 18.2507 |
| 2000's | 26 (4.77) | 29.6817 |
| 2010's | 6 (1.10) | 24.3611 |
| 2020's | 1 (0.18) | 2.80 |
| Authors | Studies |
|---|---|
| Pavão, RB | 1 |
| Moreira, HT | 1 |
| Pintya, AO | 1 |
| Haddad, JL | 1 |
| Badran, AV | 1 |
| Lima-Filho, MO | 1 |
| Lago, IM | 1 |
| Chierice, JRA | 1 |
| Schmidt, A | 1 |
| Marin-Neto, JA | 1 |
| Peeters, LEJ | 1 |
| den Uil, CA | 1 |
| Feyz, L | 1 |
| van den Bemt, PMLA | 1 |
| Daemen, J | 1 |
| Versmissen, J | 1 |
| Winchester, DE | 1 |
| Cooper-Dehoff, RM | 1 |
| Gong, Y | 1 |
| Handberg, EM | 1 |
| Pepine, CJ | 7 |
| Halna du Fretay, X | 1 |
| Mohammed Saeed, D | 1 |
| Benamer, H | 1 |
| Bangalore, S | 1 |
| Messerli, FH | 1 |
| Cohen, JD | 1 |
| Bacher, PH | 1 |
| Sleight, P | 1 |
| Mancia, G | 1 |
| Kowey, P | 1 |
| Zhou, Q | 1 |
| Champion, A | 1 |
| Hajlaoui, N | 1 |
| Tarragano, F | 1 |
| Raisky, P | 1 |
| Beaufils, P | 1 |
| Henry, P | 1 |
| Björkander, I | 12 |
| Forslund, L | 14 |
| Ericson, M | 3 |
| Rehnqvist, N | 17 |
| Hjemdahl, P | 16 |
| Kahan, T | 3 |
| Schroeder, D | 1 |
| Saada, D | 1 |
| Rafaa, M | 1 |
| Ingen-Housz-Oro, S | 1 |
| Valeyrie-Allanore, L | 1 |
| Sigal, ML | 1 |
| Schenkat, DH | 1 |
| Schulz, LT | 1 |
| Johnson, BD | 1 |
| Cheung, BM | 1 |
| Kumana, CR | 1 |
| Tsubokawa, A | 1 |
| Ueda, K | 1 |
| Sakamoto, H | 1 |
| Iwase, T | 1 |
| Tamaki, S | 1 |
| Kiemeneij, F | 1 |
| Vajifdar, BU | 1 |
| Eccleshall, SC | 1 |
| Laarman, G | 1 |
| Slagboom, T | 1 |
| van der Wieken, R | 1 |
| Beltrame, JF | 1 |
| Turner, SP | 1 |
| Leslie, S | 1 |
| Horowitz, JD | 2 |
| Oganov, RG | 1 |
| Lepakhin, VK | 1 |
| Fitilev, SB | 1 |
| Levin, AM | 1 |
| Titarova, YY | 1 |
| Sytchev, EN | 1 |
| HOFFMANN, P | 1 |
| Idrisova, EM | 1 |
| Stepacheva, TA | 1 |
| Borovkova, NV | 1 |
| Chernov, VI | 1 |
| Karpov, RS | 1 |
| Vorob'eva, EV | 1 |
| Poponina, IuS | 1 |
| Romero, M | 1 |
| Sánchez, I | 1 |
| Pujol, MD | 1 |
| Bochkareva, EV | 4 |
| Kokurina, EV | 6 |
| Voronina, VP | 1 |
| Kucheriavaia, NG | 1 |
| Butina, EK | 1 |
| Eriksson, SV | 7 |
| Held, C | 13 |
| Näsman, P | 2 |
| Chinushi, M | 1 |
| Tagawa, M | 1 |
| Nakamura, Y | 1 |
| Aizawa, Y | 1 |
| Kosicka, T | 1 |
| Kara-Perz, H | 1 |
| Głuszek, J | 1 |
| Perz, S | 1 |
| Almquist, T | 1 |
| Sinha, BC | 1 |
| Benthe, HF | 1 |
| Stone, KS | 1 |
| Scordo, KA | 1 |
| Opie, LH | 2 |
| Subramanian, VB | 11 |
| Lahiri, A | 10 |
| Paramasivan, R | 1 |
| Raftery, EB | 24 |
| Temkin, LP | 1 |
| Kimura, E | 2 |
| Kishida, H | 2 |
| Koide, T | 1 |
| Kakihana, M | 1 |
| Takabatake, Y | 1 |
| Iizuka, M | 1 |
| Uchida, Y | 1 |
| Ozeki, K | 1 |
| Morooka, S | 1 |
| Kato, A | 1 |
| Tanaka, S | 1 |
| Oya, T | 1 |
| Momomura, S | 1 |
| Murao, S | 1 |
| Mirams, JA | 1 |
| Oesterle, SN | 1 |
| Schroeder, JS | 2 |
| Kangilaski, J | 1 |
| McBride, G | 1 |
| Bolsen, B | 1 |
| Valentine, PA | 1 |
| Sutton, LD | 1 |
| Sloman, JG | 1 |
| Weser, C | 1 |
| Krikler, DM | 2 |
| Harris, L | 1 |
| Rowland, E | 3 |
| Hansen, JF | 9 |
| Grytter, C | 2 |
| Thomsen, S | 2 |
| Sigurd, B | 4 |
| Packer, M | 6 |
| Frishman, WH | 11 |
| Segal, BL | 1 |
| Kotler, MN | 1 |
| Iskandrian, AS | 1 |
| Bayer, R | 2 |
| Kaufmann, R | 1 |
| Rodenkirchen, R | 2 |
| Mannhold, R | 2 |
| Kelly, DT | 9 |
| Bowles, MJ | 9 |
| Davies, AB | 10 |
| Klein, NA | 2 |
| Klein, P | 3 |
| Strom, JA | 2 |
| Tawil, R | 1 |
| Strair, R | 1 |
| Wong, B | 1 |
| Roth, S | 2 |
| LeJemtel, TH | 2 |
| Pollack, S | 3 |
| Sonnenblick, EH | 3 |
| Banka, VS | 1 |
| Bodenheimer, MM | 1 |
| Helfant, RH | 1 |
| Sánchez Cascos, A | 1 |
| Espín, A | 1 |
| Ramírez, M | 1 |
| De Rábago, P | 1 |
| Hugenholtz, PG | 5 |
| Serruys, PW | 3 |
| Simoons, ML | 3 |
| Charlap, S | 4 |
| Meyer, J | 1 |
| Vanhaleweyk, GL | 1 |
| Johnston, DL | 3 |
| Manyari, DE | 1 |
| Kostuk, WJ | 4 |
| Kessler, H | 1 |
| Karlsberg, RP | 2 |
| Aronow, WS | 4 |
| Ellrodt, G | 2 |
| Chew, CY | 4 |
| Singh, BN | 5 |
| Henry, PD | 1 |
| Horwitz, DL | 1 |
| Hecht, HS | 2 |
| Burnam, MH | 1 |
| Hopkins, J | 1 |
| Schnugg, S | 1 |
| Zelis, R | 2 |
| Flaim, SF | 2 |
| Winniford, MD | 8 |
| Willerson, JT | 7 |
| Hillis, LD | 14 |
| Johnston, WE | 1 |
| Lowenstein, E | 1 |
| Bianchi, CP | 1 |
| Gebhardt, VA | 1 |
| Donald, A | 1 |
| Covinsky, JO | 1 |
| Hamburger, SC | 1 |
| Huxley, RL | 1 |
| Spivack, C | 2 |
| Ocken, S | 2 |
| Weiner, DA | 10 |
| McCabe, CH | 4 |
| Cutler, SS | 7 |
| Creager, MA | 1 |
| Ryan, TJ | 4 |
| Klein, MD | 10 |
| Manger Cats, V | 1 |
| Lie, KI | 1 |
| Zanolla, L | 3 |
| Righetti, B | 1 |
| Rossi, L | 1 |
| Barbieri, E | 1 |
| Sheiban, I | 1 |
| Olivieri, D | 2 |
| Trevi, GP | 4 |
| Bala Subramanian, V | 5 |
| Feldman, RL | 2 |
| Hill, JA | 2 |
| Conti, CR | 5 |
| Mehta, J | 6 |
| Hill, C | 1 |
| Scott, E | 1 |
| Tan, AT | 3 |
| Quek, S | 1 |
| Khurmi, NS | 6 |
| O'Hara, MJ | 2 |
| Breland, BD | 1 |
| Boland, MJ | 1 |
| Shevchenko, OP | 2 |
| Peres Peres, A | 1 |
| Borisova, GA | 1 |
| Sidorenko, BA | 2 |
| Katsenovich, RA | 1 |
| Kostko, SZ | 3 |
| Arifdzhanova, UA | 1 |
| Khashimov, KhA | 1 |
| Vakhidova, MA | 1 |
| Peres, AP | 1 |
| Hopf, R | 3 |
| Drews, H | 1 |
| Kaltenbach, M | 8 |
| Maclean, D | 1 |
| Feely, J | 1 |
| Scheinman, MM | 1 |
| Hess, DS | 1 |
| Carù, B | 4 |
| De Ponti, C | 7 |
| De Biase, AM | 2 |
| Parodi, O | 9 |
| Simonetti, I | 7 |
| L'Abbate, A | 9 |
| Severi, S | 2 |
| Capucci, A | 5 |
| Bassein, L | 1 |
| Bracchetti, D | 5 |
| Carini, G | 3 |
| Maresta, A | 5 |
| Magnani, B | 5 |
| Hyldstrup, L | 1 |
| Mogensen, NB | 1 |
| Nielsen, PE | 1 |
| Guarascio, P | 1 |
| D'Amato, C | 1 |
| Sette, P | 1 |
| Conte, A | 1 |
| Visco, G | 1 |
| Kroesen, P | 1 |
| Rettig, G | 1 |
| Sen, S | 1 |
| Schieffer, H | 1 |
| Bette, L | 1 |
| Lessem, J | 1 |
| D'Armiento, M | 1 |
| Pontecorvi, A | 1 |
| Bigi, F | 1 |
| de Cristofaro, AM | 1 |
| Reda, G | 1 |
| Greco, V | 2 |
| Brügmann, U | 1 |
| Blasini, R | 1 |
| Rudolph, W | 1 |
| McGourty, JC | 2 |
| Silas, JH | 3 |
| Carlens, P | 1 |
| Michels, R | 1 |
| Hope, RR | 1 |
| Lazzara, R | 1 |
| Eisenberg, JN | 1 |
| Oakley, GD | 1 |
| Shakarova, SSh | 2 |
| Martsevich, SIu | 3 |
| Metelitsa, VI | 12 |
| Vygodin, VA | 5 |
| Strel'tsov, AA | 2 |
| Silke, B | 5 |
| Verma, SP | 5 |
| Ahuja, RC | 2 |
| Nelson, GI | 3 |
| Hussain, M | 4 |
| Taylor, SH | 5 |
| Sagirov, AM | 4 |
| Romakov, AIu | 3 |
| Sumarokov, AB | 5 |
| Mazur, NA | 5 |
| de Jong, JW | 1 |
| Sućić, M | 1 |
| Schiemann, J | 1 |
| Rossi, LP | 1 |
| Antman, EM | 1 |
| Butler, JD | 1 |
| Harrison, BL | 1 |
| Walldius, G | 1 |
| Sadick, N | 2 |
| Roubin, GS | 2 |
| Harris, PJ | 3 |
| Hiroe, M | 1 |
| Meares, S | 1 |
| Bautovich, G | 2 |
| Mauritson, DR | 6 |
| Johnson, SM | 7 |
| Cary, JR | 2 |
| Galle, JS | 1 |
| Khadzhipetrov, N | 1 |
| Georgiev, S | 1 |
| Kapur, PA | 1 |
| Norel, E | 1 |
| Dajee, H | 1 |
| Cimochowski, G | 1 |
| Iurkova, VB | 1 |
| Josephson, MA | 1 |
| Leon, MB | 3 |
| Bonow, RO | 3 |
| Kieval, J | 2 |
| Rosing, DR | 3 |
| Becker, HJ | 1 |
| Kober, G | 1 |
| Dowinsky, S | 1 |
| Frishman, W | 1 |
| Kirsten, E | 2 |
| Klein, M | 1 |
| Pine, M | 1 |
| Kates, R | 1 |
| Southall, E | 1 |
| Nutt, NR | 1 |
| Thomas, RD | 1 |
| Piccolo, E | 6 |
| Cazzin, R | 3 |
| Sartori, F | 2 |
| Artusi, L | 2 |
| Pascotto, P | 4 |
| Scrutinio, D | 3 |
| Lagioia, R | 3 |
| De Toma, L | 3 |
| Mangini, S | 2 |
| Accettura, D | 2 |
| De Nicolò, M | 2 |
| Antuofermo, F | 1 |
| Rizzon, P | 2 |
| Di Ciò, G | 2 |
| Yasue, H | 1 |
| Davies, G | 2 |
| Maseri, A | 10 |
| Marzullo, P | 1 |
| Waters, DD | 4 |
| Szlachcic, J | 3 |
| Theroux, P | 5 |
| Dauwe, F | 3 |
| Mizgala, HF | 3 |
| Mauri, F | 4 |
| Ciliberto, GR | 3 |
| Parmasivan, R | 1 |
| Williams, DO | 1 |
| Corbett, J | 1 |
| Dehmer, GJ | 1 |
| Lewis, SE | 1 |
| Sandøe, E | 3 |
| Vilhelmsen, R | 2 |
| Efsen, F | 1 |
| Freeman, WR | 1 |
| Peter, T | 1 |
| Mandel, WJ | 1 |
| Subramanian, B | 3 |
| Bowles, M | 1 |
| Taams, M | 1 |
| Lubsen, J | 1 |
| Willens, H | 2 |
| Jentzer, J | 1 |
| Siegel, L | 1 |
| Kirschen, N | 1 |
| Silverman, R | 1 |
| Doyle, R | 1 |
| Arnman, K | 1 |
| Rydén, L | 1 |
| Bassan, M | 1 |
| Weiler-Ravell, D | 2 |
| Shalev, O | 2 |
| Spickett, GP | 1 |
| Brodsky, SJ | 3 |
| Raftos, J | 2 |
| Balasubramanian, V | 2 |
| Scheidt, S | 1 |
| Klein, N | 2 |
| Strom, J | 1 |
| Cohen, MN | 1 |
| Shamoon, H | 1 |
| Iorio, L | 1 |
| LeJemtel, T | 1 |
| Vincenzi, M | 1 |
| Braito, E | 1 |
| Cappelletti, F | 1 |
| Caponnetto, S | 1 |
| Distante, R | 1 |
| Masoni, A | 1 |
| Palmieri, M | 1 |
| Ricciardelli, B | 1 |
| Uslenghi, E | 1 |
| Zanini, S | 1 |
| Mazzei, MG | 2 |
| Biagini, A | 3 |
| Carpeggiani, C | 3 |
| Testa, R | 2 |
| Dipalma, JR | 1 |
| Zaret, GM | 1 |
| Martin, SS | 1 |
| Guerrero, JR | 2 |
| Allen, HB | 1 |
| Macdonald, G | 1 |
| Rouleau, JL | 2 |
| Chatterjee, K | 2 |
| Ports, TA | 1 |
| Doyle, MB | 1 |
| Hiramatsu, B | 1 |
| Parmley, WW | 2 |
| Shinbaeva, NA | 3 |
| Semple, CG | 1 |
| Thomson, JA | 1 |
| Beastall, GH | 1 |
| Lorimer, AR | 1 |
| Tartaglione, TA | 1 |
| Pieper, JA | 1 |
| Lopez, LL | 1 |
| Csik, V | 1 |
| Szekeres, L | 1 |
| Udvary, E | 1 |
| Bassan, MM | 1 |
| Albanese, C | 1 |
| Di Mario, F | 2 |
| Lumholtz, IB | 2 |
| Mortensen, SA | 1 |
| Zsotér, TT | 1 |
| Freedman, B | 2 |
| Richmond, DR | 2 |
| Check, WA | 1 |
| Dargie, H | 1 |
| Krikler, D | 2 |
| Ruedy, J | 1 |
| Parisi, AF | 2 |
| Strauss, WE | 2 |
| McIntyre, KM | 1 |
| Sasahara, AA | 1 |
| Day, M | 1 |
| Dawson, JR | 1 |
| Whitaker, NH | 1 |
| Sutton, GC | 1 |
| Freedman, SB | 2 |
| Sadick, NN | 1 |
| Fletcher, PJ | 1 |
| Morris, J | 1 |
| Pine, MB | 1 |
| Citron, PD | 1 |
| Bailly, DJ | 1 |
| Butman, S | 1 |
| Plasencia, GO | 1 |
| Landa, DW | 1 |
| Wong, RK | 1 |
| Schwartz, A | 1 |
| Low, RI | 1 |
| Takeda, P | 1 |
| Mason, DT | 1 |
| DeMaria, AN | 1 |
| Kirsten, EB | 1 |
| Kessler, KM | 1 |
| Mallon, SM | 1 |
| Myerburg, RJ | 1 |
| Meller, J | 1 |
| Medina, N | 1 |
| Yushak, M | 1 |
| Smith, H | 1 |
| Holt, J | 1 |
| Guererro, J | 1 |
| Todd, GD | 1 |
| McAllister, RG | 2 |
| Gorlin, R | 1 |
| Kuan, P | 1 |
| Reuben, SR | 1 |
| Gale, EV | 1 |
| Wilde, PM | 1 |
| Hasin, Y | 1 |
| Rod, JL | 1 |
| Lewis, BS | 1 |
| Gotsman, MS | 1 |
| Markham, RV | 1 |
| Firth, BG | 1 |
| Nicod, P | 1 |
| Ferlinz, J | 4 |
| Nikolenko, SA | 3 |
| Savvateev, KL | 2 |
| Otsu, F | 1 |
| Kusama, Y | 1 |
| Takayama, M | 1 |
| Hayakawa, H | 1 |
| Collett, JT | 1 |
| Millar Craig, MW | 1 |
| Novo, S | 2 |
| Davì, G | 1 |
| Riolo, F | 1 |
| Pinto, A | 1 |
| Avellone, G | 1 |
| Fazio, M | 1 |
| Dunn, RF | 1 |
| Michelassi, C | 4 |
| Antonelli, R | 1 |
| Lipson, LC | 1 |
| Epstein, SE | 2 |
| Corbett, JR | 2 |
| Woodward, W | 1 |
| Nayler, WG | 2 |
| Moraes, NL | 1 |
| Fiorelli, AI | 1 |
| Ribeiro, LF | 1 |
| Gomes, OM | 1 |
| Carbonin, PU | 1 |
| Di Gennaro, M | 1 |
| Lancelin, B | 1 |
| Blanchard, D | 1 |
| Aziza, JP | 1 |
| Guermonprez, JL | 1 |
| Maurice, P | 1 |
| Millar-Craig, M | 1 |
| Crawley, J | 1 |
| Turbow, ME | 2 |
| Vajola, SF | 1 |
| Romei, E | 2 |
| Lax, A | 1 |
| Jacovella, G | 2 |
| Gressier, M | 1 |
| Beaune, J | 1 |
| Amouroux, C | 1 |
| Delaye, J | 1 |
| Clermont, A | 1 |
| Mikaeloff, P | 1 |
| Estanove, S | 1 |
| Phaneuf, DC | 1 |
| Pelletier, G | 1 |
| Jespersen, CM | 10 |
| Cutler, NR | 1 |
| Anders, RJ | 2 |
| Jhee, SS | 1 |
| Sramek, JJ | 1 |
| Awan, NA | 1 |
| Bultas, J | 1 |
| Woroszylska, M | 1 |
| Wallén, NH | 3 |
| Mortensen, LS | 1 |
| el-Khoury, F | 1 |
| Maarek, M | 1 |
| Jean, M | 1 |
| Carrie, D | 1 |
| Foures, F | 1 |
| Elbaz, M | 1 |
| Ligou, V | 1 |
| Puel, J | 1 |
| Zhiberina, LA | 1 |
| Mukhitdinova, GN | 2 |
| Knyshov, GV | 2 |
| Vykhovaniuk, IV | 2 |
| Tkhor, NV | 2 |
| Furkalo, SN | 2 |
| Korchinskaia, OI | 2 |
| Wijnand, HP | 1 |
| L-Lacoste, L | 1 |
| Lam, JY | 1 |
| Hung, J | 1 |
| Waters, D | 1 |
| Acanfora, D | 2 |
| De Caprio, L | 2 |
| Di Palma, A | 1 |
| Lirato, C | 1 |
| Parlati, S | 1 |
| Furgi, G | 1 |
| Guerra, N | 1 |
| Odierna, L | 1 |
| Nicolino, A | 1 |
| Rengo, F | 3 |
| Simonelli, P | 1 |
| Papa, A | 1 |
| Macciocchi, B | 1 |
| Auriemma, F | 1 |
| Vetrano, A | 1 |
| Scaletta Romeo di Santillo, M | 1 |
| Ceriello, A | 1 |
| van Zwieten, PA | 1 |
| Pfaffendorf, M | 1 |
| Rusticali, G | 1 |
| Di Clemente, D | 1 |
| Ruggeri, A | 1 |
| Borghi, A | 2 |
| Bugiardini, R | 3 |
| Belin, A | 2 |
| Prost, PL | 1 |
| Mercadier, G | 1 |
| Grollier, G | 2 |
| Lablanche, JM | 1 |
| Wallén, H | 1 |
| Billing, E | 3 |
| Beuckelmann, DJ | 1 |
| Pimenov, LT | 1 |
| Ezhov, AV | 1 |
| Churshin, AD | 1 |
| Brogden, RN | 1 |
| Benfield, P | 1 |
| Wiman, B | 2 |
| Hauf-Zachariou, U | 1 |
| Blackwood, RA | 1 |
| Gunawardena, KA | 1 |
| O'Donnell, JG | 1 |
| Garnham, S | 1 |
| Pfarr, E | 1 |
| Timour, Q | 1 |
| Bui-Xuan, B | 1 |
| Aupetit, JF | 1 |
| Freysz, M | 1 |
| Evreux, JC | 1 |
| Faucon, G | 1 |
| Hagerup, L | 1 |
| Pedersen, F | 1 |
| Mellemgaard, K | 1 |
| Bjergaard, OP | 1 |
| Pitt, B | 1 |
| Brodin, U | 2 |
| Berglund, L | 1 |
| Angelin, B | 1 |
| Tiberti, G | 1 |
| Bossi, M | 1 |
| De Rosa, ML | 2 |
| Giordano, A | 1 |
| Melfi, M | 1 |
| Della Guardia, D | 1 |
| Ciaburri, F | 1 |
| Faich, G | 1 |
| Makuch, R | 1 |
| Gómez Pajuelo, C | 2 |
| Gómez Sánchez, MA | 1 |
| Delgado Jiménez, JF | 1 |
| Tascón Pérez, JC | 1 |
| Rodríguez Torras, ML | 1 |
| Sáenz de la Calzada, C | 1 |
| Glasser, S | 1 |
| Stone, P | 1 |
| Deedwania, PC | 1 |
| Johnson, M | 1 |
| Fakouhi, TD | 1 |
| Rajaratnam, R | 1 |
| Brieger, DB | 1 |
| Hawkins, R | 1 |
| Håkan Wallén, N | 1 |
| Hollenberg, NK | 1 |
| Williams, GH | 1 |
| Anderson, R | 1 |
| Zhiliaev, EV | 1 |
| Urzhumova, TV | 1 |
| Glazunov, AV | 1 |
| Sorokoletov, SM | 1 |
| Dzhanashiia, PKh | 1 |
| White, WB | 1 |
| Johnson, MF | 1 |
| Elliott, WJ | 1 |
| Black, HR | 1 |
| Gupta, S | 1 |
| Modi, NB | 1 |
| Sathyan, G | 1 |
| Ho Pl, PL | 1 |
| Aarons, L | 1 |
| Toyama, S | 1 |
| Suzuki, K | 1 |
| Arrigo, F | 1 |
| Coglitore, S | 1 |
| Virga, T | 1 |
| Giannetto, M | 1 |
| Bramanti, B | 1 |
| Melluso, C | 1 |
| Consolo, F | 1 |
| Sowton, E | 1 |
| Strano, A | 1 |
| Kukes, VG | 2 |
| Kniazev, MD | 1 |
| Borovkov, AI | 1 |
| Semenov, VN | 1 |
| Mamedova, AD | 1 |
| de Oliveira, JM | 1 |
| Eifert, J | 1 |
| Vohra, JK | 1 |
| Albuquerque, DC | 3 |
| Schlesinger, P | 3 |
| Benchimol, CB | 3 |
| Albanesi, FM | 2 |
| Benchimol, AB | 3 |
| Castro, I | 1 |
| Pereira, FA | 1 |
| Rodrigues, R | 1 |
| Maranhão, MF | 1 |
| Lopes, M | 1 |
| Toledo, MT | 1 |
| Rojas, RI | 1 |
| Michelotto, PV | 2 |
| Lacerda, FS | 1 |
| Furlan, L | 1 |
| Cunha, GP | 1 |
| Oliveira, PF | 1 |
| Greif, S | 1 |
| Roth, F | 1 |
| Harnoncourt, K | 1 |
| Peter, CT | 1 |
| Galli, MA | 1 |
| Müller, R | 1 |
| Adjan, M | 1 |
| Easthope, JL | 1 |
| Chiavarelli, V | 1 |
| Vajola, FS | 1 |
| Schmidt, E | 1 |
| Most, E | 1 |
| Bender, F | 1 |
| Gradaus, D | 1 |
| Martiny, W | 1 |
| Bottone, W | 1 |
| Matta, F | 1 |
| Cerrone, G | 1 |
| Minelli, M | 1 |
| Angelino, PF | 1 |
| Johansson, BW | 1 |
| Breithaupt, H | 1 |
| Walter, P | 1 |
| de Brito, FS | 1 |
| Pereira, MH | 1 |
| Cherchi, A | 2 |
| Fonzo, R | 2 |
| Zambaldi, G | 1 |
| Micheli, E | 1 |
| Santoro, GM | 2 |
| Zerauschek, M | 1 |
| Fazzini, PF | 2 |
| De'Thomatis, M | 1 |
| Falciola, N | 1 |
| Gallesio, R | 1 |
| Fagher, B | 1 |
| Persson, S | 1 |
| Svensson, SE | 1 |
| Short, D | 1 |
| Santa Maria Vanini, E | 1 |
| Gutíerrez Espejo, A | 1 |
| Vlasica Carlos, JA | 1 |
| da Rocha, PJ | 1 |
| Albanesi Filho, FM | 1 |
| Albuquerque, EN | 1 |
| Bourassa, MG | 1 |
| Naccarella, F | 1 |
| Distante, A | 1 |
| Solberg, LE | 1 |
| Nissen, RG | 1 |
| Vlietstra, RE | 2 |
| Callahan, JA | 1 |
| Kanazawa, T | 1 |
| Ikeda, S | 1 |
| Miura, M | 1 |
| Seki, K | 1 |
| Lai, C | 1 |
| Mercuro, G | 1 |
| Totaro, G | 1 |
| Raviele, A | 1 |
| Khanna, PK | 1 |
| Naryanan, GR | 1 |
| Hoon, RS | 1 |
| Ciliberto, R | 1 |
| Sozzi, G | 1 |
| Foti, FA | 1 |
| Rovelli, F | 1 |
| Andreasen, F | 1 |
| Boye, E | 2 |
| Christoffersen, E | 1 |
| Dalsgaard, P | 1 |
| Henneberg, E | 1 |
| Kallenbach, A | 1 |
| Ladefoged, S | 1 |
| Lillquist, K | 1 |
| Mikkelsen, E | 1 |
| Norder0, E | 1 |
| Olsen, J | 1 |
| Pedersen, JK | 1 |
| Pedersen, V | 1 |
| Petersen, GB | 1 |
| Schroll, J | 1 |
| Schultz, H | 1 |
| Seidelin, J | 1 |
| Ferrari, M | 1 |
| Taurino, L | 2 |
| Storelli, A | 1 |
| Roma, F | 2 |
| DPhil, BN | 1 |
| Furlanello, F | 2 |
| Lanzetta, T | 2 |
| Contini, C | 1 |
| Disertori, M | 1 |
| Miccoli, A | 1 |
| Voronkov, LG | 5 |
| Lysenko, AF | 2 |
| Paul, S | 1 |
| York, D | 1 |
| Trenkwalder, P | 1 |
| Lydtin, H | 1 |
| Pellinen, TJ | 1 |
| Lukkala, K | 1 |
| Sundberg, S | 1 |
| Heikkilä, J | 1 |
| Frick, MH | 1 |
| Molinero, E | 1 |
| Salcedo, A | 1 |
| Sagastagoitia, JD | 1 |
| Arzubiaga, J | 1 |
| Iriarte, MM | 1 |
| Fernández Vidal, P | 1 |
| Ahmed, JH | 1 |
| Elliott, HL | 1 |
| Meredith, PA | 1 |
| Reid, JL | 1 |
| Abramov, AA | 1 |
| Shek, AB | 1 |
| Galikhanova, FA | 1 |
| Levkovich, OA | 1 |
| Foale, RA | 1 |
| Vandenburg, MJ | 1 |
| Manak, NA | 2 |
| Laziuk, DG | 2 |
| Karoza, AE | 1 |
| Karpova, IS | 1 |
| Prokopchuk, VP | 2 |
| Glushko, LV | 1 |
| Zeĭnalov, FI | 1 |
| Malov, AG | 1 |
| Sergienko, VB | 1 |
| Rubanovich, AI | 1 |
| Friedensohn, A | 1 |
| Meshulam, R | 1 |
| Schlesinger, Z | 1 |
| Hopkinson, ND | 1 |
| Hui, KP | 1 |
| Smith, MP | 1 |
| Hollinrake, K | 1 |
| Vazquez de Prada, JA | 2 |
| Zueco, J | 2 |
| Ruano, J | 2 |
| Martin-Duran, R | 1 |
| Sanjose, JM | 1 |
| Colman, T | 2 |
| Pajaron, A | 2 |
| Stroganova, NP | 1 |
| Gibbs, JS | 1 |
| McAlpine, HM | 1 |
| Wright, C | 1 |
| McLenachan, JM | 1 |
| Sparrow, J | 1 |
| Sutton, G | 1 |
| Dargie, HJ | 2 |
| Fox, KM | 1 |
| Siebert, J | 1 |
| Efuni, SN | 1 |
| Seriakov, VV | 1 |
| Furkalo, NK | 3 |
| Sokolov, NF | 1 |
| Bahls, FH | 1 |
| Ozuna, J | 1 |
| Ritchie, DE | 1 |
| Grieu, P | 1 |
| Mabire, JP | 1 |
| Kleszcz, A | 1 |
| Sesboué, B | 1 |
| Breut, C | 1 |
| Scanu, P | 1 |
| Albessard, F | 1 |
| Potier, JC | 1 |
| Goldhammer, E | 1 |
| Sharma, SK | 1 |
| Slastnikova, ID | 5 |
| Rumiantsev, DO | 4 |
| Piotrovskiĭ, VK | 5 |
| Betocchi, S | 1 |
| Piscione, F | 1 |
| Perrone-Filardi, P | 1 |
| Pace, L | 1 |
| Cappelli-Bigazzi, M | 1 |
| Alfano, B | 1 |
| Ciarmiello, A | 1 |
| Salvatore, M | 2 |
| Condorelli, M | 1 |
| Chiariello, M | 1 |
| Miller, AJ | 1 |
| Grais, IM | 1 |
| Kaminsky, LA | 1 |
| Shkliar, MB | 1 |
| Soleĭko, MB | 1 |
| Alekseeva, IP | 1 |
| Kul'chevich, LV | 1 |
| Thomson, A | 1 |
| Levchenko, VA | 1 |
| Serediuk, NN | 2 |
| Gereliuk, IP | 2 |
| Vakaliuk, IP | 2 |
| Bondar', MM | 1 |
| Brill, DM | 1 |
| Fozzard, HA | 1 |
| Berman, BA | 1 |
| Ross, RN | 1 |
| Nielsen, HK | 1 |
| Krusell, LR | 1 |
| Husted, SE | 1 |
| Pluymers, RJ | 1 |
| Picca, M | 1 |
| Azzollini, F | 1 |
| Cereda, A | 1 |
| Pelosi, G | 1 |
| Reiterer, W | 1 |
| Kokarev, AN | 1 |
| Kardakov, IuI | 1 |
| Vogler, AC | 1 |
| Silber, S | 1 |
| Vogel, M | 1 |
| Theisen, K | 1 |
| Vodop'ianova, RS | 2 |
| Urumbaev, RK | 2 |
| González-Vílchez, F | 1 |
| Matsevich, SIu | 1 |
| Frederiksen, M | 1 |
| Klitgaard, NA | 2 |
| Sørum, C | 1 |
| Biagetti, L | 1 |
| Puddu, P | 2 |
| Levantesi, D | 1 |
| Marraccini, P | 1 |
| Dalle Vacche, M | 1 |
| Nielsen, H | 1 |
| Levchenklo, VA | 1 |
| Boklashchuk, MN | 1 |
| Sharaeva, ML | 1 |
| Marino, P | 1 |
| Golia, G | 1 |
| Prioli, MA | 1 |
| Padrini, R | 2 |
| Zardini, P | 2 |
| Solomon, SA | 1 |
| Shub, C | 1 |
| McGoon, MD | 1 |
| Agarwal, OP | 1 |
| Massie, BM | 1 |
| Pflugfelder, P | 1 |
| Myreng, Y | 1 |
| Myhre, E | 1 |
| Anderson, P | 1 |
| Leitold, M | 1 |
| Hader, S | 1 |
| Grauholt, AM | 1 |
| Grande, P | 1 |
| Wadt, J | 1 |
| Gratsianskiĭ, NA | 2 |
| Chikvashvili, DI | 1 |
| Masenko, VP | 1 |
| De Divitiis, O | 1 |
| Liguori, V | 1 |
| Di Somma, S | 1 |
| Brignoli, M | 1 |
| Ferraro, S | 1 |
| Petitto, M | 1 |
| Fazio, S | 1 |
| Marsullo, G | 1 |
| Gradnik, R | 1 |
| Werner, GS | 1 |
| Schmid, M | 1 |
| Klein, HH | 1 |
| Wiegand, V | 1 |
| Kreuzer, H | 1 |
| Tebbe, U | 1 |
| Romeo, F | 1 |
| Gaspardone, A | 1 |
| Ciavolella, M | 1 |
| Gioffrè, P | 1 |
| Reale, A | 1 |
| Matteoli, S | 1 |
| Trappolini, M | 1 |
| Galli, V | 1 |
| Federici, AR | 1 |
| Borgia, MC | 1 |
| Rodrigues, EA | 6 |
| DasGupta, P | 1 |
| Hains, AD | 2 |
| Vakhliev, VD | 1 |
| Bogatyrev, IV | 1 |
| Uchaĭkina, LV | 1 |
| Syrkin, AL | 1 |
| Riabokon', OS | 3 |
| Román, O | 1 |
| Gac, JC | 1 |
| Ramírez, J | 1 |
| Rebolledo, H | 1 |
| Valenzuela, MA | 1 |
| Antunez, C | 1 |
| Trivella, MG | 1 |
| De Nes, DM | 1 |
| Kohli, RS | 3 |
| Hughes, LO | 2 |
| Gibelli, G | 1 |
| Negrini, M | 1 |
| Mazzocchi, F | 1 |
| Prina, L | 1 |
| Pollavini, P | 1 |
| Manfroi, WC | 1 |
| Vieira, SR | 1 |
| Goldim, JR | 1 |
| de Freitas, FM | 1 |
| Faraco, EZ | 1 |
| Mafrici, A | 1 |
| Biraghi, M | 1 |
| Cerri, P | 1 |
| Sclarovsky, S | 1 |
| Bassevich, R | 1 |
| Klainman, E | 1 |
| Rechavia, E | 1 |
| Sagie, A | 1 |
| Agmon, J | 1 |
| Sangiorgio, P | 1 |
| Fulvi, M | 1 |
| Rubboli, A | 1 |
| Halawa, B | 1 |
| Mazurek, W | 1 |
| Schneider, W | 1 |
| Maul, FD | 1 |
| Bussmann, WD | 1 |
| Lang, E | 1 |
| Hör, G | 1 |
| Lesbre, JP | 1 |
| Lalau, JD | 1 |
| Jaubourg, ML | 1 |
| Maarek-Charbit, M | 1 |
| Sievert, H | 1 |
| Kunkel, B | 1 |
| Wirtz, M | 1 |
| Pucci, PD | 1 |
| Buonamici, P | 1 |
| Buzzigoli, A | 1 |
| Sarro, F | 1 |
| Douard, H | 1 |
| Sermon, F | 1 |
| Mora, B | 1 |
| Broustet, JP | 1 |
| Massumi, RA | 1 |
| Udhoji, VN | 1 |
| McCourty, JC | 1 |
| Tucker, GT | 1 |
| Lennard, MS | 1 |
| Allely, MC | 1 |
| Alps, BJ | 1 |
| Powell, AC | 1 |
| Elliott, SL | 1 |
| Komissarov, VA | 2 |
| Pustovoĭt, GD | 1 |
| Kukharchuk, VV | 1 |
| Karpov, IuA | 3 |
| Kutsenko, AI | 1 |
| Noeva, EA | 2 |
| Zaruba, AIu | 1 |
| James, WE | 1 |
| Leman, RB | 1 |
| Assey, ME | 1 |
| Burgess, CD | 1 |
| Katsumoto, K | 1 |
| Takeuchi, K | 1 |
| Niibori, T | 1 |
| Okuno, T | 1 |
| Kimmel, B | 1 |
| Goldberger, J | 1 |
| Phillippides, G | 1 |
| Kellett, MA | 1 |
| Mangini, SG | 1 |
| Stowe, HO | 1 |
| Keech, AC | 1 |
| Harper, RW | 2 |
| Harrison, PM | 2 |
| Pitt, A | 1 |
| McLean, AJ | 2 |
| Gill, JB | 1 |
| Cairns, JA | 1 |
| McEwan, MP | 1 |
| Findlay, IN | 1 |
| MacLeod, K | 1 |
| Gillen, G | 1 |
| Elliott, AT | 1 |
| Aitchison, T | 1 |
| Zaĭtseva, VI | 1 |
| Schneeweiss, A | 1 |
| Sadick, NA | 1 |
| Anderson, SD | 1 |
| Devenish-Meares, S | 1 |
| Papa, M | 1 |
| Artiaco, D | 1 |
| Santangelo, L | 1 |
| Covelluzzi, F | 1 |
| Cicatiello, M | 1 |
| Sjödén, G | 1 |
| Rosenqvist, M | 1 |
| Kriegholm, E | 1 |
| Haglund, K | 1 |
| Ruda, MIa | 1 |
| Marzocchi, A | 1 |
| Galiè, N | 1 |
| Marrozzini, C | 1 |
| Riabokon, OS | 2 |
| Turitto, G | 1 |
| Pezzella, A | 1 |
| Prati, PL | 1 |
| Piovan, D | 1 |
| Gridelli, C | 1 |
| Ferrini, D | 1 |
| Galvani, M | 1 |
| Tollemeto, D | 1 |
| Bernardi, P | 1 |
| Jackson, NC | 1 |
| Hafizullah, M | 1 |
| Reynolds, G | 1 |
| Lesoway, R | 1 |
| Humen, DP | 1 |
| Kendall, MJ | 1 |
| Horton, RC | 1 |
| Forsyth, D | 1 |
| Frais, MA | 1 |
| Touloukian, JE | 1 |
| Mogensen, F | 2 |
| Rasmussen, V | 2 |
| Kjøller, E | 2 |
| Knudsen, JB | 2 |
| Gormsen, J | 2 |
| Crea, F | 1 |
| Deanfield, J | 1 |
| Crean, P | 1 |
| Sharom, M | 1 |
| Bekhbudova, DA | 1 |
| Ostrovskaia, TP | 1 |
| Poole-Wilson, PA | 1 |
| Kenny, J | 1 |
| Al'perovich, BR | 1 |
| Rumiantsev, AS | 1 |
| Fulton, KL | 3 |
| Kramer, P | 1 |
| Swedberg, K | 1 |
| Curran, D | 1 |
| Namekawa, M | 1 |
| Croft, CH | 1 |
| Knight, R | 1 |
| Kaski, JC | 1 |
| Plaza, LR | 1 |
| Meran, DO | 1 |
| Araujo, L | 1 |
| Chierchia, S | 1 |
| Cucchi, G | 1 |
| Giustiniani, S | 1 |
| Robustelli, F | 1 |
| Vakhliaev, VD | 1 |
| Pomerantsev, EV | 1 |
| Serova, IV | 1 |
| Petriĭ, VV | 1 |
| Iudichev, IS | 1 |
| Ceci, V | 1 |
| Longo, A | 1 |
| Fiorella, AT | 1 |
| Aiello, P | 1 |
| Masini, V | 1 |
| Cantor, A | 1 |
| Crital, N | 1 |
| Buskila, D | 1 |
| Prajgrod, G | 1 |
| Gueron, M | 1 |
| Savenkov, PM | 1 |
| Doscicin, VL | 1 |
| Zarov, EI | 1 |
| Arsakuni, RO | 1 |
| Janezic, A | 1 |
| Machkota, S | 1 |
| Hills, EA | 2 |
| Downes, EM | 1 |
| Doshchitsyn, VL | 1 |
| Arshakuni, RO | 1 |
| Zharov, EI | 1 |
| Polakow, ES | 1 |
| Hawkins, DM | 1 |
| Hanna, C | 1 |
| Schmid, JR | 1 |
| Buttolo, R | 1 |
| Nardoni, A | 1 |
| Parratt, JR | 1 |
| Livesley, B | 1 |
| Catley, PF | 1 |
| Campbell, RC | 1 |
| Oram, S | 1 |
| Nyberg, G | 1 |
| Moyer, RR | 1 |
| Kuz'ko, NV | 1 |
| Filias, N | 1 |
| Södermark, T | 1 |
| Winge, T | 1 |
| Andersen, ED | 1 |
| Andreasen, PB | 1 |
| Messini, M | 1 |
| Cantor, SA | 1 |
| Sandler, G | 4 |
| Shkhvatsabaia, IK | 1 |
| Miasnikov, LA | 1 |
| Grigor'iants, RA | 1 |
| Dubinina, LT | 2 |
| Simonson, E | 1 |
| Berman, R | 1 |
| Luebs, ED | 1 |
| Cohen, A | 1 |
| Zaleski, EJ | 1 |
| Bing, RJ | 1 |
| Neumann, M | 1 |
| Luisada, AA | 1 |
| Clayton, GA | 1 |
| Thornicroft, SG | 1 |
| Proctor, JD | 1 |
| Wasserman, AJ | 1 |
| Gamble, E | 1 |
| Matthews, MB | 1 |
| Turck, WP | 1 |
| Datey, KK | 1 |
| Dalvi, CP | 1 |
| Sanna, GP | 1 |
| Rowe, GG | 1 |
| Stenlund, RR | 1 |
| Thomsen, JH | 1 |
| Corliss, RJ | 1 |
| Sialer, S | 1 |
| Waris, E | 1 |
| McIlhenny, HM | 1 |
| Atterhög, JH | 1 |
| Porjé, G | 1 |
| Misra, SS | 1 |
| Sircar, AR | 1 |
| De Liperi, E | 1 |
| Coli, R | 1 |
| Brunori, F | 1 |
| Singer, MT | 1 |
| Schvacabaja, IK | 1 |
| Mjasnikov, LA | 1 |
| Metelica, VI | 1 |
| Grigorjanc, RA | 1 |
| Fleckenstein, A | 1 |
| Kammermeier, H | 1 |
| Döring, HJ | 1 |
| Freund, HJ | 1 |
| Zimmermann, D | 1 |
| de Abrantes, IB | 1 |
| Villela, RA | 1 |
| Faillace, S | 1 |
| Villela, AA | 1 |
| Smejkal, V | 1 |
| Zeman, B | 1 |
| Knoch, G | 1 |
| Schlepper, M | 1 |
| Witzleb, E | 1 |
| Mignault, JD | 1 |
| Urbaszek, W | 1 |
| Hofbauer, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction[NCT02435797] | Phase 4 | 100 participants (Anticipated) | Interventional | 2015-04-30 | Recruiting | ||
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
71 reviews available for verapamil and Angor Pectoris
| Article | Year |
|---|---|
[Coronary spastic angina refractory to optimal medical therapy treated by angioplasty and stenting. A case report and review of literature].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Coronary Vasospasm; Human | 2010 |
New advances in the field of calcium channel antagonists: cardiovascular effects and structure-activity relationships.
Topics: Angina Pectoris; Animals; Calcium Channel Blockers; Calcium Channels; Cardiovascular System; Diltiaz | 2003 |
[Indications for calcium channel antagonist therapy according to the latest large clinical trials].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Calcium Channel Blockers; Cli | 2005 |
Understanding the calcium channel blockers.
Topics: Action Potentials; Angina Pectoris; Animals; Arrhythmias, Cardiac; Arteriosclerosis; Calcium; Calciu | 1984 |
Calcium blocking agents. New directions in the treatment of angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium; Diltiazem; Humans; Ion Channels; Myocardial C | 1980 |
Verapamil therapy for stable and unstable angina pectoris: calcium channel antagonists in perspective.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; De | 1982 |
[Effects of calcium antagonists on isolated myocardial tissue and their molecular mechanism of action].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atrioventricular Node; Calcium Channel Blockers; Drug | 1982 |
Clinical value of calcium antagonists in treatment of cardiovascular disorders.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calciu | 1983 |
[Use of calcium antagonists in the therapy of coronary heart disease].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium; Coronary Disease; Diltiazem; Drug Therapy, Co | 1983 |
Anti-anginal, electrophysiologic and hemodynamic effects of combined beta-blocker/calcium antagonist therapy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Drug T | 1983 |
Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.
Topics: Angina Pectoris; Angina Pectoris, Variant; Animals; Arrhythmias, Cardiac; Benzazepines; Calcium; Car | 1980 |
Calcium blocking drugs for angina pectoris.
Topics: Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; Coronary Circulation; Diltiazem | 1982 |
Calcium antagonists in the treatment of individuals with ischemic heart disease.
Topics: Angina Pectoris; Angina Pectoris, Variant; Calcium; Calcium Channel Blockers; Coronary Disease; Dilt | 1982 |
Calcium channel blocking drugs.
Topics: Anesthesia; Angina Pectoris; Animals; Calcium; Calcium Channel Blockers; Cardiomyopathy, Hypertrophi | 1983 |
Clinical pharmacology of calcium entry blockers.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium; Calcium Channel Blockers; Diltiazem; Humans; Ion Cha | 1983 |
Slow channel blockers.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Chemical Phenomena; Chemistry; Cons | 1983 |
Calcium antagonists. Clinical use in the treatment of systemic hypertension.
Topics: Angina Pectoris; Calcium Channel Blockers; Diltiazem; Humans; Hypertension; Nifedipine; Verapamil | 1983 |
[The role of calcium antagonists in the treatment of classical angina pectoris].
Topics: Angina Pectoris; Calcium Channel Blockers; Diltiazem; Double-Blind Method; Exercise Test; Humans; Ni | 1983 |
Anti-anginal effect of oral verapamil: evidence of dose-dependence of the effect.
Topics: Adult; Angina Pectoris; Angiography; Dose-Response Relationship, Drug; Exercise Test; Follow-Up Stud | 1983 |
Use of calcium channel blocking agents in angina pectoris.
Topics: Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; Clinical Trials as Topic; Dilti | 1984 |
New antiarrhythmic drugs.
Topics: Amiodarone; Angina Pectoris; Anti-Arrhythmia Agents; Blood Circulation; Bradycardia; Diltiazem; Half | 1983 |
The clinical uses of calcium antagonists.
Topics: Angina Pectoris; Angina Pectoris, Variant; Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel B | 1982 |
Part I: pharmacologic and hemodynamic actions and interactions. Pharmacologic and hemodynamic mechanisms underlying the antianginal actions of verapamil.
Topics: Angina Pectoris; Animals; Cardiac Pacing, Artificial; Coronary Circulation; Coronary Disease; Dogs; | 1982 |
Hemodynamic and clinical effects of combined verapamil and propranolol therapy in angina pectoris.
Topics: Angina Pectoris; Animals; Blood Pressure; Clinical Trials as Topic; Diltiazem; Dogs; Dose-Response R | 1982 |
[Treatment of angina pectoris with calcium antagonists].
Topics: Angina Pectoris; Calcium Channel Blockers; Coronary Disease; Diltiazem; Drug Therapy, Combination; E | 1982 |
Effects of antianginal agents on the coronary circulation.
Topics: Angina Pectoris; Animals; Arteriosclerosis; Calcium; Collateral Circulation; Coronary Circulation; C | 1981 |
Calcium antagonists.
Topics: Action Potentials; Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Bronchial Spasm; | 1980 |
Role of calcium antagonists in cardiovascular therapy.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Blood Vessels; Calcium; Calcium Channel Blockers; Cardiomyopa | 1981 |
Verapamil.
Topics: Action Potentials; Angina Pectoris; Animals; Calcium; Cardiovascular System; Heart Diseases; Hemodyn | 1981 |
Similarities and differences between calcium antagonists: pharmacological aspects.
Topics: Angina Pectoris; Antihypertensive Agents; Calcium Channel Blockers; Dihydropyridines; Diltiazem; Hum | 1993 |
Anti-ischaemic intervention with verapamil in patients recovering from acute myocardial infarction.
Topics: Angina Pectoris; Calcium Channel Blockers; Humans; Myocardial Infarction; Myocardial Ischemia; Preva | 1995 |
Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.
Topics: Angina Pectoris; Animals; Calcium Channel Blockers; Coronary Disease; Humans; Myocardial Infarction; | 1996 |
Diversity of calcium antagonists.
Topics: Angina Pectoris; Arteriosclerosis; Benzimidazoles; Calcium Channel Blockers; Diltiazem; Humans; Hype | 1997 |
Verapamil use in patients with cardiovascular disease: an overview of randomized trials.
Topics: Angina Pectoris; Calcium Channel Blockers; Cardiovascular Diseases; Female; Humans; Hypertension; Ma | 1998 |
[An anomalous origin of the left coronary artery associated with a right coronary spasm as the cause of angina and presyncope].
Topics: Adult; Angina Pectoris; Calcium Channel Blockers; Coronary Vasospasm; Coronary Vessel Anomalies; Dru | 1999 |
Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trials.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Calcium Channel Blockers; Clinical Trials as Topic | 1999 |
Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trials.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Calcium Channel Blockers; Clinical Trials as Topic | 2000 |
Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Back Pain; Constipation; Delayed-Action Preparation | 2001 |
[Calcium antagonists in cardiology].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Calcium; Coronary Disease; Human | 1978 |
Clinical use of verapamil.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Atrial Fibrillation; Heart Conduction System; Hemodynamics; H | 1977 |
Verapamil: a review of its pharmacological properties and therapeutic use.
Topics: Angina Pectoris; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Circulation; Corona | 1978 |
[Hypertrophic cardiomyopathy with obstruction].
Topics: Adolescent; Adult; Aged; Angina Pectoris; Cardiac Glycosides; Cardiomyopathy, Hypertrophic; Coronary | 1979 |
Clinical aspects of Ca-blocking agents.
Topics: Angina Pectoris; Animals; Arrhythmias, Cardiac; Calcium; Coronary Disease; Cricetinae; Humans; Hyper | 1978 |
[Treatment of angina pectoris (III)].
Topics: Angina Pectoris; Angina Pectoris, Variant; Coronary Artery Bypass; Humans; Nifedipine; Perhexiline; | 1979 |
[Calcium antagonists in the therapy of angina pectoris of effort].
Topics: Angina Pectoris; Calcium; Hemodynamics; Humans; Myocardium; Nifedipine; Oxygen Consumption; Piperazi | 1978 |
[Medical therapy of chronic coronary insufficiency].
Topics: Amiodarone; Angina Pectoris; Chronic Disease; Coronary Disease; Digitalis Glycosides; Humans; Lidofl | 1978 |
Treatment with verapamil after an acute myocardial infarction. Review of the Danish studies on verapamil in myocardial infarction (DAVIT I and II).
Topics: Angina Pectoris; Blood Pressure; Denmark; Double-Blind Method; Female; Heart Rate; Humans; Male; Met | 1991 |
[Hyperbaric oxygen and antianginal agents: experimental and clinical aspects of their interaction].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Combined Modality Therapy; Free Radicals; Hum | 1990 |
[Isoptin Retard. Pharmacokinetics and pharmacodynamics in patients with angina pectoris].
Topics: Angina Pectoris; Delayed-Action Preparations; Humans; Verapamil | 1990 |
Treating coexisting cardiovascular and pulmonary disease with calcium antagonists.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Asthma, Exercise-Induced; Bronchial Spasm; Calcium; Ca | 1986 |
Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Calcium Channel Blockers; Chronic Disease; Cl | 1985 |
Selection of optimal drug therapy for the patient with angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Calcium Channel | 1985 |
Antihypertensive therapy with calcium-channel blockers: comparison with beta blockers.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Clinical Tri | 1985 |
Calcium antagonists.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium; Calcium Channel Blockers; Coronary Circulatio | 1985 |
Combined use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina. Rationale, efficacy, and adverse effects.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Diseases; Dil | 1988 |
Pharmacokinetics of calcium channel blocking agents.
Topics: Administration, Oral; Angina Pectoris; Atrial Fibrillation; Biological Availability; Cardiomegaly; C | 1986 |
Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.
Topics: Angina Pectoris; Angina, Unstable; Calcium Channel Blockers; Coronary Disease; Diltiazem; Drug Thera | 1988 |
Comparison of the antianginal efficacy of isosorbide dinitrate (ISDN) 40 mg and verapamil 120 mg three times daily in the acute trial and following two-week treatment.
Topics: Acute Disease; Aged; Analysis of Variance; Angina Pectoris; Blood Pressure; Drug Administration Sche | 1988 |
Review of calcium-channel blockers.
Topics: Angina Pectoris; Calcium Channel Blockers; Diltiazem; Humans; Nifedipine; Verapamil | 1986 |
Treatment of angina pectoris and hypertension with sustained-release calcium channel-blocking drugs.
Topics: Angina Pectoris; Biological Availability; Calcium Channel Blockers; Delayed-Action Preparations; Dil | 1987 |
Calcium antagonists in patients with cardiovascular disease. Current perspectives.
Topics: Angina Pectoris; Angina Pectoris, Variant; Atrial Fibrillation; Atrial Flutter; Benzazepines; Cardio | 1985 |
Are calcium antagonists cardioprotective?
Topics: Angina Pectoris; Animals; Blood Viscosity; Calcium Channel Blockers; Clinical Trials as Topic; Coron | 1985 |
Calcium channel blocking agents: physiologic basis of nursing intervention.
Topics: Angina Pectoris; Angina Pectoris, Variant; Atrioventricular Node; Calcium; Calcium Channel Blockers; | 1985 |
Combination therapy with isosorbide dinitrate: current status and the future.
Topics: Angina Pectoris; Coronary Vasospasm; Diltiazem; Drug Therapy, Combination; Esophageal Achalasia; Exe | 1985 |
Calcium-channel blockers and systemic hypertension.
Topics: Acute Disease; Angina Pectoris; Animals; Calcium Channel Blockers; Chronic Disease; Diltiazem; Drug | 1985 |
Calcium channel blocking agents and the heart.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Coronary Vasospasm; Digoxin; Diltia | 1985 |
Pharmacological aspects of the coronary circulation.
Topics: Adenine Nucleotides; Angina Pectoris; Angiotensin II; Animals; Atrial Function; Blood Pressure; Coro | 1969 |
Medical treatment of angina pectoris. 8. Miscellaneous antianginal drugs.
Topics: Angina Pectoris; Digitalis Glycosides; Dipyridamole; Ethanol; Humans; Isoquinolines; Papaverine; Pip | 1973 |
Verapamil and the myocardium.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Biological Transport; Calcium; Coronary Vessels; Female; Hear | 1974 |
Comparison of therapeutic effects of coronary drugs in the USSR.
Topics: Angina Pectoris; Benzoates; Benzyl Compounds; Clinical Trials as Topic; Coronary Disease; Coumarins; | 1971 |
Drugs in the management of angina pectoris.
Topics: Aerosols; Amyl Nitrite; Angina Pectoris; Clofibrate; Delayed-Action Preparations; Humans; Nitroglyce | 1969 |
226 trials available for verapamil and Angor Pectoris
| Article | Year |
|---|---|
Aspirin plus verapamil relieves angina and perfusion abnormalities in patients with coronary microvascular dysfunction and Chagas disease: a pilot non-randomized study.
Topics: Angina Pectoris; Aspirin; Chagas Disease; Female; Humans; Male; Middle Aged; Perfusion; Quality of L | 2021 |
Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST).
Topics: Age Factors; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 2013 |
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Atenol | 2008 |
Long-term stability of heart rate variability in chronic stable angina pectoris, and the impact of an acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Coron | 2009 |
Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy.
Topics: Aged; Angina Pectoris; Atherectomy, Coronary; Coronary Angiography; Coronary Circulation; Coronary S | 2002 |
[Diltiazem and verapamil therapy in patients with angina pectoris associated with arterial hypotension].
Topics: Angina Pectoris; Calcium Channel Blockers; Cross-Over Studies; Diltiazem; Humans; Hypotension; Male; | 2004 |
[Clinical value of degree of blood pressure lowering during use of effective doses of antianginal drugs].
Topics: Adult; Angina Pectoris; Blood Pressure; Chi-Square Distribution; Data Interpretation, Statistical; E | 2004 |
Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS).
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Death, Sudden, Cardiac; Diab | 2006 |
Prognostic implications of renal dysfunction in patients with stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Disease | 2006 |
Differential index: a simple time domain heart rate variability analysis with prognostic implications in stable angina pectoris.
Topics: Aged; Angina Pectoris; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug A | 2008 |
Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise.
Topics: Adult; Aged; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Diagnosis, Computer-Assiste | 1980 |
Verapamil and beta-adrenoceptor blockade in the treatment of stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Do | 1982 |
Calcium channel blockade as primary therapy for stable angina pectoris. A double-blind placebo-controlled comparison of verapamil and propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Clinical Trials | 1982 |
Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris. A placebo-controlled double-blind randomized crossover trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; | 1982 |
Verapamil in treatment of chronic stable angina.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Blood Pressure; Chronic Disease; Clinical Trials as To | 1983 |
The clinical and hemodynamic effects of propranolol, pindolol and verapamil in the treatment of exertional angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Exercise Test; | 1984 |
Calcium channel blockers: indications and limitations 2. Use in angina and other cardiac disorders.
Topics: Administration, Oral; Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; Cardiomeg | 1982 |
Comparative effects of propranolol and verapamil alone and in combination on left ventricular function and volumes in patients with chronic exertional angina: a double-blind, placebo-controlled, randomized, crossover study with radionuclide ventriculograp
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Electr | 1983 |
Randomized, double-blind comparison of propranolol alone and a propranolol-verapamil combination in patients with severe angina of effort.
Topics: Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ele | 1983 |
Efficacy and safety of verapamil in patients with angina pectoris after 1 year of continuous, high-dose therapy.
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Hemodynamics; Humans; M | 1983 |
Anti-anginal effect of oral verapamil: evidence of dose-dependence of the effect.
Topics: Adult; Angina Pectoris; Angiography; Dose-Response Relationship, Drug; Exercise Test; Follow-Up Stud | 1983 |
Double-blind randomized crossover trial of verapamil and propranolol in chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female | 1983 |
Clinical outcome after treatment of rest angina with calcium blockers: comparative experience during the initial year of therapy with diltiazem, nifedipine, and verapamil.
Topics: Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Female; | 1983 |
Verapamil administered twice daily in stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Ad | 1984 |
Randomized double-blind comparison of gallopamil and propranolol in stable angina pectoris.
Topics: Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Exercise | 1984 |
Use of calcium channel blocking agents in angina pectoris.
Topics: Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; Clinical Trials as Topic; Dilti | 1984 |
[Comparative study of the effectiveness of korinfar, izoptin and obzidan in patients with variant stenocardia combined with effort stenocardia].
Topics: Adult; Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; Clinical Trials as Topic | 1984 |
[Changes in the physical load tolerance of stenocardia patients taking obzidan, korinfar and izoptin separately and together].
Topics: Adult; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Clinical Trials as Topic; Drug Th | 1984 |
Abrupt withdrawal of verapamil in ischaemic heart disease. The Danish Study Group on Verapamil in Myocardial Infarction.
Topics: Adult; Aged; Angina Pectoris; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; F | 1984 |
[Treatment of patients with exercise-induced angina pectoris with korinfar and isoptin].
Topics: Adult; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Female; | 1984 |
[Anti-angina effect of gallopamil in comparison with another calcium antagonist and a placebo].
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Coronary Disease; Double-Bli | 1984 |
The efficacy and safety of high-dose verapamil and diltiazem in the long-term treatment of stable exertional angina.
Topics: Angina Pectoris; Benzazepines; Clinical Trials as Topic; Diltiazem; Double-Blind Method; Electrocard | 1984 |
[Drug therapy combinations in angina pectoris].
Topics: Administration, Oral; Angina Pectoris; Blood Pressure; Drug Therapy, Combination; Exercise Test; Hea | 1983 |
Calcium inhibitors in the treatment of arterial spasm: verapamil.
Topics: Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Vasospasm; Coronary Ve | 1983 |
Propranolol v. verapamil in the treatment of unstable angina. A double-blind cross-over study.
Topics: Aged; Analysis of Variance; Angina Pectoris; Blood Pressure; Bradycardia; Clinical Trials as Topic; | 1983 |
Orthostatic response before and after nitroglycerin in metoprolol- and verapamil-treated angina pectoris.
Topics: Aged; Angina Pectoris; Blood Pressure; Heart Rate; Humans; Hypotension, Orthostatic; Metoprolol; Mid | 1983 |
[Comparison of the anti-angina effectiveness of gallopamil to isosorbide dinitrate in long-term medication].
Topics: Angina Pectoris; Clinical Trials as Topic; Female; Gallopamil; Humans; Isosorbide Dinitrate; Long-Te | 1983 |
[Acute and long-term effects of gallopamil (D 600) in stable angina pectoris--a randomized double-blind study].
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Fe | 1983 |
Verapamil or propranolol in the treatment of stable angina pectoris of effort.
Topics: Angina Pectoris; Blood Pressure; Electrocardiography; Exercise Test; Heart Rate; Humans; Nitroglycer | 1984 |
Combined therapy with Ca-antagonists and beta-adrenergic receptor blocking agents in chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Atenolol; Blood Pressure; Chronic Disease; Drug Therapy, Combination; | 1984 |
[Comparison of the anti-ischemia effect of nisoldipine and verapamil. Double-blind randomized cross-over and placebo-controlled acute and long-term study].
Topics: Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Diseas | 1984 |
Evaluation of verapamil and high dose nifedipine in patients with chronic stable angina with objective methods.
Topics: Adult; Aged; Angina Pectoris; Chronic Disease; Double-Blind Method; Drug Administration Schedule; El | 1984 |
Verapamil for unstable angina at rest: a short-term randomized, double-blind study.
Topics: Adult; Aged; Angina Pectoris; Double-Blind Method; Drug Evaluation; Electrocardiography; Female; Hum | 1983 |
Hemodynamic and clinical effects of combined verapamil and propranolol therapy in angina pectoris.
Topics: Angina Pectoris; Animals; Blood Pressure; Clinical Trials as Topic; Diltiazem; Dogs; Dose-Response R | 1982 |
Verapamil therapy for unstable angina pectoris: review of double-blind placebo-controlled randomized clinical trials.
Topics: Adult; Aged; Angina Pectoris; Arterial Occlusive Diseases; Clinical Trials as Topic; Coronary Diseas | 1982 |
Rationale for the choice of calcium antagonists in chronic stable angina. An objective double-blind placebo-controlled comparison of nifedipine and verapamil.
Topics: Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Metho | 1982 |
Clinical relevance of verapamil plasma levels in stable angina pectoris.
Topics: Administration, Oral; Aged; Angina Pectoris; Clinical Trials as Topic; Female; Heart Conduction Syst | 1982 |
Chronic stable angina: comparison of verapamil and propranolol.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Heart Rate; Humans; Male; Mi | 1982 |
Effects of oral calcium-antagonists in spontaneous angina. Verapamil and nifedipine in a double-blind cross-over trial.
Topics: Angina Pectoris; Angina Pectoris, Variant; Clinical Trials as Topic; Coronary Vasospasm; Double-Blin | 1982 |
[Nifedipine and verapamil in unstable angina. Evaluation by the Holter method].
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Fe | 1982 |
[Evaluation of the efficacy of verapamil in a slow-release preparation in the treatment of stable exertion angina].
Topics: Aged; Angina Pectoris; Clinical Trials as Topic; Delayed-Action Preparations; Exercise Test; Heart R | 1982 |
[Double-blind comparison of verapamil and propranolol in the therapy of unstable angina].
Topics: Aged; Angina Pectoris; Angina, Unstable; Clinical Trials as Topic; Double-Blind Method; Female; Huma | 1982 |
Verapamil in chronic stable angina: a controlled study with computerized multistage treadmill exercise.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Coronary Disease; Double-Bli | 1980 |
A controlled trial of verapamil for Prinzmetal's variant angina.
Topics: Adult; Angina Pectoris; Angina Pectoris, Variant; Clinical Trials as Topic; Double-Blind Method; Ele | 1981 |
Effect of verapamil and nifedipine on left ventricular function at rest and during exercise in patients with Prinzmetal's variant angina pectoris.
Topics: Angina Pectoris; Angina Pectoris, Variant; Exercise Test; Female; Heart Ventricles; Hemodynamics; Hu | 1981 |
Comparison of verapamil and nifedipine in the treatment of variant angina pectoris: preliminary observations in 10 patients.
Topics: Angina Pectoris; Angina Pectoris, Variant; Electrocardiography; Female; Humans; Male; Middle Aged; N | 1981 |
Comparison of antianginal actions of verapamil and propranolol.
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Humans; Middle Aged; Pr | 1981 |
Long-term antianginal action of verapamil assessed with quantitated serial treadmill stress testing.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Exercis | 1981 |
Treatment of stable angina pectoris with verapamil hydrochloride: a double blind cross-over study.
Topics: Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Exercise Test; Hemodynamics; Humans; | 1980 |
Superiority of verapamil to propranolol in stable angina pectoris: a double-blind, randomized crossover trail.
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Fe | 1982 |
Additive antianginal effect of verapamil in patients receiving propranolol.
Topics: Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combin | 1982 |
Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled randomized crossover study.
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Female; Hemodynamics; H | 1982 |
An objective comparison of verapamil and placebo in chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Constipation; Elec | 1982 |
Verapamil therapy for stable exertional angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Constipation; Double-Blind M | 1982 |
Long-term effectiveness of verapamil in stable and unstable angina pectoris. One-year follow-up of patients treated in placebo-controlled double-blind randomized clinical trials.
Topics: Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Constipation; Doub | 1982 |
Comparative effects of abrupt withdrawal of propranolol and verapamil in angina pectoris.
Topics: Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Catecholamines; Clinical Trials as Topic; | 1982 |
[Verapamil in effort angina: a multi-centre study].
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Exercise Test; Female; | 1982 |
Comparison of the antianginal effectiveness of nifedipine, verapamil, and isosorbide dinitrate in patients receiving propranolol: a double-blind study.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; | 1983 |
Coronary spasm management with verapamil (Isoptin).
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Coronary Disease; Elec | 1980 |
Calcium antagonists: long-awaited new therapy for heart disease.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Benzazepines; Calcium; Cardiomyopathies; Clinical Trials as T | 1981 |
Vasospastic angina.
Topics: Angina Pectoris; Angina Pectoris, Variant; Angiocardiography; Clinical Trials as Topic; Coronary Dis | 1980 |
Considerations in evaluating new antianginal drugs.
Topics: Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Drug Evaluation; Hum | 1982 |
Short-term efficacy of oral verapamil in rest angina. A double-blind placebo controlled trial in CCU patients.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Coronary Care Units; D | 1981 |
Calcium antagonist drugs in chronic stable angina. Comparison of verapamil and nifedipine.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Double-Blin | 1981 |
Verapamil in stable effort angina: effects on left ventricular function evaluated with exercise radionuclide ventriculography.
Topics: Aged; Angina Pectoris; Clinical Trials as Topic; Diastole; Double-Blind Method; Heart Rate; Heart Ve | 1982 |
[Verapamil or propranolol for the treatment of angina pectoris].
Topics: Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Humans; Propranolol; Verapamil | 1982 |
A double-blind randomized trial of propranolol and verapamil in the treatment of effort angina.
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; M | 1982 |
Verapamil versus placebo in relieving stable angina pectoris.
Topics: Aged; Angina Pectoris; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Electr | 1982 |
Randomized double-blind comparison of verapamil and nifedipine in chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Chronic Disease; Double-Blind Method; Electrocardiography; Exercise Te | 1982 |
[Comparative pharmacodynamics study of korinfar and isoptin in ischemic heart disease].
Topics: Adult; Angina Pectoris; Coronary Disease; Dose-Response Relationship, Drug; Drug Evaluation; Exercis | 1981 |
Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Double-Blind Method; Drug Evaluation; Electrocardiography; Female; For | 1981 |
[Calcium antagonists and primary prevention of coronary disease].
Topics: Adult; Aged; Angina Pectoris; Coronary Disease; Double-Blind Method; Female; Humans; Male; Metoprolo | 1995 |
Role of ischemia in postinfarction heart failure: hypothetical considerations based on use of verapamil in the DAVIT II Study. Danish Study Group on Verapamil in Myocardial Infarction.
Topics: Angina Pectoris; Computer Communication Networks; Double-Blind Method; Heart Failure; Humans; Myocar | 1994 |
Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris.
Topics: Adult; Aged; Analysis of Variance; Angina Pectoris; Chronic Disease; Constipation; Delayed-Action Pr | 1995 |
Platelet aggregability in vivo is attenuated by verapamil but not by metoprolol in patients with stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Catecholamines; Double-Blind Method; Humans; Male; Metoprolol; Middle | 1995 |
The prognostic significance of post-infarction angina pectoris and the effect of verapamil on the incidence of angina pectoris and prognosis. The Danish Study Group on Verapamil in Myocardial Infarction.
Topics: Adult; Aged; Angina Pectoris; Denmark; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; | 1994 |
Age-related changes of antianginal effects of verapamil in patients with stable effort angina. A medium term randomized double-blind placebo controlled trial.
Topics: Adult; Aging; Angina Pectoris; Double-Blind Method; Exercise Test; Female; Humans; Male; Middle Aged | 1993 |
[Treatment of ischemic heart disease in the elderly. Comparison of diltiazem, verapamil and gallopamil].
Topics: Age Factors; Aged; Angina Pectoris; Coronary Angiography; Coronary Disease; Diltiazem; Drug Evaluati | 1993 |
[The noninvasive identification of patients with angina and normal coronary arteries].
Topics: Adult; Angina Pectoris; Coronary Angiography; Electrocardiography; Exercise Test; Female; Humans; Is | 1995 |
[Comparative study of verapamil LI 120 mg 3 times a day and verapamil LP 120 mg twice a day in stable exertion-induced angina. A multicenter study].
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Dose-Response Relation | 1995 |
Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS)
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Double-Blind Me | 1996 |
[Calcium antagonist therapy of middle-aged and aged patients with angina pectoris during the outpatient stage of rehabilitation].
Topics: Age Factors; Aged; Aged, 80 and over; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agen | 1995 |
Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Cardiovascular System; Femal | 1997 |
Carvedilol versus verapamil in chronic stable angina: a multicentre trial.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Carbaz | 1997 |
Psychosocial variables in female vs male patients with stable angina pectoris and matched healthy controls.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Chi-Square Distributio | 1997 |
The prognostic significance of angina pectoris experienced during the first month following acute myocardial infarction.
Topics: Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Chi-Square Distribution; Confidence Interval | 1997 |
Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial.
Topics: Adult; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diuretic | 1997 |
Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol: results from the Angina Prognosis Study in Stockholm (APSIS).
Topics: Aged; Angina Pectoris; Apolipoproteins; Cardiovascular System; Cholesterol; Cholesterol, HDL; Choles | 1997 |
Antianginal efficacy over 24 hours and exercise hemodynamic effects of once daily sustained-release 300 mg diltiazem and 240 mg verapamil in stable angina pectoris.
Topics: Aged; Angina Pectoris; Calcium Channel Blockers; Cross-Over Studies; Delayed-Action Preparations; Di | 1998 |
Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Atenolol; Calcium | 1999 |
Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; | 1999 |
Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study in Stockholm [APSIS]).
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Elect | 1999 |
Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm.
Topics: Adrenergic beta-Agonists; Aged; Angina Pectoris; beta-Thromboglobulin; Calcium Channel Blockers; Car | 2000 |
Prognostic implications of results from exercise testing in patients with chronic stable angina pectoris treated with metoprolol or verapamil. A report from the Angina Prognosis Study In Stockholm (APSIS).
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Exerc | 2000 |
Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris | 2000 |
[Clinical aspects of trimetazidine (preductal) administration as an antianginal drug].
Topics: Administration, Oral; Aged; Aged, 80 and over; Angina Pectoris; Cross-Over Studies; Drug Therapy, Co | 2000 |
Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris.
Topics: Aged; Angina Pectoris; Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Coronary Artery | 2001 |
Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Biomarkers; | 2002 |
[Drug therapy of coronary heart disease (author's transl)].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium; Clinical Trials as Topic; Coronary Disease; D | 1977 |
Comparative effects of verapamil and propranolol in patients with angina pectoris.
Topics: Adult; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Exercise Test | 1978 |
[Treatment of angina pectoris with stenoptin. Placebo controlled double-blind study].
Topics: Angina Pectoris; Drug Combinations; Isosorbide Dinitrate; Nitroglycerin; Placebos; Verapamil | 1979 |
[Clinical and cycloergometric evaluation of verapamil in the therapeutic of angina pectoris].
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Drug Evaluation; Femal | 1977 |
[Antia-angina effect of verapamil through the clinical and ergometric evaluation].
Topics: Administration, Oral; Angina Pectoris; Clinical Trials as Topic; Drug Evaluation; Electrocardiograph | 1977 |
[Verapamil in the treatment of angina pectoris. Double-blind study with clinical-cycloergometric correlation].
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Drug Evaluation; Electrocardiography; Exerci | 1977 |
[The treatment of angina pectoris with a fixed combination of a beta-adrenoceptor blocker and a long-acting nitrate (double-blind trial) (author's transl)].
Topics: Aged; Angina Pectoris; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; D | 1977 |
[Effects of the association of Ca-antagonists with nitroderivatives or betablocking drugs in effort angina pectoris (author's transl)].
Topics: Adult; Angina Pectoris; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Electr | 1978 |
[Coronary sclerosis and angina pectoris. Clinical, double-blind study using Stenoptin].
Topics: Angina Pectoris; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Drug Combinations; | 1978 |
[Stenoptin in angina pectoris (author's transl)].
Topics: Adult; Aged; Angina Pectoris; Calcium; Clinical Trials as Topic; Double-Blind Method; Female; Humans | 1978 |
[Verapamil in the treatment of angina pectoris. Comparative double-blind study with fendilin].
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Electro | 1978 |
Effects of verapamil on myocardial performance in coronary disease.
Topics: Angina Pectoris; Blood Pressure; Cardiac Output; Clinical Trials as Topic; Coronary Disease; Heart; | 1979 |
[Effectiveness of two Ca-antagonistic drugs on angina pectoris: nifedipine and verapamil versus nitroderivative and beta-blocking drugs (author's transl)].
Topics: Angina Pectoris; Calcium; Clinical Trials as Topic; Drug Evaluation; Humans; Isosorbide Dinitrate; M | 1978 |
[Ergometric evaluation of the therapeutic effect of prolonged oral administration of delayed-action verapamil on 20 patients with stable effort angina].
Topics: Adult; Angina Pectoris; Clinical Trials as Topic; Delayed-Action Preparations; Drug Evaluation; Exer | 1978 |
Management of unstable angina at rest by verapamil. A double-blind cross-over study in coronary care unit.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Electro | 1979 |
[Verapamil in the treatment of angina pectoris. Double-blind study with clinical and ergometric evaluation].
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Electro | 1979 |
[Treatment of unstable angina with oral verapamil. Cross-over double-blind study].
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Humans; Middle Aged; Pl | 1978 |
[Controlled trial of effectiveness of verapamil in angina (author's transl)].
Topics: Angina Pectoris; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Isosorbide Dinitrate; | 1979 |
Double-blind comparison of verapamil and practolol in the treatment of angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Drug Evaluation; Exercise Te | 1977 |
Comparative effects of nifedipine, verapamil, isosorbide dinitrate and propranolol on exercise-induced angina pectoris.
Topics: Angina Pectoris; Blood Pressure; Cardiac Output; Electrocardiography; Heart Rate; Humans; Isosorbide | 1979 |
[Double blind study with verapamil and placebo. Therapeutic assay. Exertion test].
Topics: Adult; Aged; Angina Pectoris; Double-Blind Method; Drug Evaluation; Exercise Test; Female; Heart; Hu | 1979 |
[Effectiveness of verapamil in the treatment of unstable angina at rest. Double-blind crossover studies in the coronary care unit].
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Double-Blind Method; Drug Evaluation; Female; Heart Ra | 1977 |
Verapamil in ischaemic heart disease--quantitative assessment by serial multistage treadmill exercise.
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Coronary Disease; Drug Evaluation; Exercise | 1976 |
[The effects of verapamil on angina threshold during exercise (author's transl)].
Topics: Adult; Angina Pectoris; Clinical Trials as Topic; Dipyridamole; Drug Evaluation; Electrocardiography | 1976 |
Assessment of verapamil in the treatment of angina pectoris.
Topics: Aged; Angina Pectoris; Animals; Blood Pressure; Clinical Trials as Topic; Dogs; Dose-Response Relati | 1975 |
[Crossed double-blind multicentric studies of the effect of verapamil in patients with angina pectoris].
Topics: Administration, Oral; Angina Pectoris; Clinical Trials as Topic; Humans; Nitroglycerin; Placebos; Ve | 1975 |
[Effect of various antianginal agents on the frequency and duration of myocardial ischemic episodes in patients with stable angina pectoris].
Topics: Angina Pectoris; Drug Therapy, Combination; Humans; Myocardial Ischemia; Nifedipine; Periodicity; Pr | 1992 |
Efficacy of conventional and sustained-release verapamil in stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Blood Pressure; D | 1992 |
Treatment of transient myocardial ischemia in patients with stable angina: a comparative study of verapamil slow-release and nifedipine plus propranolol.
Topics: Adult; Aged; Angina Pectoris; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combinati | 1992 |
Low-dose verapamil in middle-aged and elderly patients with angina pectoris: no evidence of increased susceptibility to the cardiac effects.
Topics: Administration, Oral; Adult; Aged; Aging; Angina Pectoris; Blood Pressure; Female; Half-Life; Heart | 1992 |
Sustained-release verapamil and nifedipine in exercise-induced angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Elec | 1992 |
[Differential selection of anti-anginal drugs in stable stenocardia in relation to the data of central and intracardiac hemodynamics].
Topics: Adult; Angina Pectoris; Coronary Circulation; Female; Hemodynamics; Humans; Male; Middle Aged; Myoca | 1992 |
Treatment with verapamil after an acute myocardial infarction. Review of the Danish studies on verapamil in myocardial infarction (DAVIT I and II).
Topics: Angina Pectoris; Blood Pressure; Denmark; Double-Blind Method; Female; Heart Rate; Humans; Male; Met | 1991 |
Randomized double-blind comparison of the effects of isosorbide dinitrate retard, verapamil sustained-release, and their combination on myocardial ischemic episodes.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Coronary Disease; Delayed-Action Preparations; Double- | 1991 |
A comparison of sustained release verapamil versus atenolol for 24 h protection from exercise-induced angina pectoris.
Topics: Angina Pectoris; Atenolol; Delayed-Action Preparations; Double-Blind Method; Drug Administration Sch | 1991 |
Differences in response to single dose and steady-state therapy with verapamil in stable angina.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Blood Pressure; Coronary Disease; Double-Blind M | 1991 |
Double-blind randomised placebo-controlled dose-efficacy study of sustained release verapamil in chronic stable angina.
Topics: Aged; Angina Pectoris; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationship, Dru | 1991 |
[Evaluation of verapamil's effect on the circulation in angina pectoris].
Topics: Adult; Angina Pectoris; Double-Blind Method; Hemodynamics; Humans; Male; Middle Aged; Verapamil | 1991 |
[Anti-anginal effect of long-term use of obsidan, corinfar and finoptin in patients with stable exercise-induced stenocardia].
Topics: Angina Pectoris; Exercise Test; Humans; Nifedipine; Placebos; Propranolol; Time Factors; Verapamil | 1991 |
[Comparison of the efficacy of verapamil and diltiazem in stable exercise angina. A double-blind and crossover study].
Topics: Aged; Angina Pectoris; Clinical Trials as Topic; Coronary Angiography; Diltiazem; Double-Blind Metho | 1990 |
An exercise hemodynamic comparison of verapamil, diltiazem, and amlodipine in coronary artery disease.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Cardiac Output; Coronary Disease; Diltiazem; | 1990 |
[Relation of the anti-anginal effect and blood serum level of verapamil in patients with exercise-induced stenocardia].
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Dose-Response Relationship, Drug; Exercise T | 1990 |
The long-term treatment of stable angina pectoris with verapamil.
Topics: Angina Pectoris; Blood Pressure; Diastole; Double-Blind Method; Follow-Up Studies; Humans; Physical | 1990 |
Assessment of blindness in the Danish Verapamil Infarction Trial II (DAVIT II). Danish Study Group on Verapamil in Myocardial Infarction.
Topics: Adolescent; Adult; Aged; Angina Pectoris; Denmark; Female; Humans; Male; Middle Aged; Multicenter St | 1990 |
Bepridil versus verapamil in stable angina pectoris--a controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Bepridil; Calcium Channel Blockers; Clinical Trials | 1989 |
Comparison of the antianginal efficacy of four calcium antagonists and propranolol in stable angina pectoris.
Topics: Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Double-Blind Method; | 1989 |
[Evaluation using serial exercise tests of verapamil alone and combined with isosorbide dinitrate in exertional angina].
Topics: Adult; Aged; Angina Pectoris; Drug Evaluation; Drug Therapy, Combination; Electrocardiography; Exerc | 1989 |
Circadian variation in the pharmacokinetics of verapamil.
Topics: Angina Pectoris; Biological Availability; Circadian Rhythm; Delayed-Action Preparations; Double-Blin | 1989 |
Comparison of verapamil versus propranolol therapy in syndrome X.
Topics: Adult; Angina Pectoris; Clinical Trials as Topic; Electrocardiography; Female; Heart Rate; Humans; M | 1989 |
Elective response to propranolol or verapamil in ischemia on effort.
Topics: Adult; Angina Pectoris; Double-Blind Method; Electrocardiography; Exercise Test; Female; Humans; Mal | 1989 |
Sustained-release and instant-release verapamil in treatment of angina pectoris.
Topics: Angina Pectoris; Delayed-Action Preparations; Double-Blind Method; Electrocardiography; Exercise Tes | 1989 |
Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Calcium Channel Blockers; Chronic Disease; Cl | 1985 |
Antihypertensive therapy with calcium-channel blockers: comparison with beta blockers.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Clinical Tri | 1985 |
Comparative effects of calcium entry-blocking drugs, beta-blocking drugs, and their combination in patients with chronic stable angina.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease | 1987 |
Pharmacokinetics of calcium channel blocking agents.
Topics: Administration, Oral; Angina Pectoris; Atrial Fibrillation; Biological Availability; Cardiomegaly; C | 1986 |
The influence of fenflumizole on platelet aggregation in patients with unstable angina pectoris.
Topics: Adenosine Diphosphate; Adult; Aged; Angina Pectoris; Angina, Unstable; Anti-Inflammatory Agents; Ara | 1987 |
Bisoprolol in the treatment of angina pectoris: a double blind comparison with verapamil.
Topics: Adult; Angina Pectoris; Bisoprolol; Double-Blind Method; Drug Administration Schedule; Electrocardio | 1987 |
[The cardioprotective effect of verapamil in acute percutaneous transluminal coronary angioplasty].
Topics: Adult; Aged; Angina Pectoris; Angioplasty, Balloon; Clinical Trials as Topic; Coronary Circulation; | 1988 |
Verapamil versus acebutolol for syndrome X.
Topics: Acebutolol; Angina Pectoris; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Mi | 1988 |
[Bepridil in stable angina of effort: a double-blind comparison with verapamil].
Topics: Angina Pectoris; Bepridil; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; | 1988 |
An objective evaluation of once-daily sustained-release verapamil (480 mg) in chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Me | 1988 |
[Effects of isoptin and obsidan on the coronary blood flow and tactics in anti-angina therapy of patients with ischemic heart disease].
Topics: Adult; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Circulation; He | 1988 |
[Methodological approaches to the evaluation of the effectiveness of anti-anginal preparations in patients with stenocardia by 24-hour ECG monitoring].
Topics: Adult; Angina Pectoris; Circadian Rhythm; Clinical Trials as Topic; Electrocardiography; Exercise Te | 1988 |
[Comparative study of the effect of 3 calcium antagonists in chronic stable angina].
Topics: Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Chronic Disease; Clinical Trials as | 1988 |
Comparison of verapamil and propranolol therapy for angina pectoris at rest: a randomized, multiple-crossover, controlled trial in the coronary care unit.
Topics: Adult; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Coronary Care Units; Electrocardio | 1986 |
Sustained release verapamil, a once daily preparation: objective evaluation using exercise testing, ambulatory monitoring and blood levels in patients with stable angina.
Topics: Adult; Aged; Ambulatory Care; Angina Pectoris; Delayed-Action Preparations; Drug Administration Sche | 1987 |
Effects of a transdermal patch system containing nitroglycerin on exercise tolerance in patients with angina pectoris. Double-blind, placebo controlled, comparison with slow-release nifedipine and verapamil.
Topics: Administration, Cutaneous; Angina Pectoris; Blood Pressure; Delayed-Action Preparations; Double-Blin | 1986 |
[Anti-anginal and hemodynamic effects of single doses of propranolol, verapamil and nitroglycerin-depot in patients with stenocardia].
Topics: Adult; Angina Pectoris; Clinical Trials as Topic; Delayed-Action Preparations; Female; Hemodynamics; | 1988 |
Effectiveness of calcium antagonist drugs in patients with unstable angina and proven coronary artery disease.
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Calcium; Coronary Disease; Diltiazem; Electrocardiog | 1988 |
Sustained-release verapamil in stable angina.
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Me | 1988 |
Comparative effects of prolonged therapy with four calcium ion antagonists (diltiazem, nicardipine, tiapamil and verapamil) in patients with chronic stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Diltiazem; Female; Humans; | 1987 |
Comparison of the antianginal efficacy of isosorbide dinitrate (ISDN) 40 mg and verapamil 120 mg three times daily in the acute trial and following two-week treatment.
Topics: Acute Disease; Aged; Analysis of Variance; Angina Pectoris; Blood Pressure; Drug Administration Sche | 1988 |
Comparison of nicardipine and verapamil in the management of chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Coronary Disease; Double-Bli | 1988 |
[Verapamil versus propranolol in stable effort angina. Randomized, crossed, double-blind study].
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; | 1988 |
[Therapy of latent cardiomyopathy with verapamil].
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Female; Hemodynamics; Humans | 1987 |
[Comparative evaluation of 3 calcium antagonist drugs in patients with stable angina of effort. Double-blind placebo-controlled randomized study].
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Diltiazem; Exercise Test; Humans; Male; Midd | 1987 |
[Comparative effect of atenolol and verapamil in exertion angina. A single-blind crossed study with computerized exercise test].
Topics: Angina Pectoris; Atenolol; Clinical Trials as Topic; Computers; Exercise Test; Humans; Male; Middle | 1987 |
Calcium-channel blockers for combined angina pectoris and systemic hypertension.
Topics: Adult; Aged; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Chr | 1986 |
Regular formulation and sustained-release verapamil therapy in normotension and in mild to moderate hypertension.
Topics: Angina Pectoris; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Ad | 1986 |
Randomized placebo-controlled comparative study of nifedipine, verapamil and isosorbide dinitrate in the treatment of angina at rest.
Topics: Angina Pectoris; Clinical Trials as Topic; Coronary Disease; Delayed-Action Preparations; Dose-Respo | 1986 |
Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris.
Topics: Administration, Oral; Adult; Angina Pectoris; Clinical Trials as Topic; Drug Interactions; Drug Ther | 1986 |
Efficacy of sustained-release verapamil in chronic stable angina pectoris.
Topics: Angina Pectoris; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Delayed-Action Preparati | 1987 |
Improved left ventricular performance during exercise with verapamil or nifedipine in patients with chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardia | 1987 |
Calcium-channel blockers for combined systemic hypertension and myocardial ischemia.
Topics: Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Clinical Trials as Topic; Coronary Disea | 1987 |
A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris.
Topics: Aged; Angina Pectoris; Atenolol; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Double-B | 1987 |
Improvement in left ventricular diastolic function in patients with stable angina after chronic treatment with verapamil and nicardipine.
Topics: Adult; Aged; Angina Pectoris; Coronary Disease; Diastole; Double-Blind Method; Female; Heart Functio | 1987 |
[Comparative evaluation using an ergometric test of the efficacy of the 3 major calcium antagonists on exertion stable angina].
Topics: Adult; Angina Pectoris; Blood Pressure; Diltiazem; Double-Blind Method; Female; Heart Rate; Humans; | 1987 |
Nifedipine compared with verapamil in unstable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Drug Evaluation; Female; Follow-Up Studies; Humans; | 1986 |
[Diltiazem in spontaneous angina: comparison with nifedipine and verapamil].
Topics: Adult; Aged; Angina Pectoris; Benzazepines; Diltiazem; Drug Evaluation; Electrocardiography; Female; | 1985 |
Comparative haemodynamic effects of nicardipine and verapamil in coronary artery disease.
Topics: Adult; Angina Pectoris; Calcium Channel Blockers; Coronary Artery Bypass; Exercise Test; Hemodynamic | 1985 |
Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris: a placebo-controlled, double-blind, randomized, crossover study.
Topics: Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Double- | 1985 |
Are calcium antagonists cardioprotective?
Topics: Angina Pectoris; Animals; Blood Viscosity; Calcium Channel Blockers; Clinical Trials as Topic; Coron | 1985 |
Calcium blockers and beta blockers: alone and in combination.
Topics: Angina Pectoris; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Electrocardi | 1985 |
The effects on left ventricular performance of verapamil and metoprolol singly and together in exercise-induced angina pectoris.
Topics: Adult; Angina Pectoris; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Hear | 1985 |
[Dazoxiben compared with verapamil in the treatment of stable angina pectoris evaluated by an exercise test].
Topics: Aged; Angina Pectoris; Clinical Trials as Topic; Exercise Test; Female; Humans; Imidazoles; Male; Mi | 1985 |
Effects of verapamil in preventing early postinfarction angina and reinfarction.
Topics: Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Creatine Kinase; Electrocardiograph | 1985 |
Once-daily verapamil--an objective evaluation in stable angina pectoris using treadmill exercise testing.
Topics: Adult; Aged; Angina Pectoris; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administra | 1985 |
[Ergometric evaluation of corinfar, phenoptin, obsidan and 2% nitroglycerin ointment in exercise-induced stenocardia].
Topics: Adult; Angina Pectoris; Cardiovascular Agents; Clinical Trials as Topic; Exercise Test; Humans; Male | 1985 |
Myocardial catecholamine balance during angina: effects of calcium entry blockers, verapamil and nifedipine.
Topics: Aged; Angina Pectoris; Catecholamines; Epinephrine; Heart; Humans; Middle Aged; Myocardium; Nifedipi | 1985 |
Propranolol-verapamil versus propranolol-nifedipine in severe angina pectoris of effort: a randomized, double-blind, crossover study.
Topics: Angina Pectoris; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; Electrocardiography | 1985 |
Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Exercise Test; Female; Furan | 1973 |
Drugs for angina pectoris.
Topics: Angina Pectoris; Clinical Trials as Topic; Humans; Isosorbide Dinitrate; Propranolol; Verapamil | 1973 |
Verapamil. An anti-anginal agent.
Topics: Aged; Angina Pectoris; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middle Aged; | 1972 |
Angina drug trial: a comparison of the clinical use of vialibran and iproveratril.
Topics: Adult; Angina Pectoris; Anti-Arrhythmia Agents; Clinical Trials as Topic; Humans; Male; Middle Aged; | 1967 |
Verapamil in angina.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Clinical Trials as Topic; Humans; Nitriles; Vasodilator Age | 1968 |
Cordilox up to date.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Clinical Trials as Topic; Humans; Nitriles; Placebos; Vasod | 1969 |
Iproveratril and bronchial asthma.
Topics: Adolescent; Adult; Angina Pectoris; Anti-Arrhythmia Agents; Asthma; Clinical Trials as Topic; Female | 1970 |
[Isoptin treatment of patients with various forms of chronic coronary insufficiency].
Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Clinica | 1970 |
Investigation of verapamil in the treatment of angina pectoris.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Clinical Trials as Topic; Electrocardiography; Exercise Tes | 1970 |
Comparison of therapeutic effects of coronary drugs in the USSR.
Topics: Angina Pectoris; Benzoates; Benzyl Compounds; Clinical Trials as Topic; Coronary Disease; Coumarins; | 1971 |
Double blind evaluation of orally administered iproveratril in patients with angina pectoris.
Topics: Aged; Angina Pectoris; Anti-Arrhythmia Agents; Clinical Trials as Topic; Female; Humans; Male; Nitro | 1966 |
Clinical evaluation of verapamil in angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Blood Pressure; Clinical Trials as Topic; Elec | 1968 |
Treatment of angina pectoris.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Clinical Trials as Topic; Humans; Nitriles; Nitroglycerin; | 1968 |
Anti anginal drugs, their evaluation by double blind trial.
Topics: Adult; Aged; Angina Pectoris; Erythrityl Tetranitrate; Female; Humans; Isosorbide Dinitrate; Male; M | 1970 |
[Verapamil in the treatment of angina pectoris].
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Coronary Vessels; Heart; Humans; Nitriles; Nitroglycerin; P | 1970 |
[Isoptin in angina pectoris].
Topics: Aged; Angina Pectoris; Clinical Trials as Topic; Disability Evaluation; Humans; Male; Middle Aged; V | 1966 |
Iproveratril--a new coronary dilator.
Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Clinical Trials as Topic; Female; Humans; Male | 1967 |
[Clinical study of verampamil in the treatment of patients with chronic coronary insufficiency].
Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Arteriosclerosis; Corona | 1970 |
258 other studies available for verapamil and Angor Pectoris
| Article | Year |
|---|---|
Acute calcium channel blocker withdrawal-induced cardiac arrest.
Topics: Angina Pectoris; Calcium Channel Blockers; Coronary Vasospasm; Diagnosis, Differential; Female; Hear | 2019 |
[Diagnosis and treatment of spastic angina revealed by cardiac arrest].
Topics: Adult; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Vasospasm; Defibrillators, Im | 2014 |
[Verapamil-induced linear IgA disease mimicking toxic epidermal necrolysis].
Topics: Aged, 80 and over; Angina Pectoris; Autoimmune Diseases; Basement Membrane; Biopsy; Calcium Channel | 2011 |
Dihydroergotamine-induced vasospastic angina in a patient taking a calcium channel blocker.
Topics: Angina Pectoris; Calcium Channel Blockers; Coronary Vasospasm; Dihydroergotamine; Drug Interactions; | 2011 |
Calcium channel blockers revisited.
Topics: Angina Pectoris; Antihypertensive Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; China; Cli | 2002 |
Evaluation of a spasmolytic cocktail to prevent radial artery spasm during coronary procedures.
Topics: Aged; Angina Pectoris; Angioplasty; Coronary Angiography; Drug Therapy, Combination; Female; Humans; | 2003 |
Mibefradil: "Has the baby been thrown out with the bath water?".
Topics: Angina Pectoris; Calcium Channel Blockers; Calcium Channels, T-Type; Coronary Disease; Coronary Vess | 2003 |
[Diagnosis and therapy of stable angina in Russian Federation (International Study ATP - angina treatment pattern)].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angina Pectoris; Angiotens | 2003 |
[TREATMENT OF CORONARY CIRCULATORY DISORDERS WITH ISOPTIN IN GENERAL PRACTICE].
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Coronary Disease; Drug Therapy; Electrocardiography; Genera | 1964 |
The impact of diabetes or elevated fasting blood glucose on cardiovascular prognosis in patients with stable angina pectoris.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Blood Glucose; Cardiovascular Diseases; Diabetic Angiopathi | 2005 |
Shortening of the ventricular fibrillatory intervals after administration of verapamil in a patient with Brugada syndrome and vasospastic angina.
Topics: Adult; Angina Pectoris; Anti-Arrhythmia Agents; Bundle-Branch Block; Coronary Vasospasm; Electrocard | 2006 |
Ivabradine: new drug. Best avoided in stable angina.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Atenolol; Benzazepines; Calcium Channel Bl | 2007 |
A new coronary dilator in anginal syndrome. A preliminary report on clinical trial.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Female; Humans; Male; Vasodilator Agents; Verapamil | 1967 |
[Experimental basis for treatment with coronary dilators].
Topics: Angina Pectoris; Animals; Anti-Arrhythmia Agents; Coronary Disease; Humans; Oxygen Consumption; Prop | 1967 |
Drugs and the heart. III. Calcium antagonists.
Topics: Angina Pectoris; Aniline Compounds; Arrhythmias, Cardiac; Calcium; Cardiomegaly; Diuretics; Heart Di | 1980 |
Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan.
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Angina Pectoris, Variant; Anticoagulants; Coron | 1981 |
Long-term clinical effect of calcium inhibitors in hypertrophic cardiomyopathy compared to the effect of beta-blocking agents. A preliminary report with special reference to the beneficial effect of nifedipine on angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Blood Pressure; Calcium; Cardiomyopathy, Hypert | 1981 |
Another look at angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Coronary Artery Bypass; Humans; Vasodilator Agents; Ve | 1981 |
Calcium-entry blockade, beta-adrenergic blockade and the reflex control of circulation.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Coronary Disease; Drug Therapy, Combination; Hemodynam | 1982 |
Calcium blockers for heart disease: two approved, more to come.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Diltiazem; Drug Therapy, Com | 1982 |
But caution advised by the FDA in the use of combination therapy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Drug Therapy, Combination; Humans; Risk; United States | 1982 |
Recent concepts in the management of ischaemic cardiac syndromes.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; Co | 1982 |
[Treatment of angina pectoris with special reference to beta-blockers].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Anticoagulants; Calcium Channel Blockers; Diagnosis, D | 1982 |
Calcium-channel blockers and beta blockers: advantages and disadvantages of combination therapy in chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Atrioventricular Node; Calcium Channel Bl | 1982 |
Managing angina with calcium channel blockers.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; Dr | 1982 |
Calcium channel blocking drugs for chronic, stable angina. Verapamil.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Drug Therapy, Combination; Half-Life; Hemodynamics; Hu | 1982 |
Effects of antianginal drugs on ventricular function, myocardial blood flow and peripheral circulation.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Blood Circulation; Calcium Channel Blockers; Diltiazem | 1982 |
[Evaluation of anti-angina therapy by means of the treadmill test].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Bupranolol; Drug Therapy, Combination; Exerc | 1982 |
What is preferable in unstable angina, beta-blockade or calcium-inhibition?
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Animals; Calcium Channel Blockers; Coronary Dise | 1983 |
[Long-term study with Stenoptin in general practice].
Topics: Angina Pectoris; Cardiac Complexes, Premature; Coronary Disease; Drug Combinations; Drug Evaluation; | 1980 |
Therapeutic implications of slow-channel blockade in cardiocirculatory disorders.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium; Cardiovascular Diseases; Coronary Disease; Diltiazem | 1980 |
Calcium channels in the heart.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Diltiazem; Electric Conductivity; Heart; Hypertension; Ion Ch | 1981 |
Verapamil in chronic stable angina: amelioration of pacing-induced abnormalities of left ventricular ejection fraction, regional wall motion, lactate metabolism and hemodynamics.
Topics: Angina Pectoris; Cardiac Output; Cardiac Pacing, Artificial; Diphosphates; Heart Rate; Humans; Lacta | 1981 |
Calcium channel blockers for cardiovascular disorders.
Topics: Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calcium; Calcium Channel Blockers; | 1982 |
Calcium antagonist withdrawal syndrome: objective demonstration with frequency-modulated ambulatory ST-segment monitoring.
Topics: Aged; Angina Pectoris; Calcium; Diltiazem; Electrocardiography; Female; Humans; Male; Middle Aged; M | 1983 |
Calcium antagonists, nitrates, and new antianginal drugs.
Topics: Angina Pectoris; Calcium Channel Blockers; Humans; Hypertension; Isosorbide Dinitrate; Lidoflazine; | 1983 |
Long-term oral verapamil therapy in patients with rest angina.
Topics: Ambulatory Care; Angina Pectoris; Dose-Response Relationship, Drug; Electrocardiography; Exercise Te | 1983 |
Liver damage from verapamil.
Topics: Angina Pectoris; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Humans; Male; Middle | 1984 |
Lack of inhibition of anterior pituitary hormone release during chronic treatment with calcium antagonists.
Topics: Aged; Angina Pectoris; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; | 1984 |
Beta blockers and verapamil: a cautionary tale.
Topics: Adult; Aged; Angina Pectoris; Atenolol; Drug Therapy, Combination; Humans; Middle Aged; Verapamil | 1984 |
Left ventricular pump function in effort angina. Influence of nitroglycerin, propranolol, verapamil, and coronary bypass surgery.
Topics: Angina Pectoris; Cardiac Output; Coronary Artery Bypass; Exercise Test; Heart; Humans; Nitroglycerin | 1984 |
Treatment of unstable angina with emphasis on calcium antagonists.
Topics: Angina Pectoris; Angina, Unstable; Anticoagulants; Coronary Circulation; Coronary Disease; Electroca | 1984 |
Probable adverse interaction between oral metoprolol and verapamil.
Topics: Angina Pectoris; Drug Interactions; Drug Therapy, Combination; Heart Block; Humans; Male; Metoprolol | 1984 |
[Possibility of developing tolerance to the antianginal effect of verapamil].
Topics: Angina Pectoris; Dose-Response Relationship, Drug; Drug Evaluation; Drug Tolerance; Exercise Test; H | 1984 |
Haemodynamic dose-response effects of i.v. verapamil in coronary artery disease.
Topics: Adult; Angina Pectoris; Blood Pressure; Cardiac Output; Coronary Disease; Dose-Response Relationship | 1984 |
[Comparative effectiveness of finoptin, corinfar and their combination in patients with angina pectoris].
Topics: Adult; Angina Pectoris; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1984 |
Mechanism(s) of calcium antagonists and ischemia.
Topics: Adenosine Triphosphate; Angina Pectoris; Angina, Unstable; Calcium Channel Blockers; Coronary Circul | 1984 |
[Multicenter long-term study of gallopamil in patients with coronary heart disease].
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Coronary Disease; Electrocardiography; Female; Gallopa | 1984 |
Calcium channel blockers. New treatment for cardiovascular disease.
Topics: Adult; Angina Pectoris; Calcium; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Cardiovascu | 1983 |
Keeping pace with calcium channel blockers.
Topics: Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; Drug Interactions; Education, N | 1983 |
Effect of verapamil on serum lipoproteins in patients with angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Lipop | 1984 |
Effects of intravenous verapamil on the haemodynamic response to exercise in patients with angina pectoris.
Topics: Adult; Angina Pectoris; Cardiac Output; Cardiac Volume; Exercise Test; Humans; Infusions, Parenteral | 1984 |
Clinical use of calcium channel blockers.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Diltiazem; Drug Therapy, Combinatio | 1983 |
[Use of Falicard and Sectral in patients with COPD and ischemic heart disease].
Topics: Angina Pectoris; Atenolol; Coronary Disease; Drug Evaluation; Drug Therapy, Combination; Humans; Lun | 1983 |
Calcium channel blocking agents. Council on scientific affairs.
Topics: Angina Pectoris; Animals; Arrhythmias, Cardiac; Asthma; Calcium Channel Blockers; Cardiomyopathy, Hy | 1983 |
Verapamil treatment of intractable ventricular arrhythmias after cardiopulmonary bypass.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Cardiopulmonary Bypass; Heart Arrest, Induced; Humans; Male; | 1984 |
[Pharmacodynamic comparison of propranolol and verapamil in exertion stenocardia].
Topics: Adult; Angina Pectoris; Coronary Disease; Dose-Response Relationship, Drug; Exercise Test; Humans; M | 1984 |
Plasma verapamil levels and exercise performance.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Dose-Response Relationship, Drug; Double-Blind M | 1984 |
The effects on left ventricular performance of nifedipine and verapamil in exercise-induced angina pectoris.
Topics: Adult; Angina Pectoris; Blood Pressure; Cardiac Output; Heart; Humans; Male; Middle Aged; Nifedipine | 1984 |
Pathophysiology and treatment of coronary arterial spasm.
Topics: Adult; Angina Pectoris; Angina Pectoris, Variant; Atropine; Calcium; Coronary Disease; Coronary Vess | 1980 |
Long-term prognosis of "variant" angina with medical treatment.
Topics: Adult; Aged; Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Arteriosclerosis; Coro | 1980 |
Ergonovine testing to detect spontaneous remissions of variant angina during long-term treatment with calcium antagonist drugs.
Topics: Adult; Aged; Angina Pectoris; Angina Pectoris, Variant; Calcium; Diltiazem; Ergonovine; Female; Foll | 1981 |
Comparative effects of nifedipine, verapamil, isosorbide dinitrate and propranolol on exercise-induced angina pectoris.
Topics: Angina Pectoris; Humans; Isosorbide Dinitrate; Middle Aged; Nifedipine; Physical Exertion; Propranol | 1980 |
Vasodilators for angina pectoris.
Topics: Angina Pectoris; Humans; Nifedipine; Nitroglycerin; Vasodilator Agents; Verapamil | 1981 |
Prinzmetal's variant angina.
Topics: Aged; Angina Pectoris; Angina Pectoris, Variant; Diagnosis, Differential; Electrocardiography; Femal | 1981 |
Verapamil therapy in variant angina pectoris refractory to nitrates.
Topics: Adult; Aged; Angina Pectoris; Angina Pectoris, Variant; Electrocardiography; Ergonovine; Female; Hum | 1981 |
Comparison of metoprolol and verapamil in the treatment of angina pectoris.
Topics: Adult; Angina Pectoris; Double-Blind Method; Female; Humans; Male; Metoprolol; Middle Aged; Nitrogly | 1982 |
Additive antianginal effect of verapamil in patients receiving propranolol.
Topics: Angina Pectoris; Drug Therapy, Combination; Humans; Propranolol; Verapamil | 1982 |
Additive antianginal effect of verapamil in patients receiving propranolol.
Topics: Angina Pectoris; Drug Therapy, Combination; Humans; Propranolol; Verapamil | 1982 |
Verapamil in the long-term treatment of angina pectoris.
Topics: Angina Pectoris; Bradycardia; Calcium Channel Blockers; Constipation; Coronary Disease; Dose-Respons | 1982 |
[Double-blind comparison between verapamil and propranolol in the therapy of unstable angina].
Topics: Aged; Angina Pectoris; Angina, Unstable; Double-Blind Method; Drug Evaluation; Female; Humans; Male; | 1982 |
[Significance of transitory and asymptomatic ECG changes evaluated in a population of subjects with documented myocardial ischemia].
Topics: Angina Pectoris; Coronary Disease; Electrocardiography; Humans; Male; Middle Aged; Nitroglycerin; Ve | 1982 |
Calcium channel blockers.
Topics: Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calcium Channel Blockers; Diltiazem | 1983 |
Therapeutic uses of calcium channel blockers.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiovascular System; Diltiazem; | 1983 |
Comment on verapamil evaluation.
Topics: Angina Pectoris; Calcium Channel Blockers; Humans; Verapamil | 1983 |
Comparison of verapamil and nifedipine in chronic stable angina pectoris.
Topics: Angina Pectoris; Humans; Nifedipine; Pyridines; Verapamil | 1983 |
Mechanism of relief of pacing induced angina with oral verapamil: reduced oxygen demand.
Topics: Administration, Oral; Aged; Angina Pectoris; Cardiac Pacing, Artificial; Coronary Circulation; Femal | 1983 |
[Dose-effect dependence after taking calcium antagonists in exertion stenocardia patients].
Topics: Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Dose-Response Relationship, Drug; Drug E | 1983 |
Oral verapamil does not affect glucose tolerance in non-diabetics.
Topics: Adult; Angina Pectoris; Female; Glucose Tolerance Test; Humans; Male; Middle Aged; Time Factors; Ver | 1983 |
Pharmacokinetics of verapamil and norverapamil during long-term oral therapy.
Topics: Aged; Angina Pectoris; Biotransformation; Humans; Kinetics; Male; Middle Aged; Time Factors; Verapam | 1983 |
Comparison of two calcium antagonists, verapamil and fendiline, in an experimental model of myocardial ischaemia mimicking classical angina on effort.
Topics: Angina Pectoris; Animals; Calcium Channel Blockers; Coronary Disease; Dogs; Electrocardiography; Fem | 1983 |
[Therapeutic association in chronic stable angina: verapamil plus beta-blockers].
Topics: Angina Pectoris; Chronic Disease; Drug Therapy, Combination; Humans; Sympatholytics; Verapamil | 1983 |
[Drug information. Therapeutic main group: agents for the treatment of angina pectoris. 8. Angina pectoris agents with effect on calcium metabolism].
Topics: Angina Pectoris; Calcium; Humans; Nifedipine; Pyridines; Verapamil | 1980 |
[Drug information. Therapeutic main group: agents for the treatment of angina pectoris. 9. Angina pectoris agents with effect on calcium metabolism].
Topics: Angina Pectoris; Calcium; Humans; Nifedipine; Pyridines; Verapamil | 1980 |
[Evaluation of the efficacy of verapamil in slow-release preparations in the treatment of stable exertion angina].
Topics: Aged; Angina Pectoris; Delayed-Action Preparations; Exercise Test; Humans; Male; Middle Aged; Time F | 1982 |
Prinzmetal's variant angina)(PVA). Circadian variation in response to hyperventilation.
Topics: Angina Pectoris; Angina Pectoris, Variant; Circadian Rhythm; Electrocardiography; Humans; Hyperventi | 1981 |
Combined therapy with verapamil and propranolol in chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; F | 1982 |
Symposium on Cardiovascular Disease and Calcium Antagonists. Introduction.
Topics: Angina Pectoris; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Diltiazem; Humans; Myocard | 1982 |
The effects of calcium channel blocking agents on cardiovascular function.
Topics: Angina Pectoris; Animals; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Coronary Disease | 1982 |
The effects of intravenous verapamil on hemodynamic status of patients with coronary artery disease receiving propranolol.
Topics: Adult; Aged; Angina Pectoris; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1982 |
Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man.
Topics: Adult; Aged; Angina Pectoris; Coronary Disease; Drug Therapy, Combination; Electrocardiography; Fema | 1982 |
New angina drugs.
Topics: Angina Pectoris; Calcium Channel Blockers; Humans; Nifedipine; Pyridines; Verapamil | 1982 |
Suppression of ischemic related ventricular tachycardia by verapamil during treadmill exercise testing.
Topics: Adult; Angina Pectoris; Coronary Disease; Depression, Chemical; Electrocardiography; Exercise Test; | 1982 |
Effects of verapamil on exercise performance in chronic angina pectoris.
Topics: Administration, Oral; Angina Pectoris; Chronic Disease; Humans; Middle Aged; Physical Exertion; Vera | 1982 |
Oral verapamil for angina pectoris.
Topics: Administration, Oral; Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; Drug Inte | 1982 |
Verapamil in effort-induced angina pectoris in patients with normal coronary arteries.
Topics: Angina Pectoris; Coronary Angiography; Coronary Vessels; Exercise Test; Female; Humans; Middle Aged; | 1982 |
Hemodynamic and electrophysiologic effects of verapamil and nifedipine in patients on propranolol.
Topics: Angina Pectoris; Cardiac Output; Coronary Circulation; Drug Therapy, Combination; Electrophysiology; | 1982 |
Verapamil versus propranolol for angina at rest.
Topics: Angina Pectoris; Angina Pectoris, Variant; Coronary Disease; Coronary Vasospasm; Ergonovine; Humans; | 1982 |
Calcium channel blockers in chronic stable angina. A review.
Topics: Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Diltiazem; Electrocardiography; Humans; | 1982 |
Emergency treatment of angina during angiography.
Topics: Angina Pectoris; Cardiac Catheterization; Humans; Male; Middle Aged; Verapamil | 1982 |
[Calcium antagonists in stress angina pectoris (pharmacodynamic study)].
Topics: Adult; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; | 1982 |
Effects of calcium antagonists, especially nifedipine, on variant angina, resting angina, and unstable angina.
Topics: Aged; Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; Coronary Vasospasm; Dilti | 1982 |
Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Coronary Disease; Heart Ventricles; Hemodynamics; Huma | 1981 |
Hepatotoxicity due to treatment with verapamil.
Topics: Angina Pectoris; Chemical and Drug Induced Liver Injury; Double-Blind Method; Humans; Liver Function | 1981 |
Verapamil administration in variant angina pectoris. Efficacy shown by ecg monitoring.
Topics: Administration, Oral; Adult; Angina Pectoris; Angina Pectoris, Variant; Electrocardiography; Female; | 1981 |
Verapamil therapy in variant angina: assessment by high-fidelity frequency modulated ambulatory ECG.
Topics: Aged; Ambulatory Care; Angina Pectoris; Angina Pectoris, Variant; Electrocardiography; Female; Human | 1981 |
[The ergometric test in the evaluation of the effects of nifedipine, verapamil and ethyl cinepazat maleate in angina of effort].
Topics: Adult; Angina Pectoris; Drug Evaluation; Exercise Test; Female; Hemodynamics; Humans; Male; Middle A | 1980 |
Coronary artery spasm during exercise: treatment with verapamil.
Topics: Angina Pectoris; Angina Pectoris, Variant; Exercise Test; Female; Humans; Male; Middle Aged; Physica | 1981 |
[Hourly distribution of episodes of angina at rest. Effect of medical treatment].
Topics: Adult; Angina Pectoris; Electrocardiography; Humans; Isosorbide; Male; Middle Aged; Monitoring, Phys | 1981 |
Provocative testing with ergonovine to assess the efficacy of treatment with nifedipine, diltiazem and verapamil in variant angina.
Topics: Adult; Aged; Angina Pectoris; Angina Pectoris, Variant; Benzazepines; Coronary Angiography; Diltiaze | 1981 |
Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris.
Topics: Adult; Angina Pectoris; Blood Circulation; Drug Therapy, Combination; Electrocardiography; Ergonovin | 1981 |
[Calcium antagonists: use with discretion].
Topics: Angina Pectoris; Calcium Channel Blockers; Humans; Myocardial Contraction; Nifedipine; Verapamil | 1981 |
Calcium antagonists.
Topics: Angina Pectoris; Calcium Channel Blockers; Cell Membrane; Diltiazem; Heart; Humans; Hypertension; Mu | 1980 |
Clinical use of calcium entry blockers.
Topics: Angina Pectoris; Calcium Channel Blockers; Cinnarizine; Coronary Circulation; Coronary Vasospasm; Di | 1981 |
[Use of verapamil in the treatment of pain in acute myocardial infarction].
Topics: Adult; Aged; Angina Pectoris; Female; Hemodynamics; Humans; Infusions, Parenteral; Male; Middle Aged | 1981 |
[Arrhythmias of reperfusion in ischemic cardiopathy: clinical significance and therapeutic possibilities].
Topics: Angina Pectoris; Animals; Arrhythmias, Cardiac; Cats; Coronary Circulation; Coronary Disease; Electr | 1980 |
[Calcium inhibitors. Current indications in cardiology].
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium; Cardiovascular Diseases; Diltiazem; Humans; Nifedipi | 1980 |
Exercise-induced S-T segment elevation in variant angina.
Topics: Ambulatory Care; Angina Pectoris; Angina Pectoris, Variant; Coronary Angiography; Coronary Disease; | 1980 |
Verapamil in the long-term treatment of angina pectoris.
Topics: Angina Pectoris; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Time Factors; Verap | 1980 |
Antianginal and myocardial metabolic properties of verapamil in coronary artery disease.
Topics: Angina Pectoris; Calcium; Coronary Circulation; Coronary Disease; Electrocardiography; Hemodynamics; | 1980 |
[Effect of single dose administration of a new beta-blockader (pindolol) prior to onset of angina pectoris as evaluated by exercise tests on a bicycle ergometer].
Topics: Angina Pectoris; Drug Evaluation; Electrocardiography; Exercise Test; Humans; Isosorbide Dinitrate; | 1980 |
[Prolonged diastolic cardiac arrest during coronary angiography in a patient with Prinzmetal's angina under verapamil treatment. Reversibility under extracorporeal circulation].
Topics: Angina Pectoris; Angina Pectoris, Variant; Angiocardiography; Extracorporeal Circulation; Heart Arre | 1980 |
Refractory variant angina controlled with combined drug therapy in a patient with a single coronary artery.
Topics: Adult; Angina Pectoris; Angina Pectoris, Variant; Angiocardiography; Arteries; Coronary Vessel Anoma | 1980 |
Myocardial metabolism and anginal threshold in coronary disease after verapamil administration.
Topics: Angina Pectoris; Blood Pressure; Coronary Disease; Electrocardiography; Heart; Humans; Lactates; Mal | 1980 |
A comparative study of calcium-ion antagonists in patients with variant angina.
Topics: Adult; Aged; Angina Pectoris; Angina Pectoris, Variant; Benzazepines; Diltiazem; Electrocardiography | 1980 |
[Electrocardiographic evaluation of anti-ischemic effect of verapamil during angioplasty].
Topics: Adult; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Electrocardiography; Female; Humans; I | 1994 |
[The antianginal efficacy of verapamil and nitrosorbide used separately and jointly in patients with angina of effort].
Topics: Angina Pectoris; Dose-Response Relationship, Drug; Drug Evaluation; Drug Synergism; Drug Therapy, Co | 1993 |
[Hemodynamic basis of antianginal effect of calcium antagonists in patients with ischemic heart disease after aortocoronary shunting: myocardial reserve potentials and their mechanisms].
Topics: Adult; Angina Pectoris; Coronary Artery Bypass; Dose-Response Relationship, Drug; Exercise Test; Hem | 1993 |
Bioequivalence revisited: non-parametric analysis of two-period cross-over studies.
Topics: Algorithms; Analysis of Variance; Angina Pectoris; Bepridil; Computer Simulation; Confidence Interva | 1993 |
Oral verapamil inhibits platelet thrombus formation in humans.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Blood Pressure; Delaye | 1994 |
Primary prevention in patients with coronary heart disease: the APSIS study.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Coronary Disease; Female; Hu | 1995 |
[Calcium antagonist protects the heart from ischemia and thrombosis].
Topics: Angina Pectoris; Calcium Channel Blockers; Coronary Thrombosis; Dose-Response Relationship, Drug; Hu | 1996 |
Calcium antagonists and prevention of ventricular fibrillation induced by transient or persistent ischemia.
Topics: Analysis of Variance; Angina Pectoris; Animals; Calcium Channel Blockers; Coronary Disease; Electrop | 1997 |
[Stable angina pectoris: what is the role of calcium antagonists?].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Calcium Channel Blockers; Clinical Trials as | 1997 |
Covera-HS offers proven protection in hypertension and angina in alignment with circadian rhythm.
Topics: Angina Pectoris; Chronotherapy; Delayed-Action Preparations; Humans; Hypertension; Vasodilator Agent | 1997 |
Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina.
Topics: Adult; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Female; Humans; Hypertension; Male | 2002 |
[Conservative therapy of coronary disease].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Coronary Disease; Electrocardiography; Exercise Test; | 1976 |
[Calcium blocker (calcium antagonists) and angina pectoris].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Blood Vessels; Calcium; Diltiazem; Female; Humans; Mus | 1977 |
[Prinzmetal's angina. Considerations on a clinical case].
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Angina Pectoris, Variant; Aspirin; Electrocardi | 1977 |
The treatment of angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Coronary Angiography; Humans; Isosorbide Dinitrate; Mi | 1979 |
[Experience with the use of izoptina].
Topics: Angina Pectoris; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Follow-Up | 1975 |
Treatment of Prinzmetal's angina due to coronary artery spasm using verapamil: a report of three cases.
Topics: Angina Pectoris; Angina Pectoris, Variant; Atropine; Coronary Disease; Electrocardiography; Heart Bl | 1978 |
The management of the patient with angina.
Topics: Angina Pectoris; Anticoagulants; Clofibrate; Coronary Artery Bypass; Diazepam; Digoxin; Humans; Isos | 1977 |
[Intravenous verapamil in the treatment of acute coronary insufficiency].
Topics: Acute Disease; Adult; Aged; Angina Pectoris; Coronary Disease; Female; Humans; Male; Middle Aged; My | 1979 |
[Coronary disease and calcium antagonists].
Topics: Angina Pectoris; Calcium; Coronary Disease; Diltiazem; Humans; Nifedipine; Verapamil | 1979 |
[Comparative study of the effectiveness of verapamil and propranolol in unstable angina].
Topics: Adult; Aged; Angina Pectoris; Female; Hemodynamics; Humans; Male; Middle Aged; Propranolol; Verapami | 1978 |
Drug treatment of chronic stable angina pectoris.
Topics: Angina Pectoris; Chronic Disease; Humans; Nifedipine; Nitrites; Perhexiline; Verapamil | 1978 |
Prinzmetal's variant angina--response to verapamil.
Topics: Adult; Angina Pectoris; Angina Pectoris, Variant; Humans; Male; Verapamil | 1978 |
[Calcium antagonists].
Topics: Angina Pectoris; Arrhythmias, Cardiac; Benzazepines; Calcium; Diltiazem; Humans; Male; Middle Aged; | 1978 |
[Influence of verapamil on the exercise tolerance test in patients with angina pectoris].
Topics: Adult; Angina Pectoris; Blood Pressure; Double-Blind Method; Exercise Test; Heart Rate; Hemodynamics | 1978 |
[Calcium antagonists in acute coronary insufficiency].
Topics: Acute Disease; Adult; Aged; Angina Pectoris; Arrhythmias, Cardiac; Calcium; Coronary Disease; Female | 1978 |
[Verapamil nowadays].
Topics: Angina Pectoris; Humans; Injections, Intravenous; Tachycardia; Ventricular Fibrillation; Verapamil; | 1977 |
[Calcium antagonists in Prinzmetals angina].
Topics: Angina Pectoris; Angina Pectoris, Variant; Calcium; Humans; Male; Middle Aged; Nifedipine; Pyridines | 1976 |
Verapamil and the heart: Pharmacological and Therapeutic Considerations.
Topics: Angina Pectoris; Animals; Arrhythmias, Cardiac; Atrioventricular Node; Calcium; Dogs; Electrophysiol | 1975 |
[Venous infusion of nerapamil in the treatment of refractory angina pectoris and arrhythmia due to associated electric instability].
Topics: Adult; Angina Pectoris; Angiography; Arrhythmias, Cardiac; Atrial Fibrillation; Coronary Angiography | 1975 |
[Clinical results with verapamil in the treatment of acute coronary insufficiency].
Topics: Acute Disease; Angina Pectoris; Humans; Myocardial Infarction; Verapamil | 1975 |
[Anti-arrhythmic therapy with verapamil by intravenous infusion].
Topics: Adolescent; Adult; Aged; Angina Pectoris; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; | 1975 |
[Clinical and hemodynamic evaluation of the use of verapamil in stenocardia].
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Female; Heart Rate; Hemodynamics; Humans; Male; Middle | 1975 |
Cocaine abuse: an expanding healthcare problem for the 1990s.
Topics: Adult; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Cardiomyopathies; C | 1992 |
[Therapy of coronary disease].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Aspirin; Calcium Channel Blockers; Clinical Trials as | 1992 |
[The effect of verapamil on the course of stenocardia of effort, on the blood serum lipid level and on the basic indices of carbohydrate metabolism during the long-term use of the preparation].
Topics: Adult; Angina Pectoris; Carbohydrates; Drug Evaluation; Exercise Tolerance; Glucose Tolerance Test; | 1992 |
[Effects of calcium antagonists on functional properties of monocytes in patients with ischemic heart disease].
Topics: Angina Pectoris; Calcium Channel Blockers; Coronary Disease; Cyclic AMP; Humans; In Vitro Techniques | 1991 |
[Anti-anginal effects of calcium antagonists and intra-cardiac hemodynamics].
Topics: Adult; Angina Pectoris; Cardiac Output; Exercise Test; Humans; Male; Middle Aged; Myocardial Contrac | 1991 |
[Effects of calcium antagonists on the pattern of intracardiac hemodynamics and functional state of the myocardium in patients with angina pectoris relapsing after aortocoronary bypass operation].
Topics: Adult; Angina Pectoris; Calcium Channel Blockers; Coronary Artery Bypass; Coronary Disease; Hemodyna | 1991 |
Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin.
Topics: Aged; Angina Pectoris; Calcium Channel Blockers; Carbamazepine; Diltiazem; Drug Interactions; Female | 1991 |
Effects of intravenous verapamil on left ventricular relaxation and filling in stable angina pectoris.
Topics: Adult; Angina Pectoris; Cardiac Catheterization; Coronary Angiography; Female; Humans; Infusions, In | 1990 |
[The use of verapamil in suppositories for treating patients with ischemic heart disease].
Topics: Aged; Angina Pectoris; Arrhythmias, Cardiac; Coronary Disease; Drug Evaluation; Female; Hemodynamics | 1990 |
Effects of verapamil on the anaerobic threshold and peak oxygen consumption in effort angina pectoris.
Topics: Adult; Aged; Anaerobic Threshold; Angina Pectoris; Electrocardiography; Exercise Test; Humans; Middl | 1990 |
[The use of finoptin and alpha-tocopherol in patients with stable exertional stenocardia].
Topics: Adult; Angina Pectoris; Drug Evaluation; Drug Therapy, Combination; Humans; Male; Middle Aged; Physi | 1990 |
Calcium channel blocking drugs. Part II: Clinical applications.
Topics: Angina Pectoris; Angina Pectoris, Variant; Angina, Unstable; Arrhythmias, Cardiac; Calcium Channel B | 1985 |
[Exercise capacity of coronary heart disease patients in long-term follow-up with gallopamil in comparison with premedication with verapamil].
Topics: Aged; Angina Pectoris; Arrhythmias, Cardiac; Coronary Disease; Electrocardiography; Exercise Test; F | 1989 |
[Membrane-protective effect of finoptin in exertion-induced stenocardia].
Topics: Adult; Angina Pectoris; Calcium; Calcium-Transporting ATPases; Erythrocyte Membrane; Humans; Male; M | 1989 |
[Combination therapy with isosorbide dinitrate and verapamil in patients with coronary heart disease and hypertension: effect on blood pressure, ischemia and left ventricular function].
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Cardiac Output; Coronary Circulation; Coronary Disease | 1989 |
[Evaluation of the efficacy of a course of verapamil and nifedipine in patients with stable stenocardia by daily monitoring of the electrocardiogram].
Topics: Adult; Angina Pectoris; Circadian Rhythm; Drug Evaluation; Drug Therapy, Combination; Electrocardiog | 1989 |
[Nifedipine and verapamil in the treatment of ischemic heart disease and hypertension].
Topics: Angina Pectoris; Coronary Disease; Dose-Response Relationship, Drug; Humans; Hypertension; Nifedipin | 1989 |
[Effect of alpha-tocopherol combined with finoptin on the level of lipid hydroperoxides in plasma lipoproteins and on the functional activity of thrombocytes in patients with exertion-induced stable stenocardia].
Topics: Adult; Angina Pectoris; Calcium Channel Blockers; Drug Therapy, Combination; Humans; Hydrogen Peroxi | 1989 |
[The efficacy of the long-term therapy of patients with stable stenocardia using korinfar and finoptin].
Topics: Adult; Angina Pectoris; Drug Evaluation; Drug Therapy, Combination; Exercise Test; Hemodynamics; Hum | 1989 |
[Variations in left ventricular function during chronic therapy with verapamil in angina patients. Influence of the plasma concentration of the drug. Quantitative M-mode echocardiographic analysis].
Topics: Adult; Angina Pectoris; Echocardiography; Female; Heart Ventricles; Humans; Male; Middle Aged; Verap | 1989 |
Tolerability of combined treatment with verapamil and beta-blockers in angina resistant to monotherapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Atenolol; Drug Therapy, Combination; Drug | 1985 |
Prevention of atheromatous heart disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aloe; Angina Pectoris; Blood Glucose; Cholesterol; Cholest | 1985 |
Clinical and research applications of ambulatory Holter ST-segment and heart rate monitoring.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angina Pectoris, Variant; Blood Pressure; Corona | 1986 |
Verapamil in angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Coronary Disease; Hemodynamics; Humans; Verapamil | 1986 |
Effects of verapamil on left ventricular relaxation and filling dynamics in coronary artery disease: a study by pulsed Doppler echocardiography.
Topics: Adult; Aged; Angina Pectoris; Blood Flow Velocity; Blood Pressure; Cardiac Output; Diastole; Echocar | 1989 |
[Influence of antianginal drugs on Lypressin induced T-wave enhancement in the electrocardiogram of the rat].
Topics: Administration, Oral; Angina Pectoris; Animals; Coronary Vasospasm; Electrocardiography; Hypoxia; Is | 1986 |
[Unstable stenocardia: indicators of platelet activity and the effect of verapamil].
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; beta-Thromboglobulin; Blood Platelets; Humans; Male; | 1987 |
Dose-response scrutiny of coronary vasodilation after intracoronary verapamil in man. A quantitative cineangiographic study.
Topics: Adult; Angina Pectoris; Cineangiography; Coronary Circulation; Coronary Disease; Coronary Vessels; D | 1986 |
[Reversion of angina refractory to the use of nitrates with the utilization of intravenous verapamil during heart catheterization].
Topics: Angina Pectoris; Cardiac Catheterization; Drug Resistance; Female; Hemodynamics; Humans; Injections, | 1987 |
Improvement in left ventricular diastolic function in patients with stable angina after chronic treatment with verapamil and nicardipine.
Topics: Adult; Aged; Angina Pectoris; Diastole; Female; Humans; Male; Middle Aged; Myocardial Contraction; N | 1988 |
Unstable angina with tachycardia: clinical and therapeutic implications.
Topics: Aged; Amiodarone; Angina Pectoris; Angina, Unstable; Electrocardiography; Female; Heart Rate; Humans | 1988 |
[Calcium antagonists in the treatment of stenocardia].
Topics: Angina Pectoris; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; Drug Therapy, Co | 1988 |
[Calcium antagonists in angina pectoris].
Topics: Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; Diltiazem; Gallopamil; Humans; | 1988 |
[Interactions of propranolol with nifedipine, verapamil and diltiazem].
Topics: Adult; Angina Pectoris; Diltiazem; Drug Interactions; Drug Therapy, Combination; Humans; Male; Middl | 1988 |
Verapamil-mediated atrioventricular nodal reentrant tachycardia and the uncovering of dual-pathway AV nodal conduction.
Topics: Aged; Angina Pectoris; Atrioventricular Node; Electrocardiography; Heart Conduction System; Heart Ra | 1988 |
The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.
Topics: Adult; Angina Pectoris; Blood Pressure; Drug Therapy, Combination; Electrocardiography; Heart Rate; | 1988 |
The effects of the novel anti-anginal compound RS 43285 on myocardial conduction in the anaesthetized dog.
Topics: Acetanilides; Anesthesia; Angina Pectoris; Animals; Atrioventricular Node; Dogs; Electrocardiography | 1988 |
Verapamil in unstable angina pectoris: failure to demonstrate a relationship between efficacy and plasma levels.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Female; Humans; Male; Middle Aged | 1988 |
[Study of anti-ischemic effects of verapamil and nifedipine after long-term treatment of patients with exertion-induced stenocardia].
Topics: Adult; Angina Pectoris; Coronary Circulation; Female; Humans; Male; Middle Aged; Nifedipine; Physica | 1988 |
[Effect of verapamil on the relaxation function of the heart in patients with stenocardia].
Topics: Adult; Aged; Angina Pectoris; Humans; Middle Aged; Myocardial Contraction; Parasympatholytics; Verap | 1988 |
[Use of decimeter microwaves and drugs in patients with unstable stenocardia].
Topics: Angina Pectoris; Angina, Unstable; Combined Modality Therapy; Delayed-Action Preparations; Drug Ther | 1987 |
[Clinical effectiveness of plasmapheresis in patients with unstable stenocardia refractory to drug therapy].
Topics: Adolescent; Adult; Aged; Angina Pectoris; Angina, Unstable; Humans; Middle Aged; Nitrates; Plasmaphe | 1987 |
Use of combined calcium channel blockers for therapy of refractory angina pectoris.
Topics: Adult; Angina Pectoris; Benzazepines; Diltiazem; Dose-Response Relationship, Drug; Drug Therapy, Com | 1986 |
Calcium channel antagonists--cardiovascular therapy for the eighties?
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; | 1986 |
[Aorto-coronary bypass surgery in variant angina and ST-elevation angina].
Topics: Adult; Aged; Angina Pectoris; Angina Pectoris, Variant; Coronary Artery Bypass; Coronary Vasospasm; | 1986 |
[Evaluation of the efficacy of verapamil and nifedipine as long-term crossover therapy with individually selected doses in ischemic heart disease. Work Group for the Cooperative Study of Antianginal Preparations (SCAP)].
Topics: Adult; Angina Pectoris; Coronary Disease; Exercise Test; Humans; Male; Middle Aged; Nifedipine; Time | 1987 |
[Relation between the antianginal efficacy of calcium antagonists in angina pectoris patients and the length of treatment].
Topics: Adult; Angina Pectoris; Calcium Channel Blockers; Humans; Male; Middle Aged; Nifedipine; Time Factor | 1987 |
Conventional and slow release formulations of nifedipine and verapamil are more effective than slow release isosorbide dinitrate (ISDN) in preventing episodes of angina at rest.
Topics: Angina Pectoris; Delayed-Action Preparations; Humans; Isosorbide Dinitrate; Nifedipine; Verapamil | 1987 |
Effect of propranolol and verapamil on oxygen utilization, acidosis and fatigue during exercise in stable angina pectoris.
Topics: Adult; Angina Pectoris; Blood Gas Analysis; Cardiac Output; Hemodynamics; Humans; Hydrogen-Ion Conce | 1987 |
Calcium absorption and excretion in patients treated with verapamil.
Topics: Aged; Angina Pectoris; Calcium; Calcium Radioisotopes; Female; Humans; Intestinal Absorption; Male; | 1987 |
[Effect of isoptin on intrahepatic and central hemodynamics in ischemic heart disease].
Topics: Adult; Angina Pectoris; Coronary Disease; Drug Evaluation; Glucose Tolerance Test; Hemodynamics; Hum | 1987 |
[Unstable stenocardia: hemodynamic effect of the intravenous administration of verapamil].
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Blood Pressure; Cardiac Output; Cardiac Volume; Hear | 1986 |
[Dynamics of the anti-anginal effect and of the concentrations of verapamil and its metabolites in the blood serum of patients with stenocardia of exertion].
Topics: Adult; Angina Pectoris; Dose-Response Relationship, Drug; Exercise Test; Humans; Male; Middle Aged; | 1986 |
The effect of oral verapamil therapy on antipyrine clearance.
Topics: Administration, Oral; Adult; Angina Pectoris; Antipyrine; Half-Life; Humans; Kinetics; Male; Middle | 1986 |
Plasma levels of verapamil and its major metabolites during long-term oral treatment, in chronic stable angina. Correlation with the clinical effects of the drug.
Topics: Administration, Oral; Adult; Angina Pectoris; Drug Administration Schedule; Exercise Test; Humans; M | 1985 |
[Acute administration of verapamil in stable angina: increase of the coronary reserve during the exertion test].
Topics: Angina Pectoris; Coronary Circulation; Exercise Test; Female; Heart Rate; Humans; Male; Random Alloc | 1985 |
[Possibility of developing tolerance to the anti-anginal effect of isosorbide dinitrate and verapamil].
Topics: Adult; Angina Pectoris; Drug Tolerance; Exercise Test; Humans; Isosorbide Dinitrate; Male; Middle Ag | 1985 |
[Characteristics of patients with ischemic heart disease under dispensary observation in a regional polyclinic and the evaluation of anti-angina therapy conducted under dispensary conditions].
Topics: Adult; Ambulatory Care; Amiodarone; Angina Pectoris; Coronary Disease; Drug Therapy, Combination; Fo | 1985 |
Verapamil in angina pectoris.
Topics: Angina Pectoris; Humans; Myocardial Infarction; Physical Exertion; Verapamil | 1985 |
[Synergism of the anti-anginal action of beta-blockers and calcium antagonists in patients with ischemic heart disease].
Topics: Adult; Angina Pectoris; Blood Pressure; Coronary Disease; Drug Therapy, Combination; Heart Rate; Hum | 1985 |
Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris.
Topics: Administration, Oral; Angina Pectoris; Biological Availability; Half-Life; Humans; Kinetics; Male; M | 1986 |
Abrupt change from propranolol to verapamil. Safety and feasibility in stable angina pectoris.
Topics: Angina Pectoris; Female; Humans; Male; Middle Aged; Propranolol; Time Factors; Verapamil | 1986 |
Clearance-based oral drug interaction between verapamil and metoprolol and comparison with atenolol.
Topics: Administration, Oral; Angina Pectoris; Atenolol; Drug Interactions; Drug Therapy, Combination; Femal | 1985 |
Improved coronary supply: prevailing mechanism of action of nitrates in chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Arterial Occlusive Diseases; Cardiac Volume; Chronic Disease; Coronary | 1985 |
[Use of verapamil for treating patients with unstable stenocardia].
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Angina, Unstable; Delayed-Action Preparations; D | 1985 |
Symptomatic sinus bradycardia during concomitant propranolol-verapamil administration.
Topics: Angina Pectoris; Bradycardia; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Proprano | 1985 |
Effect of specific thromboxane-synthetase inhibition on thromboxane and prostaglandin synthesis in stable angina induced by exercise test.
Topics: Aged; Angina Pectoris; Exercise Test; Female; Humans; Imidazoles; Male; Middle Aged; Oxidoreductases | 1985 |
[Hypertrophic gingivitis caused by verapamil].
Topics: Angina Pectoris; Gingivitis; Humans; Hyperplasia; Male; Middle Aged; Phenytoin; Verapamil | 1985 |
[Synergism of the anti-angina effect of obzidan and finoptin in patients with effort stenocardia].
Topics: Adult; Angina Pectoris; Drug Synergism; Drug Therapy, Combination; Humans; Middle Aged; Physical Exe | 1985 |
[Effect of isoptin on myocardial hemodynamics and contractility during an anginal attack induced by the atrial stimulation test].
Topics: Adult; Angina Pectoris; Heart Function Tests; Hemodynamics; Humans; Male; Middle Aged; Myocardial Co | 1985 |
[Comparison between atenolol and verapamil in the treatment of unstable angina].
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Arrhythmias, Cardiac; Atenolol; Drug Evaluation; Hum | 1985 |
[Choice of a calcium antagonist in chronic stable angina].
Topics: Angina Pectoris; Drug Evaluation; Electrocardiography; Heart Rate; Humans; Nifedipine; Physical Exer | 1985 |
[Verapamil in the treatment of patients with coronary insufficiency].
Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Apnea; Arteriosclerosis; Cardiac Complexes, Pr | 1970 |
[Experience with a long-term therapy of out-patients with verapamil].
Topics: Ambulatory Care; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, P | 1970 |
Verapamil and cardiac pain.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Humans; Pulse; Verapa | 1967 |
[Use of isoptin in angina pectoris and heart rhythm disorders].
Topics: Adolescent; Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibri | 1967 |
Drugs for angina pectoris.
Topics: Angina Pectoris; Humans; Isosorbide Dinitrate; Nitroglycerin; Placebos; Propranolol; Statistics as T | 1973 |
Antiarrhythmic actions of a new coronary vasodilator agent, iproveratril.
Topics: Aconitum; Angina Pectoris; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Epinephrine; | 1967 |
[Treatment of coronary disease patients with Verapamil (Isoptin)].
Topics: Adenosine Triphosphatases; Adult; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Calcium; Co | 1972 |
[The effectiveness of using isoptin for patients with stenocardia].
Topics: Adult; Aged; Angina Pectoris; Arrhythmias, Cardiac; Female; Humans; Male; Middle Aged; Verapamil | 1972 |
[Some suggestions for the treatment of myocardial infarct in the pre-hospitalization phase].
Topics: Allied Health Personnel; Ambulances; Angina Pectoris; Arrhythmias, Cardiac; Atropine; Droperidol; He | 1973 |
[Verapamil treatment in myocardial infarction with relapsing ventricular tachycardia].
Topics: Aged; Angina Pectoris; Drug Therapy, Combination; Electric Countershock; Electrocardiography; Humans | 1973 |
[Verapamil (Isoptin)].
Topics: Angina Pectoris; Arrhythmias, Cardiac; Heart Rate; Humans; Hypertension; Myocardium; Vasodilator Age | 1974 |
[Therapy of angina pectoris. 3. Papaverine, xanthine and other drugs].
Topics: Angina Pectoris; Dipyridamole; Humans; Iproniazid; Khellin; Lidoflazine; Papaverine; Prenylamine; Ve | 1974 |
Effect of nitroglycerin, intensain, isoptin and papaverine on coronary blood flow in man. Measured by the coincidence counting technic and rubidium.
Topics: Adult; Aged; Angina Pectoris; Blood Circulation; Coronary Disease; Female; Heart Function Tests; Hum | 1966 |
[Drug therapy of angina pectoris. Evaluation of various drugs by means of work tests].
Topics: Angina Pectoris; Angiography; Anti-Arrhythmia Agents; Coumarins; Dipyridamole; Electrocardiography; | 1970 |
[Old and new concepts of antistenocardiac drugs].
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Cardiac Glycosides; Dipyridamole; Humans; Nitriles; Nitrite | 1970 |
The systemic and coronary hemodynamic effects of iproveratril.
Topics: Angina Pectoris; Animals; Blood Circulation; Blood Pressure; Cardiac Output; Coronary Circulation; D | 1971 |
[Verapamil in ischemic pain and arrhythmia].
Topics: Adult; Aged; Angina Pectoris; Arrhythmias, Cardiac; Coronary Disease; Depression, Chemical; Female; | 1972 |
Metabolism of [14C]verapamil.
Topics: Administration, Oral; Angina Pectoris; Animals; Autoradiography; Carbon Isotopes; Chromatography, Ga | 1971 |
[Clinical trials of the effect of verapamil in subjects with angina pectoris].
Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Arteriosclerosis; Coronary Disease; Female; He | 1970 |
[On the method of action of new types of coronary dilatators with simultaneous oxygen-saving myocardial effects, prenylamine and iproveratril. 2].
Topics: Angina Pectoris; Animals; Anti-Arrhythmia Agents; Calcium; Coronary Vessels; Guinea Pigs; Heart; Nit | 1967 |
[The effect of iproveratril on angina pectoris and thef adrenergic beta-receptors of man].
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Chemoreceptor Cells; Electrocardiography; Exercise Test; Hu | 1968 |
[Clinical evaluation of iproveratril].
Topics: Adult; Angina Pectoris; Anti-Arrhythmia Agents; Electrocardiography; Female; Heart Diseases; Humans; | 1968 |
[Newer therapeutic preparation in cardiac pain].
Topics: Angina Pectoris; Animals; Dipyridamole; Electrocardiography; Humans; Methods; Prenylamine; Propranol | 1969 |
[Our experiences with the beta-adrenolytic preparation Isoptin Knoll A.G].
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Coronary Disease; Electrocardiography; Female; Humans; Lana | 1969 |
[Isoptin studies on normal subjects and patients with coronary disease].
Topics: Adult; Angina Pectoris; Anti-Arrhythmia Agents; Blood Pressure; Coronary Disease; Electrocardiograph | 1963 |
Coronary cineangiographic study of intravenously administered isoptin.
Topics: Adult; Angina Pectoris; Cineangiography; Coronary Angiography; Humans; Injections, Intravenous; Midd | 1966 |
[New data on the drug therapy of angina pectoris].
Topics: Angina Pectoris; Coronary Disease; Dipyridamole; Humans; Monoamine Oxidase Inhibitors; Prenylamine; | 1966 |
[On the therapy of stenocardiac complaints with Iproveratril].
Topics: Aged; Angina Pectoris; Anti-Arrhythmia Agents; Female; Humans; Male; Middle Aged; Nitriles; Vasodila | 1966 |